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Abstract 
Dietary flaxseed lignans may have a chemopreventive and chemotherapeutic role against 
prostate and breast cancers. Flaxseed lignans, though, undergo an extensive first-pass effect and 
exist systemically primarily as glucuronide conjugates that are believed to be inactive. Their poor 
oral bioavailability (FO) likely explains the very modest benefit observed in human clinical studies. 
To fully realize the potential for lignan oral supplementation in prostate and breast cancer, 
pharmaceutical strategies are necessary to overcome the limitations imposed by poor FO. This 
dissertation involved proof-of-principle studies designed to first provide in vitro experimental 
evidence of flaxseed lignans on enhancing cytotoxicity of typical chemotherapeutic agents when 
used in combination, followed by the development of a pharmaceutical strategy to potentially 
exploit a role for lignans as adjuvant therapy against prostate cancer, and a human clinical trial to 
show oral safety and tolerability. 
Combination studies of lignans with chemotherapeutic agents were first conducted in 
prostate (PC3 and LNCap) and breast (SKBR3 and MDA-MB-231) cancer cell lines. SECO, the 
aglycone metabolite of the plant lignan, secoisolariciresinol diglucoside (SDG), was tested as it 
exhibits good FO but has had little investigation. As a major mammalian lignan converted from 
SECO, studies focused on enterolactone (ENL) and its glucuronic acid conjugate (ENL-Gluc). Typical 
chemotherapeutic agents with different mechanisms of action, including docetaxel, doxorubicin, 
cabazitaxel, MDV3100, and carboplatin were selected for combination experiments with lignans. 
A randomized, double-blind, placebo-controlled clinical trial in healthy older adults was 
conducted with oral supplementation of a standard flaxseed lignan-enriched complex (~38% SDG) 
equivalent to 600 mg SDG for 6-months, to assess efficacy, safety, and tolerability of flaxseed 
lignans. Finally, antibody directed enzyme prodrug therapy (ADEPT) system was generated by 
using anti-prostate specific membrane antigen (PSMA) antibody, D7 scFv as the carrier, and 
human β-glucuronidase (hβG) as the drug-converting enzyme. The binding affinity of fusion 
protein was assessed in purified PSMA as well as LNCap cells expressing cell surface PSMA. The 
enzymatic activity of D7-hβG fusion protein was determined using probe, 4-methylumberlliferone 
glucuronide, and prodrug, ENL-Gluc. C4-2 cells, expressing PSMA, were chosen to measure the 
conversion of ENL-Gluc into ENL by fusion protein in combination with docetaxel. 
iii 
 
In the in vitro combination studies, SECO and ENL enhanced sensitivity of cancer cells 
against therapeutic agents, in particular the ENL and docetaxel combination, while no obvious 
cytotoxicity was observed from ENL-Gluc. The in vivo assessment of flaxseed lignan-enriched 
product indicated no adverse side effects suggesting the safety and tolerability of flaxseed lignans 
for long-term oral exposure at a low pharmacological dose. Furthermore, plasma parent and total 
flaxseed lignans were significantly elevated in healthy older adults receiving lignan 
supplementation (n=19) compared with placebo (n=13), with large interindividual variation in 
systemic lignan levels observed. Interestingly, a significant reduction in systolic blood pressure 
(SBP) (from 155 mmHg to 140 mmHg) was observed in participants receiving treatment under the 
subcategory of SBP 140 mmHg, while no change was observed in placebo group with SBP 140 
mmHg (n=6). Positive outcomes from in vitro and human clinical trial data supported 
investigations into an ADEPT strategy from which the fusion protein D7-hβG was successfully 
generated. The fusion protein displayed excellent binding against cell surface or purified PSMA, 
and favorable activity in production of active mammalian lignan, ENL, from ENL-Gluc. A slight 
decrease in the IC50 value was observed in the treatment group of D7-hβG with 100 µM ENL-Gluc 
plus docetaxel compared with docetaxel alone group in C4-2 cells. This proof-of-principle 
therapeutic strategy is the first attempt to expand the utility of flaxseed lignans as adjuvant 
therapy against prostate cancer. With the advantage of the safety and tolerability profile following 
convenient oral lignan consumption, this dissertation research warrants further evaluations of the 
ADEPT strategy as adjuvant therapy against prostate as well as breast cancer both in vitro and in 
vivo.  
In general, this dissertation provides science-based evidence to support the health benefits 
of flaxseed lignan-enriched product following oral consumption as a natural health product (NHP) 
which is required by Health Canada. 
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Chapter 1 Literature Review 
1.1 Introduction 
Lignans are diphenolic compounds found in natural products with flaxseed being the richest source 
of the lignan, secoisolariciresinol diglucoside (SDG). Flaxseed lignans exist in the plant mainly as an SDG 
polymer, which is hydrolyzed into the aglycone, secoisolariciresinol (SECO), in the upper gastrointestinal 
tract. Although a minor amount of SECO can be absorbed and detected in the systemic circulation, the 
majority of plant lignan is converted into mammalian lignans, enterodiol (ED) and enterolactone (ENL), 
with ENL being the most abundant in the mammalian gastrointestinal tract. ENL undergoes extensive first-
pass metabolism during its absorption by intestinal and hepatic phase II enzymes, principally the UDP-
glucuronosyltransferase family of enzymes, before entering the systemic circulation. 
Flaxseed lignans are available commercially as a SDG-enriched flaxseed complex oral formulation, 
and extensive first-pass will result in a very low oral bioavailability of the active lignan form and presence 
of lignans as presumably inactive glucuronide (ENL-Gluc; ED-Gluc) conjugates in the systemic circulation 
and tissues. The extent of first pass metabolism is highly variable in the human population, and 
epidemiological studies do suggest that tissue and plasma concentrations of total ENL is positively 
correlated with the putative health benefits of flaxseed lignans. However, human clinical trials often 
demonstrate controversial results due to a poorly established relationship between oral dosage and 
serum concentration of flaxseed lignans, as calculation of oral intake of flaxseed lignans in human studies 
are based on daily recall of food questionnaires or use of flaxseed products with unknown lignan contents. 
Randomized, blinded human pharmacokinetic clinical trials to assess the serum concentrations of lignans 
and their metabolites following an oral administration of a standardized commercially available flaxseed 
lignan-rich complex or purified lignan forms are lacking. 
Epidemiological studies and preclinical studies suggest flaxseed lignans have putative health 
benefits against multiple human chronic diseases including breast and prostate cancer. The health 
benefits are positively correlated with elevated serum concentration of total lignans, and in particular to 
the mammalian lignan, ENL. In vitro studies have identified several putative compounds from flaxseed 
lignans that mediate anti-cancer effects via multiple mechanisms, which promise the possibility of lignans 
as a novel therapeutic candidate. In vitro and clinical trials suggest the mammalian lignan, ENL, which is 
produced in mammalian gastrointestinal tract through bacterial metabolic reactions, as a key candidate 
for anti-cancer effects. However, the ability of the plant lignan, SECO, to undergo limited absorption intact 
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suggests that it may also be considered as a novel anticancer candidate. Consequently, this literature 
review will principally focus on ENL and SECO. In addition to their putative health benefits, recent safety 
data released from in vivo studies following oral administration of flaxseed lignan-enriched products 
indicate no adverse side effects and demonstrated good tolerability with either short- or long-term daily 
administration of a pharmacological dose. This human clinical trial information is important to support a 
potential health claim for flaxseed lignans in chronic disease such as cancer. Considering the anticancer 
property and safety data from flaxseed lignans, we presume that the combination of flaxseed lignans with 
currently available cancer chemotherapeutics could increase the anti-tumor activity of these marketed 
anticancer agents in vitro and in vivo. Such synergism would allow for a dose reduction of the typical 
chemotherapeutic, reduction in side effects, and more effective therapy. 
An important issue, though, which has plagued researchers for many years and limits its ability to 
effect more than modest health benefits is the pharmacokinetic profile of flaxseed lignans. The flaxseed 
lignans undergo extensive presystemic metabolism (primarily phase II enzyme mediated reactions) before 
reaching the systemic circulation. Phase II metabolism is almost always a deactivation pathway and these 
phase II metabolites will likely have no apparent growth inhibition (or other pharmacological activity) 
against either normal or cancer cell lines following oral administration of lignan-enriched flaxseed 
complexes available commercially. Based on this understood pharmacokinetic profile, antibody-directed 
enzyme prodrug therapy (ADEPT) may offer a novel strategy to allow for specific activation of high levels 
of cytotoxic ENL from circulating phase II ENL metabolites specifically within the tumor area. In this case, 
the high circulating levels of the ENL phase II metabolites (i.e. the glucuronic acid conjugates of ENL, ENL-
Gluc) following an oral lignan-enriched flaxseed complex formulation becomes the ‘prodrug’, and 
cleavage of the glucuronide group to generate the active form, ENL, is achieved by specifically targeting a 
glucuronidase enzyme to the tumor site via a highly specific antigen-antibody interaction and fusion of 
the enzyme to the targeting antibody. Higher plasma concentrations of ENL is associated with lower risk 
of prostate and breast cancer, although the results may be still controversial and not as consistent as 
results reported in preclinical studies. Supplementation of dietary lignan precursors like SDG or SECO to 
enhance protection against cancers without obvious side effects has also been reported in the literature. 
High dose oral administration of flaxseed lignans for short and long term regimens supports the idea that 
flaxseed lignans appear safe for most people to consume. As plasma ENL is positively related with flaxseed 
lignan uptake, we believe that high oral dose administration of flaxseed lignan may provide sufficient 
circulating ENL-Gluc levels, which would undergo conversion into the pharmacologically active, ENL, via 
the action of the enzyme beta-glucuronidase delivered specifically to the tumor site by an antibody that 
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targets a specific cell-surface antigen. Activated ENL, in combination with other therapeutic agents, can 
act as an adjuvant therapy against breast and prostate cancer, which will improve therapeutic 
effectiveness and quality of life in those patients. 
Considering the accessibility and diversity of manufacturing processes of natural health products 
(NHPs), safety is the first concern of Health Canada regarding products currently on the market. Natural 
health products (NHPs) are regulated by the Natural Health Product Regulations under the Natural and 
Non-prescription Health Product Directorate (NNHPD) (former name was Natural Health Product 
Directorate (NHPD)) in Canada. NHPs are controlled similarly to pharmaceutical products, so require that 
efficacy, product quality, and safety be assured to allow for free consumer self-selection and self-care. 
The standardized flaxseed lignan complex (38% SDG, BeneFlax®) from Archer Daniels Midland meets the 
quality and safety requirements and was approved by Health Canada. Such a product could be marketed 
under the NHP framework with health claims against prostate or breast cancer with sufficient scientific 
support for such a claim. 
1.2 Drug discovery paradigm 
Drug discovery undergoes constant transformation with initial focus on small molecules to 
biologicals including proteins, peptides and RNAs, to the druggable genome including oncogenes and 
other noncoding sequences involved in the regulation of cancer proliferation or progression (1). As well, 
the identification of the differences in pathways and characteristics between tumor and normal cells has 
led drug discovery efforts to focus on the search of selective, single target drugs that can hit cancer cells 
through a tumor associated target (proteins, RNA, DNA) or other targets involving regulation of tumor 
proliferation and progression. This thinking is well explained by “key and lock model”----that is a selective 
“key” fits into the “lock” of a specific drug target (2). Drug design activity is dominated by this concept, 
which mainly reflects on the discovery of a selective compound with high affinity and activity against its 
target. However, a single target drug often fails to show similar effectiveness as it exhibits in in vitro 
studies, when the molecule is thrown into the whole biological system network. It is not surprising to 
achieve negative outcomes in in vivo studies. Those single target agents are developed separately without 
considering the network connection between the target and other biological molecules (3). Even if single 
target agents exhibit complete inhibition/activation against the directed targets, the net effect of agents 
on the entire biological system may be trivial. Both the human biological system and the tumor and tumor 
related microenvironments are very complicated network systems. Furthermore, such networks have 
different “back-up” systems and redundancies to overcome or compensate a change in the function of 
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one target (lock) caused by the agent (key), which then results in a decreased or no response to the 
proposed ‘drug’ (4). Although we may still see that single target drugs have been approved for clinical 
usage, they are usually used in combination with existing chemotherapeutic agents to achieve higher 
efficacy in cancer patients. 
A new drug discovery paradigm is emerging for development of more effective drugs with improved 
efficiency and safety, with consideration the limitation of single target agents. This new paradigm refers 
to multiple target drugs. The principle of multi-targets refer to the usage of a single agent exhibit multiple 
mechanisms or combination of different agents to inhibit multiple targets in parallel (5). In clinic, the 
concept of combination therapy has been extensively used for decades from which the multi-targets 
combination demonstrated higher efficacy, compared with single-targets therapy (6). The advantage of 
multiple targets against cancers using combination strategy also guide the direction of drug discovery 
paradigm to multi-targets way. 
The growing understanding in the distinguished cellular network between normal cells and tumor 
cells has offer potential novel targets that might lead to successful design a promising agent. Cellular 
networks may refer to cell signaling pathways, metabolic pathways, transcriptional regulation networks, 
and intercellular connections. Networks usually have some vulnerable points with which the “back-up” 
system may not be strong enough to absorb an attack from other compounds, thus, are more attractive 
as putative druggable targets. Selection of possible candidates from natural product libraries could be 
another strategy, as natural products exhibit complex in structure and multiple mechanisms of actions 
that allow us to discover novel pharmacophore against tumors. 
1.2.1 Natural Products as source of novel drug leads 
The history of mankind is replete with examples of how humans have used natural products to 
satisfy their food needs and to treat a diversity of diseases. The earliest traceable records of traditional 
medicine systems using natural products can date back to 4000 years ago with approximately 1000 plant-
derived substances being documented (7). In a comprehensive review conducted by the World Health 
Organization (WHO), by the year 1985, approximately 65% of the world’s population relied on plant-
derived drugs for their primary health care (8). Natural products have been used in cancer treatment for 
a long time, although the efficacy is circumspect as natural products are usually a complex mixture of 
multiple substances and their mechanism of action against cancer are poorly defined (7). The enthusiasm 
of generating plant-derived drugs abated in the late 1980s, and reached its lowest level in 1990s, when 
combinatorial chemistry techniques shifted the focus of drug discovery from natural products to the 
laboratory bench side (9). Combinatorial chemistry is a technique that can create a large population of 
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structurally different molecules in a short time and proceed to screening assays for drug candidates 
against a variety of targets (10). Even though the number of total synthetic NCEs approved in the 1988 
reached 24 NCEs, the percentage of totally synthetic anticancer NCEs from 1981 to 2010 only contributed 
up to 25% (9). All approved anticancer NCEs including natural products, and natural product (Botanical) 
derived drugs, is made up to 41% from late 1930s to 2010 (9).  
Researchers realized that the lack of complexity and structure diversity of these compound libraries 
from combinatorial chemistry may account for the low production of NCEs. The complexity and diversity 
in structures which are commonly shared by natural products, also make natural products favorable as 
model compounds to guide the synthesis of natural-product-derived-products or -mimics that share 
similar structures with improved efficacy (11). The advent of HTS technique in drug discovery, also made 
the concept “rediscovery natural products” more reliable. HTS is a screening tool using laboratory 
automation to measure the entire compound library directly against the drug target, by which millions of 
compounds can be done in a couple of days (12). In a recently published paper, the author analyzed 
197,201 natural product structures and found that a large overlap in chemical structures exists between 
natural products and FDA-approved drugs which indicate the potential of natural products as being a drug 
source (13). Another advantage of natural products in drug development is that they usually exhibit 
multiple targets in vivo, which is consistent with the emerging drug discovery paradigm. To date, there 
have been already many natural product derived drugs applied in clinic, such as metformin, and non-
steroidal anti-inflammatory drugs (NSAIDs) (14, 15). 
1.2.2 Dietary natural compounds in combination with primary treatment 
Clinical trial data that specifically focus on the combination effect of dietary natural compounds as 
adjuvant therapy against malignancy is limited. Thus, this section mainly focuses on introducing the 
concept of dietary natural compounds in combination with the primary treatment. Besides providing a 
tremendous library for drug discovery,  dietary natural products are also well recognized for their ability 
of enhance the efficacy of standard treatments against multiple chronic human diseases, from which a 
wide range of biological active compound have been isolated and identified, such as polyphenols, 
flavonoids, lignans and catechins (16). Resveratrol, a polyphenol antioxidant found in grapes, is identified 
as a natural health product by the NNHPD with the health claim of providing antioxidant activity. Clinical 
trials studying the complementarity of resveratrol or resveratrol containing products have reported 
enhanced improvement in disease outcomes compared with patients only receiving standard treatments 
(17-19). Recently, sulforaphane, which was found in broccoli sprouts, received increased interest for its 
anti-tumor activity (20). A phase II trial reported that patients with recurrent prostate cancer, whose prior 
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androgen deprivation therapy was allowed, had stable disease during the 22-week invention with dietary 
sulforaphane-rich broccoli sprout extract supplementation (21). For curcumin, a polyphenol antioxidant 
from turmeric, multiple clinical trials were conducted using curcumin in conjunction with a wide range of 
agents across diverse health conditions (22). The overall effect of curcumin was moderate to none, so no 
solid conclusion could be drawn from these clinical trials. Although preclinical studies report promise from 
the combination of dietary natural compounds and therapeutic agents, translation of such benefits to 
human clinical trials are always fraught with difficulties and limitations, such as the confounding effects 
of co-morbidities, gender and ethnicity, and knowledge of an appropriate dose to achieve therapeutic 
outcomes in human populations. Dietary natural compounds also generally encounter more challenges 
due to non-patentable properties. 
1.2.3 Natural health products (NHPs) 
Under the Natural Health Products Regulations (NHPR), NHPs are defined as vitamins and minerals, 
herbal remedies, homeopathic medicines, traditional medicines such as Traditional Chinese Medicines, 
probiotics and other products like amino acids and essential fatty acids (23). NHPs should be safe enough 
to use as over-the-counter products and should not require a prescription, which would allow for self-
selection and self-care by Canadians. NHPs are usually marketed for health reasons, like maintenance of 
good health, prevention of disease condition for special subjects, and reduction of health risk or alleviation 
of complications caused by certain diseases. 
1.2.3.1 Natural Health Products Regulation (NHPR) 
Before 2004, all NHPs were either regulated by Food or Drug regulations under food categories or 
drugs as there was no other category that could classify them. The NHPs market was generally disordered 
as foods and drugs have totally different evaluation systems. Under a food category, products do not 
require good manufacturing practices (GMP) to ensure the safety and quality of the NHPs nor pre-market 
evaluation. Such lack of requirements was not suitable for NHPs with intentions for health claims rather 
than simple nutrition or calorie claims. 
The NNHPD started a population-based questionnaire to request the set up a specific category for 
NHPs to standardize the marketing behavior of both products and the producers. A drug style model was 
applied to NHP approval to market meaning that a NHP had to meet criteria including safety, efficacy and 
high product quality (i.e. a standardized product) (24). NHPR, which came into effect on January 1st, 2004, 
issues product licenses for all NHPs sold in Canada and site licenses for producers who need to meet GMP. 
Safety and efficacy is the foremost focus of NHPR on NHPs. The NHPR will enforce the government’s ability 
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to remove potentially unsafe products from the market. Also the requirements of science-based evidence 
by NHPR will force companies to label their products with clear health claims, thus protecting Canadians 
and ensuring they obtain products that meet their health needs (25). Once approved by NNHPD, licensed 
products are assigned an eight-digital Natural Product Number (NPN) or Homeopathic Medicine Number 
(DIN-HM) to allow for their sale on the market. To obtain a license, detailed product information such as 
source, potency, medicinal and non-medicinal ingredients, recommended dosage and use and purpose 
(i.e. laxative effect, release of joint pains) must be submitted to Health Canada as well as appropriate 
labels on product package (26). For those companies who wish to produce NHPs a site license is required 
from Health Canada. Two documents Pathway for Licensing NHPs Making Modern Health Claims and 
Pathway for Licensing NHPs Making Traditional Health Claims have been published as guidance 
documents for industry and health care practitioners to coordinate with government regulations and also 
provide the information on the process and criteria for NHP review in Canada including types of health 
claims, risk level information, and quality claims (27, 28). Health Canada also released Quality of Natural 
Health Product Guide to ensure high quality of products from flexible production processes (29). Since 
2004, more than 70,000 NHPs have received pre-market approval and 2,000 site licenses have been issued 
(24). 
An exemption number might apply to NHPs that have been sold in shops but did not receive full 
review by NNHPD before 2013. These products should at least have undergone through initial assessment 
on efficacy and quality, with meeting the safety criteria required by the NNHPD. Health Canada will also 
continue to review current products to determine whether a product will receive approval or be 
withdrawn from the market (30). 
1.2.3.2 Benefits and risks of NHPs 
A Natural Health Products Tracking Survey conducted in 2010 by Ipsos Reid reports that about 73% 
of Canadians regularly take NHPs, a slight increase from 71% in 2005 (31). In the survey, the major reasons 
of Canadians to use NHPs are for health maintenance, illness prevention and to strengthen the immune 
system. NHPs are also widely used particularly in elderly people to prevent conditions such as 
osteoporosis, and during pregnancy and breast-feeding for additional folic acid requirements (32-34). 
NHPs are usually considered to be generally safe, but not risk free. Approximately 12% Canadians reported 
unwanted side effects with use of NHPs (35). Several key reasons account for the potential risk associated 
with NHP use. First, people may overdose themselves considering that NHPs are safe to take and yet 
expect the same effectiveness as gained from medications. For example, vitamin D supplements are used 
to prevent osteoporosis especially in older seniors (36). However, excessive vitamin D intake does not 
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help bone health, but rather increases risk of falls and fracture (37-39). Second, people commonly co-
administer more than one NHPs, functional food, and/or prescription medication. This increases the risk 
for drug-, food-, and NHP-NHP interactions. Xenobiotic metabolizing enzymes responsible for the 
pharmacological inactivation and elimination of a variety of drugs, NHPs, and nutrients is a common site 
for such interactions. For example, substrates of CYP3A4, a metabolic enzyme responsible for the 
detoxification of a broad range of substrates, are at risk for clinically significant interactions when these 
substrates are co-administered. Carbamazepine, a CYP3A4 inducer, has been known to be prone to food-
drug and NHPs-drug interactions. A systematic review of carbamazepine suggests its potential to interact 
with folinic acid and melatonin, as well as constituents of grapefruit juice and soy bean (40). Similarly, 
ginseng, an extensively used NHP world-wide, causes NHP-drug interactions via activation or inhibition of 
multiple P450 enzymes (41). Third, many NHPs on the market contain unclear ingredients at unknown 
amounts in addition to those with health-related claims, and may cause allergic reactions and other 
significant adverse effects. 
Health Canada is especially concerned about the safety and regulation of NHPs on the market since 
NHPs are broadly available to Canadians who determine their usage largely based on the information 
provided on the label. According to Health Canada, “Any substance, whether natural or synthetic, that 
has an effect on the body, has the potential to be a risk to health. Children, pregnant or breastfeeding 
women, seniors, those diagnosed with a serious disease or those scheduled for an operation are 
particularly susceptible to risk.”(42) . Thus, NHPR is to ensure Canadians have full access to safe NHPs. 
Under NHPR, producers of NHPs will be asked to provide more useful information that offers clear 
guidance on best use of the NHP. 
1.2.3.3 Flaxseed lignans as NHP candidates 
Flaxseed associated products have been approved as NHPs for some time. Whole flaxseed has been 
marketed for a long time as a source material for the purpose of a laxative effect due to its rich source of 
soluble fibre (43). Flaxseed oil, which contains an abundant amount of the plant-derived α-linolenic acid 
is also successfully marketed for the maintenance of good health, such as reduction in the risk for 
cardiovascular disease (CVD) and type 2 diabetes mellitus (T2DM) (44). With an increased understanding 
that flaxseed may contain other effective components with health benefits against multiple human 
diseases, flaxseed lignan enriched products offering a higher quantity of lignan (and other potential 
bioactive compounds such as the cyclolinopeptides) may become a strong NHP candidate (45). With 
appropriate randomized clinical trial evaluations, flaxseed lignan-enriched products may undergo 
approval as a NHP for chemopreventative and therapeutic effects in various disease states, particularly 
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prostate cancer, breast cancer, cardiovascular disease, and diabetes mellitus. First, NHPs are not 
patentable, which allows for large production of concentrated flaxseed lignans by different companies, 
even though NHPs are regulated similarly to drugs under the NHPR. Competition between companies 
would allow for a lower market price unlike innovator drug prices that are set by the company producing 
the drug. A 38% concentrated SDG complex product could provide a sufficient source of flaxseed lignans 
with moderate manufacturing costs to allow long-term daily administration. Flaxseed lignan-enriched 
complex is safe and can be purchased without prescription. Safety data released by animal and human 
studies indicate that flaxseed lignans are safe to administer except possibly during pregnancy and will be 
discussed in the section below on “safety of flaxseed lignans” (46-49). 
The problem that might postpone the widespread marketing of flaxseed lignan-enriched complex 
products is that the current epidemiological and population-based studies demonstrate controversial 
results and currently fail to provide convincing evidence of their positive health benefits in reduction of 
risk of cancer or CVD. Moreover, although a high dose of flaxseed lignans demonstrates safety following 
oral intake, the daily recommended dose of lignan is not well established. Some toxicity concerns exist in 
certain subpopulations such as in pregnancy where animal studies have shown adverse effects of lignans 
on the offspring of pregnant mothers exposed to flaxseed lignans (50, 51). However, exposure of the 
lactating dam to flaxseed lignans during suckling did not affect reproductive indices among offspring (52). 
Nevertheless, further investigations are needed to test the safety and efficacy of lignans. The role of 
lignans against breast and prostate cancer continues to attract increased interest as an adjuvant therapy 
or in combination with other chemotherapeutic agents (53). 
1.3 Flaxseed 
Flaxseed, the seed of Linum usitatissimum, is an important source of human nutrition. Flaxseed 
comes in two varieties: brown and gold form (54). Most types of flaxseed have similar nutritional 
characteristics containing 20-21% protein, 44-45.7% of oil content, 0.12-0.17% free fatty acids and lignan 
precursors (1% of dry weight) (55). Flaxseed contains all sorts of healthy components. Flaxseed oil contains 
about 57% α-linolenic acid, which is an omega-3 essential fatty acid (56). Soluble fibre is another important 
constituent in flaxseed. Flaxseed is one of the richest source of plant lignans which mainly exists in the 
seed hulls, with an average of 32 nmol/mg hull, compared with 9.2 nmol/mg in other seed portion (57). 
1.3.1 Flaxseed lignans 
Flaxseed lignans are compounds possessing a unique diphenolic structure and exist as minor 
quantities in many foods including sesame, rye bran, whole grain, berries, and vegetables, with the most 
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concentrated levels found in flaxseed (58). Lignans exist in the outer fibre layer of flaxseed mainly as 
secoisolariciresinol diglucoside (SDG) polymers, a complex composed of five SDG molecules 
interconnected together by four hydroxy-methylglutaric acid (HMGA) residues with p-coumaric and 
ferulic acid glucoside as end units linked directly to the glucosyl moiety of SDG (59). The concentrations 
of SDG in flaxseed vary from 0.97 to 3.09% (w/w) in defatted flaxseed meals with different cultivars and 
growing conditions (48). SDG was first identified as a precursor of mammalian lignans, which led to an 
important outcome that flaxseed rich in SDG can be used as a source of mammalian lignans (60). The 
cleavage of the glucose groups of SDG is probably mediated by β-Glucosidase and bacterial fermentation 
in the gastrointestinal tract (GIT), to yield to its aglycone form secoisolarisiresinol (SECO) (61). Clavel et al 
have identified four SDG-deglycosolating bacteria strains Clostridium sp. SDG-Mt85-3Db (DQ100445), B. 
ovatus SDG-Mt85-3Cy (DQ100446), B. fragilis SDG-Mt85-4C (DQ100447) and B. fragilis SDG-Mt85-5B 
(DQ100448), which are responsible for transformation in human intestine (62). B. fibrosolvens, P. 
anaerobius and F. succinogenes have been identified with the capacity to convert SDG into SECO in cow 
rumen (63). SECO is then biotransformed into the mammalian lignan, enterodiol (ED), via demethylation 
and dehydroxylation, which undergoes further oxidation to enterolactone (ENL) by facultative aerobes 
(Figure 1-1) (64-66). In a recent study, Ruminococcus gnavus was found to be involved in the conversion 
from SECO to ENL (67). Other plant lignans in flaxseed such as matairesinol, pinoresinol, lariciresinol, have 
also been reported to be converted into the mammalian lignans ENL and ED (68, 69). The majority of ED 
is converted into ENL rather than absorbed directly. Only a small amount of conjugated ED can be 
detected in plasma or urine as the majority of it is converted to ENL (68). Mammalian lignans undergo 
extensive first-pass metabolism, primarily through conjugation with glucuronic acid or sulfate before 
entering the systemic circulation (70). 
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Figure 1-1. Biotransformation of secoisolarisiresinol diglucoside (SDG) to enterolactone (ENL) by 
microflora in gastrointestinal tract. SDG undergoes glycolysis and fermentation in the gastrointestinal 
tract (GIT) to cleave the glucose groups and yield its aglycone form secoisolarisiresinol (SECO). SECO is 
then further converted into mammalian lignans, enterodiol (ED) and ENL, which involves diverse bacteria 
and serial chemical reactions. The majority of ED is metabolized to ENL while only a small amount ED is 
absorbed into the systemic circulation (68). 
1.3.2 Flaxseed lignans (plant and mammalian lignans) pharmacokinetics 
Pharmacokinetics (PK), the study of the time course of drug absorption, distribution, metabolism 
and excretion in the body provides important guidance on the dosage and administration route of a drug 
to allow for optimal efficacy and decreased risk of toxicity. Flaxseed lignans have been administrated in 
humans as a food supplement for a long time (71). Although in vitro and animal experiments highly 
suggest the health benefits of flaxseed lignans against multiple diseases following oral consumption, 
human clinical trials on flaxseed lignan supplement reveal controversial results on the investigation of 
health benefits. A major explanation for these conflicting results may be due to a lack of pharmacokinetic 
information as the plasma concentration of flaxseed lignans in human clinical studies likely fluctuate at 
nanomolar levels, well below concentrations required for pharmacological effect (72-74). Moreover, 
flaxseed lignans primarily exist in the plasma as their phase II conjugates, which are likely to be an inactive 
form (75). How the flaxseed lignans exhibit health benefit through oral consumption is still unclear. So it 
will be useful to study the pharmacokinetic profile of flaxseed lignans in humans following a known lignan 
dose (Figure 1-2). 
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Figure 1-2. Pharmacokinetic profile of flaxseed lignans. 
1.3.2.1 Absorption of flaxseed lignans 
Flaxseed lignans following oral administration undergo complicated physical processes before the 
bioactive compounds reach the systemic circulation. Flaxseed lignans are absorbed into blood mainly as 
mammalian lignans, ENL and ED, with a small portion of SECO. SDG is not detectable in plasma and urine 
either as its original form or phase II conjugates [69]. SDG could be detected in fecal samples whose 
concentration is higher in germ-free rats on flaxseed diet, which also indicate the involvement of bacteria 
in the cleavage of the glucose groups (76). 
Although a significant proportion of SECO is converted to the mammalian lignans, a small amount 
of SECO can be absorbed and detected in the systemic circulation, which may also contribute to lignan 
health benefits (77). A recent study reported that SECO may have important biological activities in 
reversing depression-like behavior in rats (78). SECO is first detected in the small intestine in rats with a 
small portion absorbed into the systemic circulation (61). In male Wistar rats following oral bolus of 40 
mg/kg SECO, SECO exhibits a very fast absorption profile. The elimination half-life (T1/2) of SECO is 3 to 4 
h (79). SECO reaches peak serum concentration at 7.2 ± 1.0 h and has a rapid elimination half-life (T1/2) of 
4.2 ± 0.3 h in healthy postmenopausal women after single oral dose of SDG extract (80). 
ENL was traceable in plasma 9 h after consumption of processed flaxseed or SDG extract in human 
(81, 82). In males, ENL had an absorption half-life of 8.4 h, and had an elimination half-life of 15.1 h with 
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its maximum plasma concentration reached after 24.1 h (83). ENL shows a very low bioavailability due to 
an extensive first pass effect during absorption from the gastrointestinal tract (84). In a single dose 
intraperitoneal injection of ENL (10 mg/kg body weight) in mice, only 2.2% of ENL was detected as its 
unconjugated form in the plasma at Cmax at 0.5 h (85). Milling and crushing flaxseed rich in lignan 
precursors is shown to substantially enhance the bioavailability of ENL as compared to whole flaxseed in 
humans (86). An in vitro study in Caco-2 cells demonstrated that ENL could pass the colon epithelial 
membrane via free diffusion and undergoes extensive conjugation (>99%) in the colon epithelial cells (87). 
ENL exists in plasma and biological fluids predominately as glucuronide and sulfate conjugates. ED can 
also be detected in plasma and exhibits a similar absorption profile as ENL. The maximum concentration 
was reached at 19.7 ± 6.2 h after a single dose of purified SDG (1.31 µmol/kg body weight) in healthy 
males. ED had a short elimination half-life of 4.4 ± 1.3 hours in humans (83). 
In rats, a substantial portion of mammalian lignans undergo enterohepatic circulation and excretion 
into bile predominately as glucuronide conjugates. These conjugates are then unconjugated to the 
mammalian lignans with reabsorption from the intestinal tract or excretion into feces (60). Interestingly, 
although the majority of lignans present in plasma and urine were mammalian lignans, plant lignans could 
account for 77% of total lignans that are excreted into the bile 3-hour-postprandially in pigs with rye bran 
diets (88). This phenomenon suggests that enterohepatic circulation could occur without complete 
conversion of plant lignans to mammalian lignans. Enterohepatic circulation results in reabsorption of 
mammalian lignans and fluctuation of their plasma concentrations as secondary peaks could be detected 
in the oral plasma concentration-time profile (89). Factors affecting the bioavailability of lignans include 
diet, transit time, and diversity and activity of intestinal microflora (90). The transformation from plant 
lignans to mammalian lignans is not complete. In a pig study feeding with rye and wheat bread, 
mammalian lignans only accounted for 34-57% of the faecal lignan excretion with 43-66% constituting the 
original plant lignans (88). Due to the interindividual variation, large differences could be observed in the 
plasma and urinary excretion of mammalian lignans (91). As bacteria are involved in the transformation 
of plant to mammalian lignans, factors that affect the species and amount of bacteria would impact the 
production of mammalian lignans. Oral antimicrobials could decrease serum concentrations of 
mammalian lignans, an effect that could last up to a year (92). A human bacteria associated rat experiment 
also suggests microflora activity in lignan production (93). Since lignans are mainly obtained from food 
consumption,  the diet could also affect lignan production and absorption, and might further contribute 
to interindividual variation in plasma concentrations (90). Foods which are milled and finely crushed will 
provide a higher mammalian lignan source than others such as wheat bran or ground flax seeds due to 
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improved bioavailability (86). Other factors including constipation, gastrointestinal inflammation, and 
diarrhea also affect the biotransformation and absorption of ENL into the systemic circulation (92, 94). 
1.3.2.2 Distribution of flaxseed lignans 
Flaxseed lignans are widely distributed to the whole body. ENL can be detected in liver, lung, kidney, 
heart and brain in rats with higher levels found in liver and kidney, which may due to their role as the 
major organs involved in lignan metabolism and elimination (85, 95). The concentration of ENL in the body 
varies considerably by geographical region with different dietary habits and cultures, but typically stays at 
the lower nanomolar range. The median serum ENL concentration in Finnish men was 13.8 nM (range: 0-
95.6 nM) and 16.6 nM (range: 0-182.6 nM) in women (94). American men seem to have the similar ENL 
serum concentration as Finnish men at 16.6 nM (range 1.1–70.8 nM) (96). For south Asians, the plasma 
ENL was estimated around 13.9 nM (SD 17.5), compared with 28.5 nM (SD 23.3) in native British (97). 
Although present at low levels in the plasma, ENL seems to concentrate in some body fluids such as 
prostatic fluid. In a population based study, the prostatic fluid mean concentrations of ENL were 103.9, 
543.0 and 68.0 nM for Hong Kong, Portuguese and British men, respectively. Extremely high 
concentrations of ENL (2,011.2 nM) in prostatic fluid was reported in some Portugese men, while the 
mean plasma concentrations of ENL were similar, at 20.8, 12.1 and 12.1 nM in samples from Hong Kong, 
Portugal and Britain, respectively (98). Serum ENL concentration is positively associated with oral intake 
of lignan precursors including flaxseed, other seeds, berries, whole grains (99). In an 8-week, placebo-
controlled study, serum ENL significantly increased in subjects receiving 300 or 600 mg/d of SDG, which 
were at 54.49 and 167.33 nM respectively, compared with 7.59 nM detected in the control group (48). 
ENL is excreted both in urine and feces. On average 98% (96.0-98.9) ENL is excreted in urine as 
mono- and di-glucuronide conjugates with disulphate conjugation only contributing to ~2% of total 
urinary excretion. Similar results were found in vervet monkey, baboon and rat (100). ENL is also detected 
in physiological fluids such as breast milk, prostatic fluids, or excreted into the intestinal luminal via 
enterohepatic recirculation (101). In dairy cows, uptake of flaxseed meal results in elevated mammalian 
lignan concentrations in milk (102, 103). Human ATP-binding cassette sub-family G protein (ABCG2) might 
be involved in the excretion of ENL into the milk, as the milk/plasma ratio was significantly decreased in 
abcg2 knockout mice (104). Interestingly, ENL is the major mammalian lignan detected in milk and the 
concentration of ENL dramatically returns to baseline within a week after withdrawal from 20% flaxseed 
supplementation (105). 
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1.3.2.3 Metabolism of flaxseed lignans 
SECO is oxidized in vitro by rat liver microsomes via addition of a monohydroxylatic group to the 
aromatic or aliphatic moiety. The major metabolite of SECO is enterodiol, which can be further converted 
to ENL (68, 106). In rats and other animals, biotransformation can be detected in small intestine, while in 
humans, ED and ENL can be detected in the transverse and descending colon (65). SECO undergoes 
extensive phase II metabolism with 95% of glucuronide or sulfate conjugates detected after 48 hours in 
Caco-2 cells (87). In vivo studies show that a significant portion of SECO is detected in plasma or urine. 
Mammalian lignans are known to undergo both phase I and phase II metabolism. Phase I 
metabolism represents a minor contribution to the overall metabolism of ENL. ENL is biotransformed with 
an additional hydroxyl group to the aromatic or aliphatic moiety when incubated with hepatic microsomes 
from aroclor-treated male Wistar rats, with similar results observed from different species including rats, 
pig, and human (107). The rate of phase I oxidation was much slower relative to its phase II transformation. 
It remains unknown whether oxidative metabolites of ENL are biologically active. Glucuronidation of ENL 
occurs in colon epithelial cells and liver with mono-glucuronic conjugate as the major metabolite, and 
small amounts of di-glucuronic conjugate (75). UDP-Glucuronosyltransferase (UGT) isoforms, UGT2B9*2 
and UGT2B33, are mainly responsible for the glucuronidation of enterolactone in rhesus monkey liver (75). 
The intestine also contributes to the glucuronidation of ENL, but the net effect is uncertain as flaxseed 
lignans also increase the caecal β-glucuronidase activity that catalyzes the hydrolysis of glucuronic acid 
from ENL-Gluc (108). 
About 98% of ENL exists in plasma and excreted in urine and bile predominantly as glucuronic acid 
conjugates, with sulfate conjugate only contributing to 2% of the total ENL (109, 110). The percentage of 
ENL conjugate may vary between genders. In a female urine samples from rats, disulfic acid conjugate of 
ENL was found up to 21.2 % while only 6.3% was found in a male urine sample (111). Similar results can 
be observed with ENL glucuronide, where only 91.7% of ENL was conjugated with glucuronide in male rats 
comparing with 95.2% in female rats (111). 
1.3.3 Flaxseed lignans health benefit 
Flaxseed lignans have been well known for their benefits against multiple human diseases including 
CVD, type II diabetes mellitus and cancers (112, 113). ENL and ED are the putative bioactive compounds 
from flaxseed lignans found in plasma, with ENL is the most abundant lignan present systemically (63). 
Human clinical trials do suggest that the high serum ENL concentration is inversely associated with risk of 
disease, although the health benefits have not been conclusively established. The main way to acquire 
flaxseed lignans in the body is through consumption of lignan containing food such as flaxseed, whole 
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grain, fibre, as well as vegetables and fruits (114). The benefit gained from the lignans may vary in terms 
of the diverse diets, but the health benefit and serum/urinary lignans concentration is positively related 
with dietary lignan quantity (48). In an eight-week double-blind, randomized, placebo-controlled study in 
hypercholesterolacemic subjects, 600 mg/d of dietary SDG significantly decreased LDL-cholesterol 
concentration, which is a strong predictor of CVD (48). ENL can influence lipid metabolism and reduce 
oxidative stress, which may mitigate the development of CVD via direct or indirect mechanisms (115). 
T2DM is another common global disease, by which patients suffer more from its complications rather than 
the disease itself (116). Dietary flaxseed lignans may lower plasma glucose and delay the development of 
T2DM in rats (117). In a human clinical trial with a daily oral dose of 360 mg of flaxseed derived SDG for 
12 weeks, elevated C-reactive protein in T2DM was modulated by lignan consumption (49). In addition to 
health benefits against chronic diseases, flaxseed lignans also exhibit protection against prostate and 
breast cancers. In the next section I will mainly focus on the anticancer effect of lignans related with 
prostate and breast cancer. 
1.3.3.1 Mammalian lignans as multi-target agents 
Considering the huge investment into single target drug research enormous numbers of lead 
candidates fail in in vivo experiments and never meet the clinic. The development of multiple target agents 
has emerged as a leading direction in drug discovery and development research (118). To meet the 
multiple target discovery requirement, compounds extracted or derived from natural products might pose 
as strong candidates as they often exhibit multiple mechanisms of action (119). Secoisolariciresinol 
diglucoside (SDG), the major lignan of flaxseed, undergoes deglycosylation, demethylation and 
dehydroxylation to yield ED and ENL in human intestine by microflora (Figure 1-1). Although recent studies 
supporting the biological activity of SECO in vitro, ED and ENL are still the major mammalian lignans under 
investigation that exhibit multiple mechanisms against multiple human diseases. 
ENL and ED have weak estrogenic and antiestrogenic activity due to their weak binding to estrogen 
receptor α (ERα) and β in vitro, but no detectable estrogenic activity in mice (120). When in the absence 
of estradiol, the biological concentration (1 µM) of ENL exhibits a stimulatory effect on MCF-7 breast 
cancer cell proliferation, but causes slight inhibition when in the presence of estradiol (121). Interesting, 
6-hydroxy-ENL, a metabolite of ENL also binds weakly and preferably to ERα with estrogenic effects (122). 
Both ED and ENL can induce ERα transcriptional activity in a dose-dependent manner in MCF-7 cells 
mediated through different mechanisms (123). In ovariectomized mice with human breast cancer 
xenografts, injection of purified lignans as well as 10% flaxseed (as a source of mammalian lignans) 
inhibited estradiol-induced tumor growth and angiogenesis (124). 
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Mammalian cells have two classes of high affinity estradiol binding sites so called type I and II (125). 
Type I sites represent the classical ERs with high affinity and finite capacity to bind estradiol. Type II 
estradiol binding sites (type II EBS) regulate estrogen-stimulated normal and malignant cell growth and 
proliferation (126). ED and ENL as well as other phytoestrogens have been found to competitively bind to 
type II EBS (127). Phytoestrogens like quercetin, bind to type II EBS with high affinity and inhibit growth in 
a number of cell types, suggesting that this may be another mechanism by which phytoestrogens 
modulate cell proliferation (126, 128). Despite the very limited data on mammalian lignans and type II EBS, 
the type II EBS may be one of the targets that contribute to the antiestrogenic effects of mammalian 
lignans. Estrogen is synthesized by aromatase and 17β-hydroxysteroid dehydrogenase in breast cancer 
tissues and cell lines which can influence the exposure of tissue to estrogen (129, 130). ED and ENL reduce 
the production of estradiol via decreasing activity of aromatase and 17β-hydroxysteroid dehydrogenase, 
which may be another mechanism of antiestrogenic activity (131). 
ENL can bind to sex hormone binding globulin (SHBG) and interfere with 5α-dihydrotestosterone 
binding (132). In Mexican-American women, the plasma concentration of ENL is positively related to the 
plasma SHBG (133). Increase of plasma SHBG is also observed in another study consuming sesamin, a 
lignan processor (134). SHBG is the major plasma sex hormone binding protein for estradiol and 
testosterone, which can lower the percentage of unbound steroids in the plasma, and result in prolonged 
activity of steroids (135). Unbound SHBG then can interact with cell surface receptors, meaning that SHBG 
may be involved in regulation of cell function (136). Consequently, a putative assumption is that the 
relationship between ENL and SHBG may have an important effect on regulation of cell function. 
ENL also affects multiple proteins involved in cancer proliferation. In vitro studies show that ENL 
promotes apoptosis by disruption of mitochondrial membrane potential that leads to release of 
cytochrome c into cytosol in the LNCap cell line (137). The inhibitory effect of ENL on the PC3 cell line can 
also be achieved via inhibition of insulin-like growth factor/insulin-like growth-1 receptor (IGF1/IGF-1R) 
signal pathway (138). LNCap and PC 3 are typical models that represent the androgen dependent and 
androgen independent situations in prostate cancer, respectively, that almost encompass all prostate 
cancer phenotypes. The inhibition effect of ENL on these two cell lines may suggest a use for ENL in cancer 
treatment. In previous work in my lab, we found ENL caused cell death possibly via inhibition of fatty acid 
synthase (FASN) expression, an enzyme highly regulated in prostate tumors during tumor progression and 
metastasis (139). 5α-Reductase is a cytosolic enzyme that converts testosterone to 5α-dihyrotestosterone, 
the most active androgen that can bind to androgen receptors and trigger the translocation of the 
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complex into nuclei (140). ENL can inhibit 5α-reductase and 17 β-hydroxysteroid dehydrogenase in benign 
prostatic hyperplasia tissue homogenates (141). 
Lignans have been found with anti-metastatic activity. Matrix metalloproteinases (MMPs) are 
responsible for cell invasion in cancer metastasis via degrading extracellular matrix. Differential 
expression of MMPs between normal and malignant breast cancer cells have been identified with 
upregulated expression of several types of MMPs (142). Mammalian lignans exert a potent inhibitory 
effect on cell adhesion and migration of MCF-7 and MDA MB-231 cells via MMP-9 (143). The mechanistic 
study shows that ENL in vitro significantly down-regulates the metastasis-related MMP2, MMP9 and 
MMP14 gene expressions (144). 
Lignans also interact with other enzymes involved in inflammation. Increasing evidence reveals that 
long-term inflammation may be associated with some chronic diseases including cancers (145). There is 
substantial evidence that chronic inflammation can precede solid cancer development including colon 
cancer (146). Heme oxygenase-1 (HO-1) mediates the antioxidant and anti-inflammatory actions in the 
vasculature via down-regulation of nuclear factor-κB (NF-κB) activation and decreased production of the 
pro-inflammatory cytokines interleukin (IL)-1β, IL-6, and tumor necrosis factor-α (TNF-α) (147). ENL, 
interestingly, shows an inducible effect on the expression of HO-1 which may be an indirect antioxidant 
effect contributing to the anti-cancer property (148). 
1.3.3.2 Prostate and Breast Cancer 
Prostate and breast cancer remains the leading cause of death in males and females in North 
America, respectively. Prostate cancer contributes up to 24.5% of the expected new cases in male, while 
breast cancer contributes up to 26.1% of the total new cases in females (149). Prognosis and overall 
survival of tumors vary greatly depending on cancer type, stage and treatment. Although targeted 
therapies have improved survival for advanced prostate and breast cancers, tumor relapse occurs due to 
multiple mechanisms (150). Prostate and breast cancer are both sex hormone driven cancers, and have 
similar biological characteristics, treatments and progressions (151). 
Two decades ago, a patient diagnosed with metastatic cancer meant that the cancer had spread to 
the whole body, like bone, soft tissue, brain, or liver, and the patient was considered terminal. In a 
prospective study, the 5-year survival of patients with metastatic breast cancer after diagnosis was only 
7%. In 2004, this number increased to 40% in females with recurrence or metastatic breast cancer (152). 
With advances in treatment options, it is possible to manage and control cancers like breast and prostate 
cancer from relapse or progression for a long time, and these treatments often involved similar 
management practices as those for diabetes mellitus. However, the age-adjusted mortality rate of all 
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cancers in all races only decreased by 13% over the past 35 years (153). The major factor that contributes 
to mortality is so-called treatment induced resistant metastatic cancers, which are usually related with 
non-specific systemic chemotherapy (154). Chemotherapy has made great progress in prolongation of 
overall survival and improvement in the quality of life of patients, but the issue of resistance remains an 
ongoing concern since its first use in cancer treatment. 
1.3.3.2.1 Prostate cancer 
1.3.3.2.1.1 Brief introduction to prostate cancer 
According to the American Cancer Society, prostate cancer is the most common cancer among men 
in the United States (155). In 2011, an estimated 240,000 new cases were expected to be diagnosed, and 
approximately 33,720 men were expected to die from the disease (156). Androgen plays a crucial role in 
initial tumor growth by stimulating proliferation and inhibiting apoptosis of prostate cancer cells (157). 
Based on the role of androgen in cancer growth, hormone deprivation either through surgery or medical 
castration was considered to be the gold standard treatment for decades with success in approximately 
70% of patients with primary prostate cancer (158). However, the response to androgen deprivation is 
not durable in patients with advanced prostate cancer, and with time, serum prostate specific antigen 
(PSA) concentration increases, indicating reactivated androgen-receptor signaling. Those prostate tumors 
that maintain a high rate of proliferation in the absence of androgen during progression are characterized 
as castration-resistant and are invariably fatal. These tumors usually exhibit high resistance to most of 
chemotherapeutic agents and have a poor prognosis (159). 
Castration Resistant Prostate Cancer (CRPC) is a late stage of prostate cancer, insensitive to 
androgen deprivation therapy. CRPC is more like a treatment-induced prostate cancer, when patients with 
prostate cancers are treated androgen deprivation therapy for one to three years. The cancer carries a 
poor prognosis with a survival time of 16–18 months on average from the beginning of progression (160). 
The mechanisms involving resistance are complicated. In attempts to gain insight into the underlying 
mechanisms, researchers found that CRPC has higher expression of androgen receptors (AR), which lead 
to enhanced activation of the receptor with low androgen levels (161) (Figure 1-3). Increased AR copy 
number is found in 25%-30% of patients with CRPC (162). Also, CRPC produces mutations on the androgen 
receptor gene, which increase the number of ligands that can activate the receptor and, following nuclear 
translocation, to initiate the proliferation of cancer cells (163). Moreover, higher androgen receptor levels 
can convert antagonists to agonists, such as with Bicalutamide, which showed typical antagonist activity 
in parental LAPC4 cells but functioned as an agonist in LAPC4 cells with overexpression of ARs (164). Many 
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AR-regulated proteins, like prostate specific antigen, continue to increase in CRPC, despite the low levels 
of serum testosterone by androgen ablation therapy (165). A high intratumoral androgen level via de novo 
steroidogenesis during progression may also contribute to the resistance, with enhanced expression of 
the enzyme involved in the synthesis of dihydrotestosterone from cholesterol (166). 
Many drugs that promise high antitumor activity in vitro and in animal models fail in the human 
clinical trial stage or are retrieved from the market because of unexpected severe side effects. Thus, we 
have a limited arsenal from which to choose appropriate chemotherapeutic drugs. In patients with CRPC, 
who failed the first line treatment, tumors usually produce cross-resistance to a whole range of drugs with 
different structures and mechanisms. Simply increasing the dosage regimen or use of multi-agent 
chemotherapy with current agents to achieve the equal therapeutic efficacy is related with more side 
effects. 
 
 
Figure 1-3. Androgen-axis in prostate cancer. During androgen-dependent progression, androgen binds 
to androgen receptors (AR) to activate the nuclear translocation process, thereby stimulating the genes 
involved in cell proliferation. In castration resistance prostate cancer (CRPC) progression, prostate cancer 
relies on various cellular pathways, including androgen receptor amplification, and mutation (140). 
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1.3.3.2.1.2 Prostate cancer and flaxseed lignans 
Both hereditary and environmental factors are involved in the risk of prostate cancer, within which 
the relationship between age, race and family history have been clearly identified (167). However, diet 
and lifestyle is considered as an important factor contributing to the incidence and mortality of prostate 
cancer (168). For example, traditional Asian food is rich in phytoestrogenic compounds and has 
demonstrated health benefits against prostate cancer (169). Studies in animal models of prostate cancer 
have demonstrated that feeding a rye-bran diet can decrease tumor development during the early stage 
of tumorogenesis (170, 171). In a transgenic adenocarcinoma of the mouse prostate (TRAMP) model, 
which can mimic the progression of human prostate cancer, 5% flaxseed supplement inhibited the growth 
and progression of prostate cancers, and after 30 weeks treatment, the tumors in the flaxseed group were 
less aggressive compared with the control group (172). As described above, the findings in the 
experiments with lignan-rich diet containing are in agreement with the putative significance of dietary 
lignans in prostate carcinogenesis (173). 
In human studies, the literature is scant and controversial. A presurgical trial of flaxseed 
supplementation (30 g/d) for 30 days resulted in a significant increase in the urinary concentrations of 
total ENL and ED. Importantly, urinary ENL was significantly and inversely correlated with Ki67 protein in 
tumor tissue, a protein marker associated with cell proliferation (174). In a Swedish study, high serum ENL 
concentrations were associated with decreased risk of prostate cancer, but the significance of serum ENL 
with localized or advanced prostate cancers were not persistent after adjustment for additional factors 
(73). Only ENL levels between 15.3 and 23.9 nM showed the strongest inverse association with prostate 
cancer risk. Another inverse association with increased serum concentrations of ENL and prostate cancer 
risk was reported from Scottish men (74). Reduced risk of prostate cancer was also found in men with 
higher intakes of total lignan precursors compared with men taking lower amounts of lignan precursors 
(175). Bylund et al. conducted a short-term pilot study on relationship between plasma ENL concentration 
and prostate tumor cell apoptosis and proliferation in men consuming lignan-rich rye bran bread (176). In 
this study, high dose intake of lignan-rich rye bran bread is suggested to increase tumor cell apoptosis in 
human, but there was no visible changes found in plasma levels of PSA after 7 week dietary intervention 
between groups (176). In two other studies, no significant association between plasma ENL and risk of 
prostate cancer were found (177, 178). 
As mentioned before, ENL can concentrate in prostate tissues (98). It would be better to study the 
association between prostate tissue ENL concentration and risk of prostate cancer. However, this would 
require invasive examination, which is ethically unacceptable in human subjects. Until now, the lowest 
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observable effect level for any lignan in prostate cancer is not known. Moreover, it is impossible to identify 
what amount is necessary to fulfill the requirement for positive health effects based on the available 
literature. For instance, the composition of flaxseed may vary considerably depending on differences in 
cultivation conditions and processing (48). Therefore, systematic investigating the role of dietary 
components in cancer is sometimes very difficult. 
1.3.3.2.2 Breast cancer 
1.3.3.2.2.1 Brief introduction to breast cancer 
Breast cancer is one of the most frequently diagnosed malignant tumors in females (179). Breast 
cancer can be classified into many types according to cellular receptor characteristics, such as estrogen 
receptor (ER), HER2, and progesterone receptor (PR). HER2, is a key protein in the regulation of cell growth 
and survival in breast cancer (180, 181). About 25-30% of breast cancers overexpress HER2/neu protein, 
which leads to a more aggressive form of the disease (182). A recent study showed that women with HER2 
positive breast cancer is less responsive to hormone therapy and chemotherapy, and have a higher 
likelihood of poor prognosis regardless of the type of treatment (183, 184). Triple-negative breast cancer 
(TNBC), which lacks expression of the ER, PR, and HER-2 represents approximately 15 % of all breast 
cancers (185). Patients with TNBC often are associated with increased risk of recurrence and poorer 
prognosis in the first few years after diagnosis. There are few target therapies or drugs that can greatly 
improve outcomes of women, and systemic multi-agent chemotherapy regimens do not effectively 
prolong overall survival. 
1.3.3.2.2.2 Breast cancer and flaxseed lignans 
With its estrogenic and antiestrogenic activity, the health benefits of flaxseed derived mammalian 
lignans are broadly studied in breast cancer. In cell culture experiments, ENL exhibits apparent anti-
proliferative effect against breast cancer cells in a dose-dependent manner (131). In rodent studies, ENL 
is associated with lowered risk of breast cancer following oral flaxseed or SDG-enriched complex 
supplementation as a source of lignan (186). Supplementation of 10% flaxseed in diet inhibits metastasis 
in ER-negative breast cancer xenograft nude mice, which is consistent with results observed from human 
clinical trials and in vitro studies (52, 187, 188). However, administration with SDG (0.2 g/Kg) in nude mice, 
which is equivalent to the 10% flaxseed, showed a slight increase in tumor growth in both xenograft 
studies. Interestingly, dietary flaxseed has been reported to enhance the anticancer effect of tamoxifen 
on the growth of human estrogen-dependent breast cancer in nude mice, which indicates the potential 
application of flaxseed lignan-rich complex as adjuvant therapy against cancers (189, 190). 
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Despite the reliable results from rodent studies, the effect of lignans on human health is more 
complicated and controversial. In postmenopausal women, consumption of flaxseed increases the 
excretion of ENL into urine in a dose-response manner (191). Urinary concentration of ENL in 
postmenopausal women with breast cancer is significantly lower than healthy women (192). A population-
based study reported that postmenopausal patients with breast cancer who have higher serum ENL levels 
may have better survival (193). The serum ENL level was significantly inversely associated with risk of 
breast cancer, in a case control study conducted in Eastern Finland after adjustment for all known risk 
factors for breast cancer. The inverse association between serum ENL and risk of breast cancer was seen 
both among premenopausal and postmenopausal women (194). The protection of serum ENL against 
breast cancer may differ according to estrogen receptor status. In a cohort study, similar results have been 
observed between the lowered risk for breast cancer with higher concentration of ENL, which could be 
restricted almost entirely to ERα-negative breast cancer (195). In contrast, no association between 
phytoestrogen consumption and breast cancer risk was found in a multiethnic study (196). No indication 
of a relationship between plasma ENL and subsequent breast cancer risk also is reported in two other 
studies (197, 198). In a nest case-control study, no effect of lignans on breast cancer risk were observed 
in pre- or perimenopausal women, and in postmenopausal women (197). No decreased likelihood of 
breast cancer with higher serum concentration of ENL was observed in a prospective cohort study (198). 
The conflicting results reported in human studies probably are due to low levels of lignan intake from the 
normal dietary sources as compared with restricted lignan-rich diets in rodent studies. 
1.3.4 Safety of flaxseed lignans 
Flaxseed has been consumed for centuries to meet the nutritional needs of various populations, 
and has served as an edible oil and an ingredient in wood products. Flaxseed is a promising functional 
food used in the food industry as it is rich in α-linolenic acid (ALA) and lignans (199). Flaxseed lignans have 
received attention for their chemo-protective properties against prostate and breast cancer in animals 
and humans. The safety of flaxseed lignans will be discussed here. 
Consumption of 10% dietary flaxseed by male and female rats for 8 weeks did not affect behavior 
and blood glucose levels or cause liver damage (200). Dosage of 40 mg/kg for 2 months in both normo- 
and hyper-cholesterolemic rabbits had no adverse effects on blood cell counts and platelets (201). In an 
8-week human intervention clinical study with intake of 600 mg SDG daily, no adverse side effects were 
reported related with to the consumption of lignans in hypercholesterolacemic patients (48). Dietary 
milled flaxseed (32 g) for up to 12 weeks had no effect on HbA1c or fasting glucose levels in patients with 
well-controlled T2DM (202). In a 6-week randomized, double-blind study, no significant differences in 
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endothelial functions were found in healthy postmenopausal women with 500 mg/d SDG (203). In 
addition, flaxseed-derived lignan capsule (360 mg) has been well tolerated in patients with no differences 
observed between treatment and control groups (204). No reports on hypoglycaemia or hypotension in 
healthy senior participants after 6-month treatment on flaxseed lignans suggest that uptake of flaxseed 
lignans 543 mg per day is safe (47). In previous studies in my laboratory, no clinically significant changes 
in behaviour and haematology were found in female Wistar rats consuming with 3 mg/kg SDG for 4 weeks 
(205). 
Earlier preclinical studies suggest a possible safety concern with supplementation of 40% flaxseed 
lignan in the diet of pregnant rats where effects on gestation and postnatal maturation was observed 
(206). Administration of 5% and 10% of flaxseed orally in rats resulted in dose-dependent hormone related 
effects, especially low birth weight pups at 10% flaxseed group (51). The effects may be induced by lignans, 
as reduction of 17β-estradiol and estrone sulphate and an increase in prolactin levels have been observed 
in post-menopausal women (207). A daily supplement up to 200 mg/kg SDG (equivalent to 10% flaxseed 
diet) up to 4 weeks did not significantly change body weight or organ weight in mice during the 
experimental period (208). New studies support the evidence that long-term supplement (8-week) with 
flaxseed seems to lower rate of weight gain in healthy male and female juvenile and young adult rats (200). 
Supplementation with flaxseed lignans caused increased concentrations of mammalian lignans ENL in 
breast milk possibly suggesting that women who are pregnant or lactating should refrain from high 
flaxseed lignan supplementation (101). Beside additional supplementation of flaxseed lignans, dietary 
flaxseed lignans seems no effect on pregnancy. No difference on birth weight and body weight were found 
to be related with prenatal ENL exposure in women (209). 
In conclusion, most of the interventional studies suggest that flaxseed lignans are safe during long-
term daily use, but more investigations are needed to adequately determine their safety in pregnancy and 
lactation. 
1.4 Targeted Therapy 
Cancer treatments include surgery, chemotherapy, radiation therapy, targeted therapy and others 
(66), but systemic chemotherapy is the most common treatment used in cancer therapy especially in 
advanced metastatic cancers. Lack of therapeutic specificity remains a significant problem that has been 
plagued scientists for many years. New chemotherapeutic agents may have sufficient activity to 
completely destroy the tumor, but severe side effects often offset the benefit gained from the treatment 
and in some cases has led to the withdrawal of the drug from market (210). This side effect is usually due 
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to accumulation of drug at non tumor sites, which precludes the use of promising therapeutics in the clinic. 
Despite extensive research into the development of selective cytotoxic agents, selectivity usually comes 
at the expense of reducing cancer cell eradication and therapeutic effectiveness. 
Recent years has witnessed enhanced understanding of cellular pathway between tumor and 
normal cells. This knowledge has been used to generate tumor specific therapies by directly targeting 
genes or proteins involved in tumor development and progression. This technique is known as targeted 
therapy and is divided into direct or indirect approaches. Direct approaches target tumor associated 
proteins or molecules to arrest the cell cycle or to alter downstream signalling pathways involved in cell 
proliferation (211). Indirect approaches utilize tumor cell surface expressed proteins that serve as a target 
guiding the distribution of fusion proteins to the desired tumor sites. The approach usually is achieved by 
conjugation of an effective molecule to carrier (212). 
1.4.1 Antibody-directed targeted therapy 
Antibody-directed targeted therapy, also called immunoconjugate therapy, is a form of 
immunotherapy that selectively delivers toxic agents to the tumor by using tumor specific monoclonal 
antibodies as carriers (213). Immunoconjugates are now becoming a significant component of anticancer 
treatments as they can target cancer cells with more precision and potentially lower side effects. 
Immunoconjugates are comprised of three parts: an antibody specifically targeting a tumor expressed 
antigen, an effector molecule mediating direct or indirect effects against tumor, and a linker that couples 
the antibody and effector molecule together. Depending on the effector molecule attached to the 
antibody, immunoconjugates can be divided into many types, including antibody drug conjugate 
(chemotherapeutic agents), radioimmunotoxin (radionuclide), immunotoxin (protein toxin), 
immunocytokines (cytokines), and antibody-enzyme conjugate (enzymes) (214). 
The type of linker chosen depends on the purpose of the immunoconjugate, which can be flexible 
or cleavable. Stability of the linker in the systemic circulation is very important because it affects the 
efficiency of delivery of the effector molecules to the target sites (215). Protease-cleavable linkers are 
generally more stable in the circulation than disulfides and hydrazones (216). Use of a cleavable linker is 
preferred for antibody-drug conjugates as release of drug from the conjugate into cytosol is needed to 
cause the toxicity after the conjugate targets the tumor antigen and is subsequently internalized into the 
intracellular environment (217). Flexible linkers are more often applied as an antibody-enzyme conjugate 
as these can provide space for accurate protein folding, which is necessary to ensure maintenance of 
protein function (218). 
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1.4.1.1 Antibody-drug conjugates (ADC, Immunoconjugate) 
Cytotoxic agents, like docetaxel and doxorubicin, are usually nonspecific. These drugs exert their 
chemotherapeutic effect by preventing rapid growth and division of cancer cells; however, rapidly dividing 
cells that also exist in normal tissue are more sensitive to cytotoxic drugs including the hair follicle, 
gastrointestinal epithelia, and bone marrow (219, 220). Consequently, the specific delivery of drug to the 
tumor site and to create relatively high concentrations of drug within the tumor area, would minimize the 
toxicity of the drug to nonspecific tissues. This can be achieved by the combination of antibody fragments 
with a toxic agent, called an antibody-drug conjugate (221). The release of drug to the intracellular 
environment depends on receptor-mediated internalization, as this requirement ensures that the 
conjugate results in selectivity, higher efficacy, and lower resistance (222). A study in which doxorubicin 
was chemically coupled with a mAb against insulin-like growth factor found that the conjugate is not a 
substrate for the multidrug resistant associated P-glycoprotein efflux pump and can bypass multiple drug 
resistance in vivo (223). 
1.4.1.2 Directed enzyme prodrug therapy (DEPT) 
The difference of DEPT from direct targeting therapies is to control the possible toxicity caused by 
pharmacologically active drugs during the process of absorption and distribution to the tumor sites. In 
this approach, a drug-activating enzyme is localized to tumors by an antibody, virus or bacteria. At the 
tumor site, the localized enzyme then converts a nontoxic or lower toxicity prodrug into a cytotoxic drug, 
which results in a high local concentration of drugs with a reduced risk for systemic cytotoxicity (224). This 
target system exploits different carriers and includes gene/virus-directed enzyme prodrug therapy 
(G/VDEPT), bacteria-directed enzyme prodrug therapy (BDEPT), polymer-directed enzyme prodrug 
therapy (PDEPT), and antibody-directed enzyme prodrug therapy (ADEPT). 
Gene/virus-directed enzyme prodrug therapy (G/VDEPT) delivers a suicide gene coding prodrug-
converting enzyme to the tumor, and its expression results in the formation of cytotoxic metabolites 
against cancer cells (225). In G/VDEPT approach retroviral replication-defection vector are the common 
choice for delivery of the suicide gene to the tumor area. A bystander effect is an important feature of the 
G/VDEPT approach, by which the enzyme or activated drug could diffuse to surrounding non-transduced 
cancer cells and thereby mediate their destruction (226). The bystander effect could be mediated by cell 
necrosis and the extent of bystander effect was related to transfection rate (227). The immune system 
could also trigger the bystander effect, when the suicide gene expressing cells release tumor antigens that 
could stimulate the immune system to kill tumor cells that do not express the drug-activating enzyme 
(228). As a result of the bystander effect, eradication of the entire tumor is possible even when that gene 
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product is expressed in less than 25% of tumor cells (229). The bystander effect is integral to all 
enzyme/prodrug therapies and is a key point that determines the efficacy of those approaches. The major 
concern related with G/VDEPT is the possibility of introducing foreign genes as well as productive virus 
into the human body which might incorporate into the human genome. 
Bacteria-directed enzyme prodrug therapy (BDEPT) uses anaerobic bacteria found naturally to 
introduce the enzyme to the tumor (230). The enzyme will then express in the tumor with amplification 
of bacteria in the hypoxic zones of the tumor (231). The hypoxic condition makes the environment favor 
anaerobic bacterial survival and growth (232). This property also allows for penetration of the drug to the 
center area of tumors which is usually inaccessible by systemic chemotherapy. As the bacteria remains 
sparse at oxygenated areas, this restrains the localization of bacteria within the tumor area. Clostridia and 
Salmonellae bacteria coding for cytosine deaminase that could convert 5-fluorocytosin into 5-fluorouracil 
have been successfully applied in BDEPT and tested for safety in cancer patients (233). In addition to 
cytosine deaminase/5-fluorocytosin, several well-established enzyme/prodrug systems exist, such as 
P450s/cyclophosphamide/ifosfamide and nitroreductase/5-(Aziridin-1-yl)-2,4-dinitrobenzamide (234). 
Cytochrome P450 (P450) enzymes are the most important human drug-metabolizing enzymes and are 
responsible for the oxidation of endogenous and exogenous substrates. CYP2B1 could metabolize the 
prodrug cyclophosphamide and ifosfamide into the toxic agents, phosphoramide mustard and acrolein, 
and this strategy has demonstrated a considerable reduction in effective dosage (235). 
Polymer-directed enzyme prodrug therapy (PDEPT) uses polymers for the delivery of drugs and 
enzymes. In PDEPT, the enhanced permeability and retention effect (EPR) of the macromolecule allows 
for accumulation of polymeric prodrug and polymer-enzyme conjugate in tumor tissues rather than 
normal tissues. The polymeric prodrug is subsequently activated at the tumor site by the polymer-enzyme 
conjugate via removal of the polymer group from the prodrug (224, 236, 237). Typical polymers utilized 
in drug delivery include N-(2-hydroxypropyl) methacrylamide (HPMA) and poly (lactide-co-glycolide) (238, 
239). Two pairs of enzyme/prodrug combinations, HPMA copolymer-cathepsin B and HPMA-co-MA-GFLG-
doxorubicin, HPMA copolymer-β-lactamase and HPMA Copolymer-C-Dox, have been tested separately for 
in vivo selectivity and efficiency (240, 241). 
1.4.2 Antibody-directed enzyme prodrug therapy (ADEPT) 
ADEPT is a combination of the above therapies in that it uses an antibody as carrier which is 
conjugated to a prodrug converting enzyme instead of an effector molecule. It is well known that solid 
tumor tissue is a mix of highly heterogeneous cells (242, 243). Unlike ADC, which is designed to 
predominantly kill tumor cells that express the specific antigen, ADEPT is designed to expand the anti-
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cancer effect towards surrounding cells not expressing the respective ligand via the bystander effect 
which is the major driver for DEPT approach. 
ADEPT was first proposed in the mid-1980s and seeks to overcome the problems of lack of tumor 
selectivity as well as reduction of the side effects of chemotherapeutic drugs. ADEPT acts by binding an 
antibody-enzyme conjugate to the cancer cell membrane for preferential activation of nontoxic anticancer 
prodrugs to highly cytotoxic drugs specifically within tumor sites. In this approach, a drug-activating 
enzyme is targeted to the tumors by a tumor-targeting antibody. At the tumor sites, the localized enzyme 
then converts a nontoxic or lower toxicity prodrug into a cytotoxic drug, which results in a high local 
concentration of drug and thereby lowers the risk for systemic cytotoxicity (244, 245) (Figure 1-4). 
Importantly, the drug is not covalently bound to the immunoconjugate. A small molecule cytotoxic agent 
will be free to diffuse within the tumor, even those areas that cannot be accessed by the enzyme 
conjugate (246). Tumor cells are highly heterogeneous as a consequence of genetic change and 
environmental differences, and therefore, are difficult to target completely (243). The bystander effect 
will allow for targeting of the entire tumor via death antigens released from dying cells or by diffusion of 
small activated drugs throughout the tumor tissue. 
In ADEPT, there are two ways to engineer an antibody to the enzyme. Chemical coupling involves 
the use of chemical ligation and enzyme based strategies to attach an antibody to an enzyme, which allows 
for native expression of the individual proteins and folding in the optimum tertiary structure (247). 
Despite the preserved activity of both antibody and enzymes, chemical coupling faces technical challenges 
in establishing optimized reaction conditions as well as low efficiency in production (248). With the 
discovery of flexible linkers and improvement in molecular technology, the second method, genetic fusion, 
is predominantly used for chimera protein production. 
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Figure 1-4. Principle of Antibody-Directed Enzyme Prodrug Therapy (ADEPT). ADEPT is a two-step process. 
A nontoxic or lower toxicity prodrug is administrated orally or by injection. The drug-activating enzyme is 
delivered to the surface of tumor cells by the tumor-targeting antibody. At the tumor sites, the localized 
enzyme converts a prodrug into a cytotoxic drug, which results in a high local concentration of drug and 
lowering of systemic cytotoxicity. In this example, the prodrug is represented by ENL-Gluc and the active 
drug by ENL. 
1.4.2.1 Clinical trials using Antibody Conjugates 
Development of novel antibody drug conjugates (ADC) for solid tumors and metastases has 
revealed new interest in the recent years with improved localized efficacy of active drug and limited 
systemic toxicity. Besides brentuximab vedotin and ado-trastuzumab emtansine (T-DM1), more than 40 
ADC are currently under investigation in clinical trials for use as potential therapeutics against multiple 
cancers (221, 249). Brentuximab vedotin is composed of a conjugate of anti-CD30 antibody and the potent 
antimicrotubule drug monomethylauristatin E (MMAE) connected by a protease-cleavable linker which 
allows for the release of free MMAE in the cytosol after uptake by targeted cells (250, 251). An open-label 
phase II trial of brentuximab vedotin in refractory Hodgkin’s lymphoma reported an overall response rate 
(ORR) of 75% with a 7.8 month disease free rate in the patients receiving treatment compared to 4.1 
months in patients using previous therapy (252). It should be noted that issues of toxicity remain. 
Peripheral neuropathy is a common adverse side effect observed in a class of antimicrotubule agents, 
which is also the major side effect of brentuximab vedotin. However, three cases reported that 
ENL Gluc
Gluc
Antibody-Enzyme conjugate ENL
Cancer Cell
PSMA
D7-hβG 
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brentuximab vedotin may cause a rare disease called progressive multifocal leukoencephalopathy, that 
required the FDA to issue a black box warning one year after approval in 2012 (253). 
T-DM1 is an ADC composed of trastuzumab and DM1 which is proposed to function through 
trastuzumab targeting and inhibition of HER2 positive cell growth and DM1 binding to tubulin and thereby 
disrupting cell division (254). T-DM1 was well tolerated in patients with HER2-positive metastatic breast 
cancer with mild reversible toxicity, with maximum tolerated dose (MTD) at 2.4 mg/kg weekly 
administration and at 3.6 mg/kg every 3 weeks (255, 256). Additional information on efficacy and safety 
was demonstrated by single-arm phase II trials which confirmed the single agent activity of T-DM1 (257). 
Patients with HER2-positive metastatic breast cancer receiving T-DM1 was associated with increased 
progression-free survival (PFS) from 9.2 months to 14.2 months compared with patients who received 
trastuzumab plus docetaxel, although overall survival (OS) was similar between treatment groups (258). 
A large scale phase III EMILIA study demonstrated that T-DM1 has improved efficacy and tolerability 
versus the standard of care treatment with increased PFS of 9.2 versus 6.4 months, and OS of 30.9 versus 
25.1 months, that was compatible with primary EMILIA results (259, 260). Based on supportive data from 
this phase III trial, T-DM1 was approved by the FDA in 2013 (261). Interestingly, a new phase II study is 
under way to study whether the addition of docetaxel plus T-DM1 would improve the efficacy of the ADC 
only (262). Although the ADC showed significant improvement in clinical outcomes, side effects occurred 
more frequently in all patients receiving T-DM1 with a longer treatment duration as well (261). 
Gemtuzumab ozogamicin was used for treatment of acute myeloid leukemia which was first 
commercially available in 2010 (263). The ADC was withdrawn from market in 2010 because a significant 
increase in death was reported in patients receiving the treatment during a post approval phase III clinical 
trial (264). The accelerated approval process of gemtuzumab ozogamicin by FDA was accelerated without 
a comprehensive review conducted at that time, which also accounts for the unexpected side effect. Along 
with the approval of other ADCs, the possibility of resurrection of gentuzumab ozogamicin was discussed 
based on the outcomes from several phase III clinical trials (265, 266). 
Besides approved ADCs, most of the ADCs in late clinical trials target leukemia or lymphomas, as 
antigens in these cancers  are expressed homogeneously in most cancer cells and tumors are more 
accessible to antibodies (267). The approval of T-DM1 demonstrates the utility of ADCs in solid tumors 
and their metastases. PSMA is highly expressed in prostate cancer with restricted detection in normal 
tissues, suggesting that PSMA is a potential target (268). Anti-PSMA-vcMMAE (PSMA ADC) is designed to 
conjugate a fully humanized anti-PSMA mAb to MMAE via a cleavable linker (269, 270). PSMA ADC was 
tolerated at a dose of up to 2.0 mg/kg and 2.8 mg/kg in two phase I trials in patients with pre-treated 
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prostate cancer (271, 272). The antitumor activity was reflected by the decline of serum PSMA and 
reduction of bone pain caused by cancer (271, 272). The maximum tolerated dose of PSMA ADC was 
determined at 2.5 mg/kg after completing a dose escalation (273). The safety and tolerability was further 
investigated in two phase II trials (274, 275). 
There is limited clinical trial information using DEPT. Several phase I/II clinical trials were conducted 
in patients with localized prostate cancer using a virus expression bacterial nitroreductase in conjunction 
with prodrug CB1954 via direct intraprostatic injection (276, 277). Both virus and prodrug were well 
tolerated and all treatment related side effects were transient without additional treatment. In another 
phase I study using the same VDEPT in liver cancer, safety and antitumor activity were observed (278). In 
this GDEPT system, the immunoresponse against bacterial nitroreductase was a major drawback (279). At 
this time, G/VEDPT therapeutics require intratumoral injection, which is not practical in tumor metastases. 
Limited clinical data exists for antibody directed therapy in which a drug activating enzyme was 
introduced to the antibody instead of a direct effector. To date, both antibodies and enzymes of non-
human origin have been used in ADEPT. A fusion protein was developed against colorectal cancer by 
conjugating a bacterial carboxypeptidase to mouse anti-carcinoembryonic antigen (CEA). The clinical trial 
was restricted to Phase I due to toxicity from the activated drug and additional administration of a clearing 
antibody to accelerate the plasma clearance of fusion protein (280). A modified phase I/II trial using a 
different prodrug was conducted in which no tumour responses were detected due to the very short half-
life of the activated drug (281). Four years later, a MFECP1 Phase I trial was carried out using a scFv 
antibody. In this Phase I trial, both fusion construct and activated drug were deemed to be safe and well 
tolerated in patients with advanced colorectal cancer (282). 
Although more antibody drug conjugates are under preclinical or clinical investigation, the severe 
side effects caused by ADC cannot be ignored. The toxicity of ADC has led to black box warnings or 
withdrawal from the market. V/GEDPT restricts the distribution of active drug in the tumor area, but this 
system suffers from gene expression problems, which may not always be stable. ADEPT, is a combination 
of ADC and V/GEPT, in which antibody would promise tumor selectivity and the prodrug could minimize 
the availability of active drug in the systemic circulation.  The development of technology to generate 
humanized antibody could alleviate the immunoresponse, while the bystander effect mediated by active 
drug at the tumor site may achieve improved tumor regression. 
32 
 
1.4.2.2 Prostate specific membrane antigen (PSMA) 
Prostate specific membrane antigen (PSMA) is a 100-kDa type II transmembrane glycoprotein that 
has been clinically well validated as a marker for prostate cancer. The PSMA protein contains a short 
intracellular domain (amino acids 1-18), a transmembrane domain (amino acids 19-43), and a large 
extracellular domain (amino acids 44-570; Figure 1-5) (283). The cellular localization of PSMA is at the 
membrane of prostatic epithelial cells. PSMA is expressed abundantly in prostate adenocarcinoma relative 
to benign prostate and other normal tissues. The high expression also indicates the grade of prostate 
cancers. Almost 94.1% of prostate cancer specimens have been found with positive PSMA staining, by 
which stronger PSMA staining was significantly associated with later tumor stage, a high Gleason grade 
(284). Further studies found that patients with overexpressed PSMA either with primary or metastases 
had earlier PSA recurrence (284-286). 
PSMA is also widely expressed on the tumor neovasculature of non-prostatic tumors with high 
expression indicating poor prognosis. Willian et al reviewed PSMA expression in multiple types of cancers 
(287). Contrary to prostate cancer, PSMA is mainly expressed in the neovasculature that supply the tumors. 
In breast cancer, PSMA expression is restricted in tumor-associated vasculature with stronger staining 
detected in metastatic or invasive tumor specimens. The strength of expression support the linkage 
between PSMA and poor prognosis as brain metastases had a lower overall survival compared with 
primary carcinomas (288). Reverse linkage between high level of tumor-associated neovasculature PSMA 
and reduced survival in squamous cell carcinoma of the oral cavity also suggest the significant prognostic 
role of PSMA in malignant tumors (289). 
PSMA expression can be detected in a limited number of normal tissues with the most consistent 
sites including brain, small intestine, proximal renal tubules, and salivary glands (290, 291). The expression 
in normal tissues is very low, at least 100-1000 fold less than carcinomatous tissues, which is primarily 
located in cytoplasm in normal prostate tissue (268, 291, 292). Moreover, PSMA expression is below the 
detection limits in most human tissues, which make it an attractive target for diagnostic and therapeutic 
purposes. With extrapolation of animal experimental data to human, species differences should be taken 
into consideration. For example, PSMA is not expressed in small intestine or normal prostate tissues in 
rodents (293, 294). 
PSMA is also known as glutamate carboxypeptidase II (GCPII) and exhibits both folate hydrolase and 
N-acetyl-α-linked acidic dipeptidase enzyme activity. PSMA, is a zinc metalloenzyme that catalyzes the 
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hydrolysis of neurotransmitter N-acetyl-L-aspartyl-L-glutamate (NAAG) to N-acetyl-L-aspartate and L-
glutamate in the central nervous system (295). Both NAAG and L-glutamate are neurotransmitters 
mediating memory, learning, and other brain physiological functions (296, 297). 
PSMA protein in the brush border surface of the small intestine facilitates the removal of glutamate 
residues from folylpoly-γ-glutamates to form folates allowing for subsequent folate uptake (298, 299). 
Genetic variation of PSMA may be associated with impaired intestinal absorption of dietary folates, 
resulting in low blood folate levels and consequent hyperhomocysteinemia (300). The specific biochemical 
function of PSMA in prostate tissue is unclear except that the cytoplasmic tail MXXXL is involved in the 
internalization of PSMA (301). 
PSMA expression is highly upregulated in prostate cancers, especially higher-grade cancers, 
metastatic disease, and castration-resistant prostate cancer (302). Researchers once believed that PSMA 
levels could be upregulated after androgen deprivation therapy leading to a more aggressive prostate 
cancer disease state (303). In contrast to the current understanding of PSMA in prostate cancer 
progression, new evidence suggests that long-term androgen-deprivation may induce time-dependent 
down-regulation of PSMA levels (304). 
 
Figure 1-5. Schematic diagram of prostate specific membrane antigen (PSMA). PSMA contains a small N-
terminal cytoplasmic domain (CD), a hydrophobic transmembrane domain (TM), and a large extracellular 
domain (ED) (283). Tac-MWNLL at the N-terminal of PSMA induces PSMA internalization with or without 
antibody binding (301). The internalization rate of PSMA reaches 60% at 1 hour, and stays constant at 30 
hours (270, 305). Reactivity of both cytoplasmic and membrane PSMA can be detected by 
immunofluorescence assay when co-incubation cells with J591 (306). This property can prevent 
cytoplasmic detoxification of enterolactone (ENL) to ensure continuous cytotoxicity to cancer cells. 
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1.4.2.2.1 Antibody against PSMA 
The differential expression of PSMA in normal and prostate cancer cell membranes make it a 
promising target for site-specific therapy. PSMA was first characterized by the murine monoclonal 
antibody (mAb) 7E11-C 5.3, which recognizes and binds a PSMA intracellular or cytoplasmic epitope (307). 
ProstaScint, 7E11-C5.3 antibody labeled with indium-111, was the first anti-PSMA antibody approved by 
the FDA for diagnostic imaging in prostate cancer patients (308). However, 7E11-C5.3 only targets the 
cytoplasmic domain of PSMA, thus cannot bind to variable cells. In subsequent years, great efforts were 
made to develop mAb against PSMA. A number of anti-PSMA antibodies have been evaluated. Liu et al 
developed four mAbs, J591, J533, E99 and J415, against the extracellular domain of PSMA (306). J591 
showed improved activity over 7E11-C5.3 and has been taken forward for a number of clinical trials with 
different radionuclides. Phase I clinical trials with 177Lu-J591 or 90Y-J591 showed high specificity in targeting 
bone and soft tissue metastases of prostate cancer without obvious immune responses (309, 310). A 
phase II trial of 177Lu-J591 against castration-resistant prostate cancer was well tolerated by patients and 
showed a reasonable decline in PSA serum levels, which moved 177Lu-J591 closer to FDA approval (311). 
177Lu-J591 is currently under another clinical trial to assess the response of neovasculature against the 
agent in patients with non-prostate metastatic solid tumors (312). 
The large size of J591, though, will affect tumor penetration of a fusion protein when considering 
the additional attachment of the antibody with an effective protein. Also the murine derived antibody has 
the potential of causing an immune-response. To achieve a faster blood clearance and better penetration 
of antibody into the tumor tissue, smaller antibody fragments are considered more ideal candidates. scFv 
(Figure 1-6), consisting of the variable VH and VL chains, offers the advantage of being approximately 
three-fold smaller than intact IgG with a greatly reduced potential for immunogenicity due to its lack of 
an Fc portion. A J591 scFv was derived from J591 mAb and tested for binding specificity against LNCap 
cells, which interestingly showed lower internalization than J591mAb (313). Elsasser-Beile et al raised two 
anti-PSMA scFv A5 from 3/A12 and D7 from 3/F11, and both showed an excellent and high affinity to 
PSMA expressed in cells (314). Additionally, an immonotoxin, Pseudomonasexotoxin A (PE40), was ligated 
to the C- terminal of D7, causing high cytotoxicity against prostate cancer cells in vitro and significant 
inhibition of tumor growth in vivo with very moderate impact on the effect of binding affinity of D7 against 
PSMA (315). All the above evidence highly supports the role of PSMA as a marker for prostate cancer. 
Anti-PSMA has been well developed using molecular cloning and hybridoma technology in which scFv D7 
could potentially be a carrier candidate for the ADEPT approach. 
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Figure 1-6. Typical scFv format. A variable heavy chain (VH) and a variable light chain (VL) are connected 
by a (GGGGS)3 (curve with arrow) flexible linker. (GGGGS)3 is a 15 amino acid sequence containing 
glycerine and serine. 
1.4.2.3 Human β-glucuronidase (hβG) 
With ADEPT, the choice of the right enzyme that can convert a prodrug into an active molecule is 
critical to ensure successful clinical utility. Selection of the enzyme in ADEPT mainly depends on the 
property of the prodrug. The enzymes that have been used for ADEPT can be divided into three classes 
according to their origin: class I (enzymes of non-mammalian origin with no mammalian homologues), 
class II (enzymes of non-mammalian origin with a mammalian homologue) and class III (enzymes of 
mammalian origin) (316). The initial rationale to use class I enzymes in ADEPT is to design a stable and 
nontoxic prodrug that is not a substrate for endogenous enzymes. However, these enzymes can cause a 
severe immune response in humans. In contrast to class I enzymes, class III has minimal immunogenic 
effect. Alkaline phosphatase, carboxypeptidase A, and β-glucuronidase (βG) are the most extensively used 
class III enzymes in ADEPT (317). Based on the pharmacokinetic information from flaxseed lignans, ENL 
exists in systemic circulation mainly as its phase II glucuronic conjugate ENL-Gluc which concentrates in 
prostate tissues. As we are focusing on the activation ENL from ENL-Gluc, which is a substrate for βG, hβG 
is the priority consideration to exploit the usage of flaxseed lignans facilitating cancer therapy (318). It has 
been shown that expression of βG on the surface of bacteria can enhance activation of prodrugs (319). 
So, delivery of βG to the cancer cell membrane via a specific carrier could take advantage of the conversion 
of the ‘prodrug’ ENL-Gluc, to the ‘cytotoxic drug’, ENL. 
βG (EC 3.2.1.31) is a tetrameric glycoprotein composed of identical subunits (75 kD) (320). Human 
βG largely sequesters in lysosomes, and catalyzes hydrolysis of β-D-glucuronic acid residues from the non-
reducing end of mucopolysaccharides (321). Human βG (hβG) usually has highest activity at pH 4, and only 
2% of the enzyme retains activity at neutral pH (322). Thus, the activity of βG is very low in serum and 
extracellular areas of normal tissue. This is an advantage in the employment of βG in the ADEPT approach 
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(323, 324). The hypoxic microenvironment in tumors results in anaerobic metabolism and production of 
lactic acid in the tumor where the pH may be much more lower than normal tissue and blood (325, 326). 
In healthy humans, the minor amount of serum βG activity is related to diet, age and ethnic group. 
Higher βG activity is significantly associated with gender (male), age (≥30 years), race, overweight (≥25 
kg/m2), while intake of calcium, iron, and magnesium are related with lower βG activity (327). The 
endogenous activity of βG can be elevated in the tumor site and other tissues under some circumstances 
(328). Elevated activity of βG in tumor tissues primarily comes from invading monocytes and granulocytes 
into the necrotic area and may be associated with tumor invasion and metastasis (329). Therefore, the 
more aggressive forms of cancers are likely to be the best targets for ADEPT. High intake of defatted 
flaxseed is also positively correlated with βG activity in human, which is another advantage of using ADEPT 
in combination with oral administration of flaxseed lignan-enriched products, that may help to increase 
prodrug cleavage ability in tumors (330). Moreover, experiments involving transformed bacteria 
expressing βG on the cell surface found enhanced activation of glucuronide prodrugs (319). Such 
experiments support the application of βG in ADEPT for activation of lignan prodrugs. 
1.4.3 Advantage of ADEPT 
Use of oral flaxseed administration with ADEPT has several advantages as a therapeutic approach 
against prostate cancer. First, selective activation of prodrug in the tumor area will result in relatively high 
concentrations of the active drug at target tissues including metastases. For the flaxseed lignans, leakage 
of ENL into the systemic circulation should not be able to cause severe side effect as ENL demonstrates 
limited cytotoxicity as a single agent (331). ENL inhibits growth of MCF-7 cells at >10 µM, concentrations 
much higher than the physiological levels of ENL in the plasma (usually fluctuating around nanomolar 
levels) following oral consumption of flaxseed products (332). 
Second, ENL glucuronide circulating in the system is a detoxification metabolite of ENL and does 
not display inherent pharmacological activity. The modified clinical phase I trial using flaxseed lignan 
enriched products has been shown to be safe following oral administration twice daily (333). Large daily 
doses of flaxseed lignans would provide abundant amounts of circulating ENL-Gluc accessible to the tumor 
sites with specific activation of ENL-Gluc to ENL at the tumor. SECO, a major flaxseed lignan with most of 
it converted into ENL, has been found to inhibit cell proliferation (334). A small amount of SECO could also 
been detected in plasma, which provides an additional source of glucuronic conjugate. 
Third, glucuronic acid conjugation is an important detoxification mechanism of xenobiotics. Many 
chemotherapeutic agents are deactivated via glucuronidation, which is an important factor contributing 
to reductions in effective drug concentrations at tumor sites. Conjugated βG could reactivate the drug 
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through cleavage of the glucuronic acid group within the tumor area. This activity may decrease the 
required drug dosage needed to achieve the pharmacodynamic concentration of drug at the tumor site 
with concomitant reductions in risk for serious side effects. 
The difference in expression levels and cellular locations makes PSMA antigen a novel marker for 
imaging and targeting (268). Also the universal expression of PSMA in the neovasculature area indicates 
the potential utility of PSMA against a wide range of solid tumors. Anti PSMA antibody has a long history 
in diagnostic imaging in prostate cancer patients before rising interest in its therapeutic role (308). PSMA 
ADC is a fully human anti-PSMA mAb currently under phase II clinical trials. With the development 
technology in antibody, newly developed scFv D7, derived from 3F/11 shows excellent affinity to PSMA 
expressing cells and lower propensity for the development of an immunoresponse which could allow for 
a further decreasing in immonoresponse (314). 
Fifth, the bystander effect is also an important factor that influences the consideration of using 
ADEPT. The activated drug should have diffusible properties to cross cell membranes and tight junctions 
between cells to achieve a reasonable bystander effect, thereby reducing the risk of tumors evading 
therapy by antigen loss. ENL, the active from of ENL-Gluc, has been found to permeate well across the cell 
membrane (87). Antibody-enzyme as a fusion protein structure can be totally cleared from the body. scFv 
D7 causes a minimal immunoresponse and βG is mammalian in origin. G/VDEPT and BDEPT, as examples, 
still receive significant criticism due to a need to introduce virus or bacteria into the human body. 
Finally, ADEPT has also been used with other prodrugs against prostate cancer. Many drugs could 
be made synthesized as glucuronic acid conjugates making their oral or intravenous administration safe. 
Following systemic availability, the glucuronide group will undergo cleavage primarily at the tumor sites 
where the antibody-βG fusion protein is located. Activated drug could be ideally confined to the tumor 
target, therefore reducing toxicity compared to systemic administration of cytotoxic chemotherapy. 
1.5 Rationale 
Recent improvements in therapeutic management strategies have allowed for longer-term 
management and improved quality of life for patients suffering from metastatic cancers like breast and 
prostate cancer. However, severe side effects and multidrug resistance accompanying systemic 
chemotherapy restrict the utility of a number of anticancer drugs in the clinic. To increase productivity 
and efficacy of chemotherapeutic agents, drug discovery is moving towards a multiple target paradigm. 
Such a paradigm results in an increased interest in natural product extracts or derived compounds as 
these usually exhibit multiple mechanisms. Sufficient evidence demonstrate that flaxseed lignans are 
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associated with lower risk of breast and prostate cancer following oral supplementation. ENL is suggested 
to be the putative bioactive compound that mediates the health benefits by multiple mechanisms, but 
exists in the systemic circulation primarily as its phase II metabolite, ENL-Gluc. Therefore, this thesis 
research is to evaluate the combination effect of ENL with existing chemotherapeutics against breast and 
prostate cancers in vitro. Based on the preliminary outcomes in this study, an antibody-directed enzyme 
prodrug therapy (ADEPT) proof-of-concept study will be employed to offer a novel strategy to produce 
high levels of cytotoxic ENL within the tumor area with significantly reduced non-specific activation in 
other tissues and organs of the body. 
This project is designed to exploit the anti-cancer utility of flaxseed lignans via an understanding of 
the pharmacokinetic profile of flaxseed lignans in the mammalian system. ADEPT is developed to support 
the use of flaxseed lignans as anticancer products, since standardized flaxseed products are natural 
products with possible access on the market. 
1.6 Research Hypothesis and Objectives 
The general aim of my PhD research is to provide experimental support for the use of flaxseed 
lignans as adjuvant therapy against human breast and prostate cancer. Figure 1-7 highlights the major 
points of this project which is based on the pharmacokinetic profile of flaxseed lignans following oral 
consumption. The flaxseed lignans exist in the systemic circulation (Figure 1-7, A) both as glucuronide and 
sulfate conjugates, this thesis will only focus on the flaxseed lignans and their glucuronide conjugates. 
Epidemiological evidence suggests moderate health benefits associated with dietary flaxseed lignans 
against prostate and breast cancer, with the knowledge that extensive phase II conjugation of flaxseed 
lignans occurs in the gastrointestinal tract and liver (113). Considering the expression of both UGTs and 
hβG in tumor cells (329, 335) we speculate the existence of active unconjugated flaxseed lignans (SECO, 
ED or ENL) in tumor sites (Figure 1-7, B). The continuous conversion between unconjugated and 
glucuronide conjugate by UGTs and hβG in tumor cells, would allow the tumor cells to be exposed to some 
level of unconjugated active compounds (Figure 1-7, B). It is likely that there may be a mixture of flaxseed 
lignans and their glucuronide conjugates in this environment. The combination study using flaxseed 
lignans and their metabolites with chemotherapeutic agents were conducted to confirm the putative 
compounds that contribute to the anticancer effect in vitro (Figure 1-7, C).  
Based on the combination results from the cytotoxicity study, my research will include a proof-of-
principal study involving the usage of a pharmaceutical strategy, ADEPT, to promote localization of high 
concentrations of the pharmacologically active lignan at the tumor site (Figure 1-7, D). We anticipate that 
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the antibody-enzyme fusion protein could break the dynamic equilibrium between lignans and their 
metabolites and drive the reaction towards the unconjugated form (SECO, ED and ENL). The human clinical 
trial will investigate relevant plasma levels of flaxseed lignans and their metabolites following oral 
consumption of BeneFlax® (Figure 1-7, E), which will work as the source of the glucuronide conjugates 
(Figure 1-7, A) in the tumor tissues that will be further converted into unconjugated forms by the 
antibody-enzyme. The research hypothesis and objectives of my dissertation research are given as follows. 
 
Figure 1-7. The focus of this thesis based on the pharmacokinetic profile of flaxseed lignans following 
oral route.  
1.6.1 Hypotheses 
1. Flaxseed lignans, enterolactone and secoisolariciresinol, in combination with chemotherapeutic 
agents will enhance the cytotoxic effects of these chemotherapeutic agents in breast and prostate 
cancer cell lines of different phenotypic characteristics. 
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2. Specific targeting of glucuronidase using antibody directed enzyme prodrug therapy strategy will 
increase sensitivity of prostate cancer cells to chemotherapeutic agents when co-administered 
with enterolactone glucuronide. 
3. The flaxseed lignan enriched product, BeneFlax®, will be well tolerated in elderly healthy adults 
following once daily oral administration for 6 months at a dosage equivalent to 600 mg SDG. 
1.6.2 Objectives 
a. To determine whether flaxseed lignans enhance the cytotoxic activity of chemotherapeutic agents 
in prostate cancer cell lines with different characteristics. 
b. To determine whether flaxseed lignans enhance the cytotoxic activity of chemotherapeutic agents 
in breast cancer cell lines with different phenotype. 
c. To generate and validate an antibody-enzyme fusion protein D7-hβG (hβG, human beta-
glucuronidase) that specifically recognizes prostate specific membrane antigen (PSMA) expressed 
on prostate cancer cell membranes. 
d. To determine whether combination of D7-hβG fusion protein and enterolactone-glucuronide plus 
docetaxel could lead to increased cytotoxicity in prostate cancer cell lines. 
e. To determine the plasma concentration of flaxseed lignans and their metabolites in healthy older 
adults following once daily oral administration of flaxseed lignan-enriched complex, BeneFlax®, 
for six months at dosage equivalent to 600 mg SDG. 
f. To determine the safety and tolerability of a standard flaxseed lignan complex in healthy older 
adults. 
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1.7 Organization of the thesis 
This is a manuscript-based thesis which comprises six chapters. 
Chapter 1 gives general introductions and necessary background information related to this project.  
Chapter 2 presents the manuscript on the results of combination studies of flaxseed lignans with 
chemotherapeutic agents with different mechanisms of action in the prostate cancer cell lines PC3 and 
LNCap. Chapter 2 partially addresses Hypothesis 1, as well as Objective 1. My contribution to this 
manuscript includes all experiments and preparation of the written document. 
Chapter 3 presents the outcomes of combination studies of flaxseed lignans with therapeutic 
agents against metastatic breast cancer cell lines, SKBR3 and MDA-MB-231, and will be published as a 
paper. The role of chapter 3 is to address Objective b which is raised from Hypothesis 1. The major 
contribution of the first author included design and conduct of all the experiments, as well as preparation 
of the written manuscript.   
Chapter 4 presents the construction and validation of the pharmaceutical strategy, antibody 
directed enzyme prodrug therapy (ADEPT), as proof-of-concept for the possible application of ADEPT and 
flaxseed lignans as adjuvant therapy with docetaxel. This manuscript is used to evaluate Hypothesis 2 and 
its derived Objective c and d. Dr. Ji provided technical instruction for the cloning of fusion protein. Dr. 
Wolf provided the D7 antibody and expression plasmid pSectag 2a. The major contribution of the first 
author included design and conduct of all the experiments, as well as preparation of the written 
manuscript.   
Chapter 5 presents the report of a double-blind, randomized, placebo-controlled clinical trial to 
assess the safety, tolerability, and anti-inflammatory effects of a SDG-enhanced flax lignan complex, 
BeneFlax, following once daily oral administration in an older healthy population. This chapter tested 
Hypothesis 3 and Objective e and f. My contributions to this manuscript include vital sign measurements, 
blood sample collection, final data analysis, partial validation of the lignan analytical method, 
determination of plasma levels of lignans, and preparation of the written document. 
Chapter 6 discusses and summarizes the major findings of this project and the future research work. 
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Chapter 2 Flaxseed lignans enhance the antiproliferative effects of prostate cancer 
chemotherapeutics in vitro 
 
Yunyun Di1, Philipp Wolf2, Ed S. Krol1, Jane Alcorn1,* 
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Saskatchewan, 107 Wiggins road, Saskatoon, SK, S7N 5E4, Canada 
2Department of Urology, Medical Center, University of Freiburg, Freiburg, Germany. 
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Relationship of this manuscript to the thesis: 
One of the aims of the thesis is combination studies of flaxseed lignans with chemotherapeutic agents in 
prostate cancer cell lines. This manuscript provides experimental data of flaxseed lignans on enhancing 
the cytotoxicity of chemotherapeutic agents with different mechanisms of action when used in 
combination. We found ENL and SECO, but not ENL-Gluc, displayed an anti-proliferative effect against the 
studied prostate and breast cancer cell lines, with ENL demonstrating greatest potency both alone and in 
combination with various anticancer drugs. These initial investigations are essential complementary 
studies to our additional proof-of-concept investigations into a pharmaceutical strategy that might 
improve therapeutic efficacy of oral lignan administration in cancer. 
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2.1 Abstract 
The literature suggests dietary lignan consumption is associated with lowered prostate cancer 
incidence and mortality. Prostate cancer remains a leading cause of morbidity and mortality in men 
indicating a need to identify more effective treatments. Adjuvant therapies are known to benefit cancer 
patients, but the potential of flaxseed lignans as an additional treatment to drugs used to treat prostate 
cancer is unknown. As an initial investigation into a possible adjuvant role, the purpose of this project was 
to study the potential for flaxseed lignan and lignan metabolites to enhance the antiproliferative effect of 
typical chemotherapeutic agents with different mechanisms of action in prostate cancer cell lines in vitro. 
The cytotoxicity of flaxseed lignan alone or in combination with current typical chemotherapeutic agents 
was determined using Calcein AM cell viability assay. We found that the flaxseed lignan, enterolactone 
(ENL), demonstrated the most potent combination effect against prostate cancer cell lines and 
significantly decreased the IC50 values of all studied drugs. Its glucuronic acid conjugate form, ENL-
glucuronide, had no cytotoxic activity alone or additional benefit in combination with other anticancer 
agents. Furthermore, secoisolariciresinol and ENL significantly increased the cytotoxicity of abiraterone 
and MDV3100 in LNCap cells under low androgen conditions. The in vitro evaluations provide preliminary 
support for use of flaxseed lignans as adjuvant therapy in prostate cancer. 
2.2 Introduction 
Prostate cancer affects one in seven males during their lifetime with 24,000 newly diagnosed cases 
expected in 2015 (336). Many of the new diagnoses will be androgen dependent prostate cancer where 
survival rates are relatively high when caught at early stages (336). However, advanced prostate cancer, 
in particular castration resistant and metastatic cancer, has poor overall prognosis and survival (337, 338). 
The available anticancer drug regimens fail to provide effective treatment in such patients. Interestingly, 
the incidence and mortality of prostate cancer in Europe and North America is 14- and 22-fold higher, 
respectively, compared with China (339-341). Differences in diet and lifestyle caused by geography and 
economics appear to impact prostate cancer risk (342, 343). One important dietary difference is the high 
lignan content of the Asian diet and subsequent circulating levels of lignans, which are thought to be an 
important factor in lowering prostate cancer incidence and mortality (169, 344).  
Lignans are natural diphenolic compounds found in grains, seeds, and vegetables with flaxseed 
being the richest source of the lignan, secoisolariciresinol diglucoside (SDG) (57). The major flaxseed lignan, 
SDG, exists as a polymer in the flaxseed hull, whereby five SDG molecules are interconnected by four 
hydroxyl-methylglutaric acid (HPMA) molecules to produce an oligomeric complex (59, 345). Upon oral 
ingestion, it is believed the oligomer undergoes hydrolysis, and glycolytic cleavage of the glucose groups 
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from SDG liberates the aglycone metabolite, secoioslariciresionol (SECO), in the mammalian 
gastrointestinal tract due likely to the activity of the gastrointestinal microbiota (61, 62). A fraction of 
SECO is absorbed systemically, but a significant portion of SECO undergoes further conversion to the 
mammalian lignans, enterodiol (ED) and enterolactone (ENL), by activity of the colonic bacteria (79, 80, 
87, 346). SECO, ED, and ENL undergo extensive first-pass metabolism and exist principally in the systemic 
circulation and tissues as glucuronide and sulfate conjugates, which are believed to be inactive forms (347). 
The plant lignan, SDG, likely does not undergo absorption as no study has reported detectable systemic 
levels of SDG and in vitro evaluations indicate a lack of permeation of SDG in the Caco-2 permeability 
assay system (87, 348). 
The lignan or lignan metabolites involved and the mechanism by which lignans may exert 
chemopreventive or therapeutic benefit against prostate cancer is uncertain. Several reviews on the 
relationship between plasma or urine levels of total lignans (free and conjugated forms) and human health, 
though, have found an inverse relationship between elevated plasma or urine levels of total lignans with 
prostate cancer risk suggesting an anticancer role of flaxseed lignans (113, 349). This assertion is 
supported by studies, for example, where whole ground flaxseed supplementation for 30 days was found 
to inhibit cancer cell proliferation in localized prostate cancer in presurgical cancer patients (174, 350). 
Further investigation found that the anti-proliferative effect of flaxseed lignans might involve 
mitochondrial dysfunction and inhibition of insulin-like growth factor signaling pathway in LNCap and PC3 
prostate cancer cell lines (137, 138).  
The reported effects of flaxseed lignan consumption on prostate cancer, though, are quite modest which 
likely relate to the observation that the systemically available form represents largely lignan metabolites 
whose affects against prostate cancer cells are relatively unknown (351). Cytotoxic activity, particularly in 
combination with the current prostate cancer therapies, might identify lignans as a possible adjuvant 
therapy in prostate cancer. The purpose of this study, then, was to investigate several possible lignan 
metabolites from flaxseed that might contribute to an antiproliferative effect in prostate cancer cell lines. 
Furthermore, their combination with typical and novel prostate cancer chemotherapeutic agents with 
different mechanisms of action against prostate cancer cell lines in vitro was also investigated. The use of 
the PC3 (androgen receptor negative) and LNCap (androgen receptor positive) cell lines allowed us to 
capture the phenotypic diversity of prostate cancer in our comparison of the combination effect of 
flaxseed lignan metabolites with these chemotherapeutic agents. This study will provide important 
preliminary evidence to support the utility of flaxseed lignans as adjuvant therapy to prostate cancer 
chemotherapeutic agents in the future. 
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2.3 Material and Methods 
2.3.1 Materials 
Enterolactone glucuronide (ENL-Gluc) was synthesized according to a previously established 
method (347). Secoisolariciresinol (SECO) (purity > 95%) was previously prepared in our laboratory from 
SDG (352). Abiraterone and cabazitaxel were purchased from Selleck Chemicals (Houston, TX, US). 
Chemicals including enterolactone, docetaxel, doxorubicin hydrochloride, 0.01% poly-L-lysine solution 
(70-150 kDa), charcoal stripped Fetal Bovine Serum (CS-FBS), 0.25% (w/v) trypsin – 0.53 mM EDTA solution, 
and penicillin (100 U/mL)/streptomycin (100 μg/mL) solution, cell culture grade water were bought from 
Sigma-Aldrich (Oakville, ON, Canada). MDV3100 was purchased from Toronto Research Chemicals (TRC) 
(Toronto, ON, Canada). Calcein AM powder was purchased from Biotium (Hayward, CA, US). 10X Calcein 
AM DW buffer was obtained from Travigen (Gaithersburg, MD, USA). PC3 cells, LNCap cells, F-12K medium, 
RPMI 1640 medium, cell culture grade dimethylsulfoxide (DMSO) and Dulbecco's phosphate buffered 
saline (D-PBS) were purchased from ATCC (American Type Culture Collection, Manassas, VA, US). RPMI 
1640 medium without phenol red was bought from Invitrogen Inc. (Burlington, ON, Canada). Black-walled 
96-well plates were purchased from ThermoFisher Scientific (Toronto, ON). T-75 flasks (Rectangular 
canted neck with vent caps, growth area of 75 cm2) were purchased from Corning (NY, US). 
The stock of all compounds were dissolved in DMSO except ENL-Gluc in cell culture grade water, 
and all stock solutions were kept at -80°C until use. The working range for ENL was from 3.12-1000 µM, 
and for ENL-Gluc was from 3.12-400 µM. The concentration of SECO started from 1000 µM with 2 times 
serial dilutions. Docetaxel was diluted in cell culture medium with concentrations ranging from 0.06-1000 
nM. Abirateone and MDV3100 were diluted in cell culture medium with working concentrations from 
0.039 to 10 µM. The working concentration for 5-flurouracil (positive control) was 0.78-100 µM. DMSO 
(<1% in cell culture) was used as vehicle control.  
2.3.2 Cell Culture Conditions 
Prostate cancer cell lines, PC3 and LNCap, were grown in T-75 flasks and cell culture media (20 mL) 
was changed every two to three days. Cells were harvested at 80% of confluence (exponential phase) 
using 0.25% (w/v) trypsin–0.53 mM EDTA solution and counted using TC20TM Automated Cell Counter 
(Mississauga, ON, Canada) stained with 0.4% trypan blue. For all experiments, cells were thawed from 
cryostorage in liquid nitrogen vapour and passaged once before treatments. All the experiments were 
conducted within three passage numbers after receiving cells. PC3 cells were cultured in F12K media 
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supplemented with 10% FBS. LNCap cells were maintained in RPMI-1640 media supplemented with 10% 
FBS and switched to phenol-red free RPMI-1640 + 10% CS-FBS during treatment. All culture media was 
supplemented with 1% penicillin/streptomycin. All cell lines were cultured in 5% CO2 incubator 
(ThemoFisher Scientific, Toronto, ON) with 95% humidity at 37°C. 
2.3.3 Cytotoxicity Using Calcein AM Cell Viability Assay 
PC3 cells were seeded onto black-walled 96-well plates at 4,000 cells per well and kept under 5% 
CO2 at 37°C overnight. The media was aspirated, the cells washed with 150 µL D-PBS once, and 100 µL of 
fresh media containing the desired concentration of drugs with or without flaxseed lignan metabolites 
was added (with DMSO < 1% as negative control and 5-flurouracil as positive control). After treatment for 
72 hours, the media was removed and cells were washed with 150 µL D-PBS once, and then incubated 
with 100 µL of 1X Calcein AM DW buffer containing 5 µM Calcein AM for 45 min. The Calcein AM was light 
sensitive and unstable in aqueous phase and therefore it was prepared from powder immediately prior 
to use. The fluorescence was read from the top at an excitation wavelength of 485 nm and emission of 
528 nm using a Synergy HT microplate reader (Bio-Tek Instruments, Winooski, US) installed with Gen5TM 
software (Bio-Tek Instruments, Winooski, US). The cell viability was calculated using the fluorescence 
intensity from treated wells normalized to fluorescence intensity from vehicle control wells.  
LNCap cells were seeded at 10,000 cells per well in 96 well plates pre-coated with poly-L-Lysine (70 
kDa – 150 kDa) and attached overnight before treatment. The cells were washed as above and 100 µL 
phenol-red free RPMI-1640 + 10% CS-FBS containing the desired concentration of drugs and lignan 
metabolites was added to the wells. After a 72 h exposure, 100 µL of fresh culture medium containing the 
same concentrations of cytotoxic drugs and lignan metabolites were added to each well of the 96-well 
plate, respectively, resulting in a total volume of 200 µL per well, and cells were again incubated for 
another 72 h before reading. Experiments were conducted in triplicate on at least three different 
occasions. 
2.4 Data Analysis 
Fluorescence data of the cytotoxicity assays were normalized to control wells. Concentration-
response curves to determine IC50 values were generated using a four parameter nonlinear regression 
equation with variable slope in GraphPad Prism (GraphPad Prism 6.0 software, La Jolla, CA). Data that 
could not fitted by logistic curves were presented as histograms and were analyzed using two-way ANOVA 
with Tukey’s post hoc analysis. Significance was set at p ≤ 0.05. 
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In order to assess whether lignans increase the sensitivity of prostate cancer cells to various 
chemotherapeutic agents, the dose reduction index (DRI) was calculated according to the following 
equation:  
DRI = ୍େఱబ,   ఽౢ౥౤౛
୍େఱబ,   ి౥ౣౘ
                     Equation 1 
DRI was proposed by Chou to calculate the possible dose-reduction for each drug in the therapeutic 
applications, in the absence of a full combination study (353). DRI presents the fold decrease in dose 
reduction required to achieve the same cell response as drug alone. IC50, Alone means IC50 of drug in absence 
of the flaxseed lignans. IC50, Comb represents the IC50 of drugs in combination with flaxseed lignans. A DRI 
greater than 1 indicates increased sensitivity of cells to the combination treatment. 
2.5 Results 
2.5.1 Antiproliferative Effects of Flaxseed Lignans Against Prostate Cancer Cell Lines 
Cell viability was conducted in PC3 and LNCap cells to assess the antiproliferative effect of flaxseed 
lignans against prostate cancer using the Calcein AM cell viability assay. LNCap and PC3 are typical models 
that represent the androgen dependent and androgen independent situations in prostate cancer, 
respectively, that almost encompass all prostate cancer phenotypes. SECO, ENL, and ENL-Gluc were 
chosen to test the cytotoxicity against prostate cancer cell lines, PC3 and LNCap (Figure 2-1), as 
quantifiable systemic levels of these lignan metabolites are observed following oral ingestion of SDG. For 
data that were not able to generate an IC50, the results were shown as % cell inhibition at the maximum 
concentration used in the cytotoxicity assay (Table 2-1). ENL exhibited the most potent toxicity with a 
calculated IC50 of 52 µM in LNCap and an IC50 of 95 µM in PC3. SECO also displayed low to moderate 
toxicity (Table 2-1). No obvious cytotoxicity was found with ENL-Gluc in either PC3 or LNCap cells. Given 
the lack of inherent cytotoxicity and limiting quantities of ENL-Gluc, only select combination studies with 
ENL-Gluc were conducted as indicated below. 
48 
 
 
Figure 2-1. Percent cell viability of PC3 (Panel A) and LNCap (Panel B) cells following exposure to the the 
lignan metabolites, secoisolariciresinol (SECO), enterolactone (ENL), and enterolactone glucuronide (ENL-
Gluc). Cell lines were exposed to the lignan metabolites for 72 h for PC3 (Panel A) or 144 h for LNCap 
(Panel B) and cell viability was measured using Calcein AM fluorescence. Data represent mean ±SD of 
triplicates performed on ≥ three different occasions. DMSO < 1% was used as vehicle control and 5-
Flurouracil was used as positive control (data not shown). In LNCap cells data is not shown for ENL-Gluc 
but information is reported in Table 2-1. 
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Table 2-1. IC50 values of flaxseed lignan metabolites, secoisolariciresinol (SECO), enterolactone (ENL), and 
enterolactone glucuronide (ENL-Gluc), in PC3 and LNCap prostate cancer cell lines. 5-Flurouracil was used 
as positive control with the IC50 value calculated at 12 µM (data not shown). Experiments were repeated 
in triplicate on ≥ three different occasions.  
 
PC3 LNCap 
SECO ENL ENL-Gluc SECO ENL ENL-Gluc 
IC50  µM 
95% CI 
58.1%* 95 9.7%* 324 52 6.6%* 
- 55-166 - 260-403 47-59 - 
*IC50 values were not achievable. Values displayed are for % inhibition achieved at 1000 µM for SECO and 
400 µM for ENL-Gluc. 
2.5.2 Combination Effects of Flaxseed Lignans with Chemotherapeutics in PC3 Cell Line. 
The classic chemotherapeutic agents used in prostate cancer treatment, docetaxel and doxorubicin, 
were first tested for the combination effect with flaxseed lignan metabolites. Since cancer cells generate 
drug resistance against docetaxel after chronic treatment, as this drug is a substrate for the plasma 
membrane-associated P-glycoprotein (P-gp) efflux transporter involved in multidrug resistance, 
cabazitaxel, a fourth generation taxane, was also tested which shares similar mechanisms of action with 
docetaxel (binding to tubulin and induction of microtubule stabilization to prevent microtubular 
depolymerization), but has poor affinity to P-gp (354-357). Docetaxel and doxorubicin inhibited the 
growth of PC3 cells with an IC50 value of 0.9 nM and 0.2 µM, respectively (Table 2-2). At a concentration 
of 50 µM, SECO reduced the IC50 value of docetaxel by 60% to 0.4 nM. ENL significantly reduced the IC50 
value of docetaxel to 0.09 nM with a 90% growth inhibition at 50 µM (P<0.01). No significant difference 
was found between the combinations of 50 µM of SECO or ENL with doxorubicin in PC3 cells (Table 2-2). 
DRI values were also calculated from the IC50 values according to equation 1. DRI represents the fold 
reduction in dosage of a cytotoxic drug when used in combination to achieve the same cell cytotoxicity 
when the drug is administrated alone. A DRI value greater than 1 indicates flaxseed lignan synergy with 
the anticancer effect of chemotherapeutics. SECO in combination had only a limited effect on docetaxel 
and doxorubicin cytotoxicity (Table 2-3). However, ENL displayed a marked concentration dependent 
increase in the DRI with docetaxel with 50 µM ENL resulting in a DRI of 10.2 compared with docetaxel 
alone (Table 2-3). ENL combination with doxorubicin caused a more limited increase in the cytotoxicity of 
this drug (Table 2-3). 
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Cabazitaxel inhibited the growth of PC3 cells with an IC50 of 1.12 nM (Table 2-2). PC3 cells were also 
treated with cabazitaxel in combination with 25 and 50 µM lignan metabolites to determine whether 
these metabolites could lower the IC50 value of this chemotherapeutic agent (Figure 2-2). Both ENL and 
SECO decreased the IC50 values of cabazitaxel in a concentration-dependent manner (Table 2-2). SECO at 
50 µM reduced the IC50 value of cabazitaxel by 73% (IC50 of 0.3 nM). ENL at 50 µM caused an 86% reduction 
in cabazitaxel IC50 value to 0.16 nM compared with cabazitaxel alone (P<0.01). No difference in IC50 was 
found with administration of ENL-Gluc with cabazitaxel (Figure 2-2). 
Table 2-2. IC50 values of cabazitaxel, docetaxel, and doxorubicin in combination with different 
concentrations of secoisolariciresinol (SECO) and enterolactone (ENL) in PC3 cells. Data are reported as 
mean (n≥3) IC50 values with 95% confidence interval (CI). Combination with lignan metabolites decreased 
the IC50 values of drugs in a concentration-dependent manner. Only selected combination study was done 
for ENL-Gluc, which was shown in Figure 2-2.  
 Drug only 
Plus SECO Plus ENL 
25 µM 50 µM 25 µM 50 µM 
Cabazitaxel IC50 (nM) 
(95% CI) 
1.12 0.7 0.3 0.3 0.16 
(0.7-1.9) (0.4-1.4) (0.2-0.5) (0.2-0.45) (0.09-0.3) 
Docetaxel IC50 (nM) 
(95% CI) 
0.9 0.6 0.37 0.2 0.09 
(0.56-1.6) (0.27-1.4) (0.18-0.77) (0.12-0.46) (0.04-2.4) 
Doxorubicin IC50 (µM) 
(95% CI) 
0.2 0.18 0.16 0.14 0.07 
(0.14-0.28) (0.12-0.27) (0.1-0.27) (0.07-0.26) (0.02-0.26) 
 
 
Table 2-3. Dose Reduction Index (DRI) for the combination treatment of chemotherapeutic agents with 
flaxseed lignan metabolites, secoisolariciresinol (SECO) and enterolactone (ENL), in PC3 cells. The IC50 
values of drug alone were set as baseline. 
 Drug only 
Plus SECO Plus ENL 
25 µM 50 µM 25 µM 50 µM 
Cabazitaxel 1 1.6 3.8 4 7.2 
Docetaxel 1 1.5 2.5 3.9 10.2 
Doxorubicin 1 1.1 1.3 1.5 2.9 
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Figure 2-2. Cytotoxicity of cabazitaxel in combination with different concentrations of secoisolariciresinol 
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(SECO), enterolactone (ENL), or enterolactone glucuronide (ENL-Gluc) in PC3 cells. PC3 cells were treated 
with different combinations of cabazitaxel and flaxseed lignan metabolites for 72 hours and cell viability 
was measured using Calcein AM fluorescence. Data were plotted in GraphPad Prism and IC50 values were 
estimated using the four parameter variable slope method. ENL (Panel A) and SECO (Panel B) enhances 
the cytotoxicity of cabazitaxel in a concentration-dependent manner, while ENL-Gluc (Panel C) has no 
obvious effect. Data represent mean ± SD of three replicates on three different occasions. 
2.5.3 Combination Effects of Flaxseed Lignans with Chemotherapeutics in LNCap cells 
In patients first diagnosed with metastatic prostate cancer, androgen deprivation therapy (ADT) is 
a preferred treatment and improves survival when surgical resection is not an option. However, patients 
treated with ADT for more than one year may develop Castration-resistant prostate cancer (CRPC), and 
MDV3100 and Abiraterone are thought to be novel treatments for patients with CRPC (337, 338). Hence, 
the combination effect between these drugs and flaxseed lignans was measured in androgen receptor 
positive LNCap cells. To mimic a similar environment as low plasma androgen levels in vivo, LNCap cells 
were treated in RPMI medium supplemented with 10% CS-FBS to create a low androgen environment. 
Although Abiraterone and MDV3100 show promising anti-cancer effects at nM level in vivo, this cannot 
be exactly replicated in in vitro experiments. Nonetheless, in combination, SECO and ENL significantly 
increased the cytotoxicity of Abiraterone and MDV3100 in LNCap cells under low androgen conditions 
(Figure 2-3). ENL-Gluc combined with either MDV3100 or Abiraterone lead to no change in cytotoxicity. 
The combination of 50 µM SECO with Abiraterone reduced cell viability by 15% on average with the 
highest inhibition achieved with 2.5 µM Abiraterone (22.6%), suggesting the concentration combination 
might be useful in future studies (P<0.0001). ENL in combination with Abiraterone inhibited the overall 
growth by 39% on average. The best combination was observed at 50 µM ENL with 2.5 µM abiraterone, 
which gave a growth inhibition of 64.6% (P<0.0001). Combination effects were also detected for MDV3100 
with SECO and ENL, but not ENL-Gluc (Figure 2-3). The combination of 50 µM SECO with MDV3100 
reduced cell viability by 13% on average, while ENL decreased cell viability by 42% on average (P<0.0001). 
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Figure 2-3. Combination effect of secoisolariciresinol (SECO), enterolactone (ENL), and enterolactone 
glucuronide (ENL-Gluc) with Abiraterone and MDV3100 ranging from 0.39 to 10 µM in LNCap cells. 
Combination of 50 µM SECO with Abiraterone reduced cell viability by 15% on average, while ENL 
decreased it by 39%. Combination of 50 µM SECO with MDV3100 reduced cell viability by 13 % on average, 
while ENL decreased it by 42 % (P<0.0001). ENL-Gluc did not improve the cytotoxicity of Abiraterone or 
MDV3100. The significance was determined by comparing drug plus lignan group vs. drug only group at 
the same concentration. 
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2.6 Discussion 
Epidemiological studies suggest the beneficial role of flaxseed lignans against multiple human 
diseases including prostate cancer. Such studies report an inverse relationship between plasma lignan 
concentrations and risk of prostate cancer (113). Further, oral supplementation of flaxseed lignans may 
impede prostate cancer cell proliferation (174, 350, 358). Preliminary studies from the literature suggest 
the combination of lignans with available chemotherapeutic agents in vitro enhance their cytotoxicity in 
different breast cancer cell lines (359, 360). We conducted a combination study in prostate cancer cell 
lines to offer preliminary support for use of orally administered flaxseed lignans as adjuvant therapy to 
improve the anti-cancer effect of currently available chemotherapeutic agents as well as allow a dosage 
reduction to reduce risk of adverse effects and development of resistance to these cancer 
chemotherapeutic agents. The combination study involved both androgen receptor positive and negative, 
and both conventional and newer chemotherapeutic agents with different mechanisms of action. We 
premised this focus on the understanding that prostate cancer often initiates as an androgen ablation 
sensitive stage with androgen deprivation therapy (ADT) as a preferred treatment (165). However, with 
prolonged treatment patients may develop CRPC with a requirement for more novel treatments to 
prolong survival and quality of life (361, 362). Unfortunately, even the latest treatments option only 
extends medium survival of patients with CRPC for up to six months as drug resistance has emerged in 
clinic with these newer agents (337, 338, 363, 364). The recent interest in flaxseed lignans for their 
protective role against prostate cancer may identify this Natural Health Product as an adjuvant therapy 
that can extend survival and quality of life beyond the current treatment options.  
Our study demonstrates the flaxseed lignan metabolites, SECO and ENL, significantly increases the 
sensitivity of prostate cancer cells to multiple chemotherapeutic agents used in treatment of prostate 
cancer. However, the mammalian lignan, ENL, causes more prostate cancer cell cytotoxicity when used 
alone or in combination with other anticancer drugs, compared with the minor effect observed from SECO. 
ENL is considered as the key lignan metabolite associated with the health benefits of flaxseed lignan 
consumption (169), while SECO is usually recognized as a mammalian lignan (i.e. ENL) precursor.  The 
ability of SECO to cause limited cytotoxicity alone and in combination with other anticancer drugs 
deserves attention since SECO exhibits better oral bioavailability than ENL (79); hence, SECO is more 
systemically available following the oral consumption of secoisolariciresinol diglucoside, the plant lignan 
form found in the hull of flaxseed (57). Furthermore, all three flaxseed lignan metabolites did not exhibit 
biphasic effects on cell viability observed in some studies (365). This information is important to support 
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the health benefits of flaxseed lignans in vivo, where the plasma concentrations are usually fluctuating at 
low nanomolar range.    
Although the literature indicates chronic oral consumption of flaxseed results in the accumulation 
of ENL (80), much of the systemically available ENL is in the form of phase II enzyme conjugates, principally 
conjugates of glucuronic acid (366). Both SECO and ENL undergo considerable first pass metabolism by 
the phase II metabolizing enzymes, UDP-glucuronosyltransferasaes and sulfotransferases, in both 
enterocytes and hepatocytes (75, 347). Glucuronic acid conjugates of SECO and ENL formed within 
enterocytes undergo multidrug resistance-like protein 3 (MRP3) mediated efflux at the basolateral 
membrane of the polarized intestinal epithelium making these conjugated metabolites available 
systemically (77). Glucuronidated metabolites typically have no biological activity. However, 
epidemiological evidence links the prostate cancer benefits of flaxseed consumption with ENL levels and 
given that ENL is principally found as a conjugated metabolite systemically, we assessed the cytotoxicity 
of ENL-Gluc alone and in combination with other chemotherapeutic agents. Our studies confirm the lack 
of cytotoxic activity of ENL-Gluc as we failed to observe any obvious cytotoxic effect either alone or in 
combination. Lack of efficacy of the glucuronide metabolite is consistent with the general understanding 
that phase II metabolism represents a deactivation pathway (367).  
Docetaxel, a classic chemotherapeutic agent used in prostate cancer treatment, is the mainstay for 
treatment of patients with CRPC. Docetaxel is usually used in combination with other therapeutic 
regimens to achieve higher tumor response and such combination treatments allow docetaxel dosage 
reductions to decrease incidence of systemic side effects associated with high docetaxel doses (368, 369). 
Nonetheless Docetaxel’s common toxicities including neutropenia, neuropathy, and fatigue, often results 
in the eventual discontinuation of treatment. Furthermore, in CRPC the utility of docetaxel is often limited 
by lack of responsiveness to the drug or development of drug resistance after multiple serial treatments 
(368, 370). Upregulation of MDR1 expression in prostate cancer cells accounts for docetaxel resistance 
(371), and cabazitaxel was designed to overcome taxane resistance mediated by MDR1 efflux transporter 
(372). ENL is reported to inhibit MDR1 (373-375), and consequently, its combination with docetaxel could 
improve overall responsiveness of patients to this mainstay treatment. Interestingly, in the PC3 cell line, 
which does not express MDR1, our data demonstrates that co-administration of 50 µM ENL with docetaxel 
significantly increased the sensitivity of PC3 cells with a dose reduction index of 10.2 fold, compared with 
docetaxel alone (Table 2-3). Furthermore, SECO at 50 µM, also significantly decreases the IC50 value of 
docetaxel demonstrating a dose reduction index of 2.5 fold. Similar effects occur with the combination of 
ENL and SECO with cabazitaxel, a chemotherapeutic agent that is not a substrate of MDR1. Studies have 
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demonstrated that inhibition of tumor-associated fatty acid synthase, a known oncogene, could 
resensitize cancer cells against docetaxel (376, 377). Previous research in our lab also indicated ENL 
inhibits fatty acid synthase (FASN); whether this mechanism of action explains the combination effect 
between the taxanes and lignans requires further investigation (89). This might also help to explain the 
more limited enhancement in cytotoxicity when the lignan metabolites are co-administered with 
doxorubicin, as inhibition of FASN expression could cause the inhibition of topoisomerase II which was 
the target of doxorubicin (378, 379) (Table 2-2, Table 2-3 and Appendix B-Figure B-3). Nonetheless, ability 
of lignan metabolites to inhibit key cellular processes such as fatty acid synthesis and to inhibit a key 
mechanism of multidrug resistance, i.e. MDR1 upregulation, holds promise for the lignan metabolites to 
improve overall tumor response and therapeutic effectiveness of the taxanes used in prostate cancer 
treatment.  
In patients first diagnosed with metastatic prostate cancer, androgen deprivation therapy (ADT) is 
a preferred treatment and improves survival when surgical resection is not an option (165). Androgen has 
a critical role in prostate cancer since its binding to the androgen receptor and subsequent translocation 
of the androgen receptor complex to the nucleus results in stimulation of tumor proliferation and 
inhibition of apoptosis of prostate cancer cells (157). Lignans are reported to inhibit aromatase, 5α-
reductase, and 17β-hydroxysteroid dehydrogenase, key enzymes in androgen metabolism (141, 380, 381).  
Furthermore, lignans may increase the levels of sex hormone-binding globlulin (SHBG), which in turn 
would decrease circulating levels of the free biologically active form of androgens, since SHBG is the major 
circulating binding protein for androgens (382). Hence, androgen withdrawal could induce cancer cell 
senescence, which results in tumor shrinkage and a slower tumor progression. The benefits of lignans in 
prostate cancer, then, may relate in part to their ability to modulate circulating levels of free androgen 
(383).  
In a number of patients treated with ADT for more than one year castration-resistant prostate 
cancer may develop, which exhibits a fast progression and is associated with a poor prognosis.  Enhanced 
intratumoral de novo synthesis of androgen and increased sensitivity of androgen receptors occurs in 
CRPC to maintain androgen receptor signaling and tumor progression (384-386). MDV3100 and 
abiraterone were recently approved for the treatment of CRPC and function to block the androgen-
dependent signaling pathway (387-389). MDV3100 is an antagonist of the androgen receptor (AR) and 
impedes its nuclear translocation (388), while Abiraterone is an irreversible CYP17A1 inhibitor, an enzyme 
that plays an important role in androgen synthesis (389) and whose inhibition in peripheral tissues results 
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in loss of production of precursors needed for intratumoral androgen synthesis (390, 391). Significant side 
effects, though, limit these drugs’ overall effectiveness (338).  
To demonstrate a possible combination effect of flaxseed lignans with MDV3100 or abiraterone, 
we utilized in LNCap cells maintained under very low androgen culture conditions. The LNCap cell line is 
an important model to study the progression of prostate cancer to a castration-resistant stage under long-
term low androgen deprivation culture (392). LNCap cells are tested in this specific study as the literature 
reports activation of androgen dependent signaling pathways in CRPC (385). Solubility issues limited our 
ability to calculate appropriate IC50 values for Abiraterone and MDV3100 in LNCap cells. Nonetheless, the 
limited cytotoxic effect of abiraterone alone is not surprising as inhibition of CYP17A1 enzyme in human 
castration resistant prostate cancer cell lines has limited efficacy on cell proliferation (393). Likewise 
MDV3100 alone shows limited cytotoxicity likely due to culture conditions (i.e., use of 10% charcoal 
stripped FBS supplemented phenol red free RPMI 1640 for 7 days which did not provide adequate time to 
allow the LNCap cells to produce sufficient androgen or alter androgen receptor sensitivity). In 
combination with the lignan metabolites, we demonstrate significant reductions in percent viable cells 
with both abiraterone and MDV3100, an effect most prominent with ENL. This combination effect might 
involve lignan-mediated inhibition of androgen-dependent signaling pathways. Possible interference with 
androgen receptor translocation to the nucleus to explain the anti-proliferative effects is supported by a 
recent study that examined the cross-resistance between docetaxel, cabazitaxel, abiraterone, and 
MDV3100. This study demonstrated that the cytotoxic effect of docetaxel and cabazitaxel on CRPC 
involved inhibition of androgen receptor translocation (394). Inhibition of fatty acid synthase by the 
lignans also may contribute to the anti-proliferative effect of the combination treatments, and this 
warrants investigation (395).  
In conclusion, our in vitro evaluations provide preliminary support for use of flaxseed lignans as 
adjuvant therapy with the mainstay prostate cancer chemotherapeutic agents. In particular, the 
mammalian lignan, ENL, demonstrates modest cytotoxicity alone, but when used in combination with 
chemotherapeutic agents known to have different mechanisms of action in prostate cancer, significantly 
increases the sensitivity of androgen-dependent and -independent prostate cancer cell lines to these 
chemotherapeutic agents. These results suggest that flaxseed lignan metabolites in combination with 
chemotherapeutic agents may be more effective for prostate cancer treatment than drug alone and the 
enhanced sensitivity might allow for dosage reductions to decrease dose related systemic side effects of 
these drugs. Our results warrant further in vitro studies to understand the underlying mechanism for the 
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combination effects, as well as possible human clinical trials to evaluate flaxseed lignan supplementation 
as adjuvant therapy in prostate cancer treatment.    
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Relationship of this manuscript to the thesis:  
In addition to combination effects observed from the co-treatment of flaxseed lignans with 
chemotherapeutic agents in prostate cancer cell lines, this manuscript demonstrates that similar 
combination effects were observed in metastatic breast cancer cell lines, SKBR3 and MDA-MB-231. This 
section further elucidates the possibility of flaxseed lignans as adjuvant therapy in conjunction with 
primary chemotherapy in vitro against different cancer types.   
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3.1 Abstract 
Systemic cytotoxic chemotherapy remains the mainstay of metastatic breast cancer; however, 
prognosis and overall survival is unfavorable due to inadequate treatment response and/or unacceptable 
toxicity. Natural compounds and their active metabolites receive increasing attention as possible adjuvant 
therapy with cancer chemotherapeutics to improve treatment response, survival rates, and quality of life 
of breast cancer patients. This study investigated the combination of flaxseed lignans with classic 
chemotherapeutic agents with different mechanisms of action to determine whether flaxseed lignans 
could enhance the cytotoxic effect of such drugs in the metastatic breast cancer cell lines, SKBR3 and 
MDA-MB-231. The experimental data suggests that flaxseed lignans significantly enhanced the ability of 
chemotherapeutic agents to cause cytotoxicity in SKBR3 and MDA-MB-231 breast cancer cells. Our cellular 
evaluation suggests a future direction in improving chemotherapeutic efficacy in metastatic breast cancer 
by adjuvant therapy with the flaxseed lignans. 
3.2 Introduction 
Breast cancer is the most common cancer in women worldwide contributing to 29% of all new cases 
in 2015 (336). The median overall survival for female metastatic breast cancer is only 18-24 months (396). 
Given this unfavorable prognosis, systemic cytotoxic chemotherapy remains the mainstay of treatment 
for metastatic breast cancers with the specific cytotoxic agent dependent on tumor cell molecular 
subtypes (397). Combinations of chemotherapeutic drugs with different mechanisms of action are 
commonly chosen to achieve greater tumor response; unfortunately, increased toxicity has been 
associated with this treatment strategy (398). Such treatment side effects influence the overall efficacy 
by decreasing quality of life and can result in termination of treatment (399). The overall efficacy is further 
restricted once tumor cells generate multidrug resistance (400), especially in patients already receiving 
multiple drugs (401). As effective treatments for metastatic breast cancer remain elusive, one area of 
research has investigated natural compounds of dietary origin and their active metabolites for possible 
adjuvant therapy with cancer chemotherapeutics (402). Epidemiological evidence for one class of natural 
compounds, the lignans, suggests a compelling association between dietary lignan consumption, serum 
lignan concentrations, and health benefits including reductions in risk for certain cancers such as breast 
cancer (48, 403-405). 
Lignans, are natural compounds possessing a unique diphenolic structure and exist in minor 
quantities in many foods but have appreciable levels in flaxseed (58). Dietary consumption of the flaxseed 
lignan, secoisolariciresinol diglucoside (SDG), results in glucosidic cleavage in the gastrointestinal tract to 
yield SECO (secoisolariciresinol), which is further converted to the mammalian lignans, enterodiol (ED) 
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and enterolactone (ENL), by the intestinal microflora (62). The literature suggests ENL is the major 
bioactive lignan (61), but the SDG metabolites are extensively metabolized by enterocytic and hepatic 
UDG-glucuronosyltransferase enzymes during their absorption process yielding high systemic levels of 
glucuronide conjugates of these lignan metabolites and low levels of ENL, ED, and SECO (77, 87). 
Nonetheless, several studies report improved survival of patients with postmenopausal breast cancers 
with high circulating total ENL levels (i.e. ENL plus ENL glucuronide (ENL-Gluc) (193, 406-408). ENL, and to 
a more limited extent, SECO, are known to possess antiproliferative properties (80, 409). In vitro studies 
suggest multiple mechanisms are potentially involved in the inhibition of breast cancer cell growth (410, 
411). As well, animal experiments demonstrate that dietary supplementation with flaxseed lignans 
enhances the inhibitory effect of tamoxifen through upregulation of estrogen receptor- and growth 
factor-signaling pathways (359, 360). Such data indicates the potential application of flaxseed lignans as 
adjuvant therapy against breast cancer. 
Human clinical trial data thus far indicates flaxseed lignan supplementation is safe and well 
tolerated in healthy volunteers as well as patients with chronic disease and the frail elderly (47, 412). 
Considering the safety profile, the combination of flaxseed lignan supplementation with standard breast 
cancer chemotherapeutic regimens may improve therapeutic outcomes of these standard regimes 
resulting in an improvement in overall survival or quality of life for the patient. The purpose of this project 
is to investigate the ability of several lignan metabolites of SDG, namely SECO, ENL, and ENL-Gluc, to 
enhance the cytotoxic effect of cancer chemotherapeutics, docetaxel, doxorubicin, and carboplatin 
against SKBR3 (HER2 positive) and MDA-MB-231 (triple negative) breast cancer cells in vitro. This study 
will provide important preliminary evidence to support the utility of flaxseed lignan oral supplementation 
as adjuvant therapy to breast cancer chemotherapeutic agents. 
3.3 Materials and Methods 
3.3.1 Reagents 
Enterolactone glucuronide (ENL-Gluc) was synthesized according to a previously established 
method (347) (Appendix A). Secoisolariciresinol (SECO) (purity > 95%) was previously isolated from raw 
flaxseed in our laboratory (352). Chemicals including enterolactone, D-saccharic acid 1, 4-lactone 
monohydrate, docetaxel, doxorubicin hydrochloride, carboplatin, 0.25% (w/v) Trypsin – 0.53 mM EDTA 
solution, fetal bovine serum (FBS) uridine 5’-diphosphoglucuronic acid trisodium salt (UDPGA), and 5-
fluorouracil were purchased from Sigma-Aldrich (Oakville, ON, Canada). Calcein AM powder was 
purchased from Biotium (Hayward, CA, US). 10X Calcein AM DW buffer was obtained from Travigen 
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(Gaithersburg, MD, USA). ATCC-formulated Leibovitz’s L-15 medium, McCoy’s 5A medium, cell culture 
grade dimethylsulfoxide (DMSO), and Dulbecco's Phosphate-Buffered Saline (D-PBS) were purchased 
from ATCC (American Type Culture Collection, Manassas, VA, US). The CellTiter-Glo® luminescent cell 
viability kit was from Promega (Madison, US). Water was filtered using a Millipore Milli-Q system with a 
Quantum EX cartridge (Mississauga, ON). 
Stock solutions of all chemicals were prepared in DMSO and stored at -80 C  until use, while 
carboplatin and ENL-Gluc were dissolved in double distilled H2O. The working range for ENL and ENL-Gluc 
was from 3.12 - 1000 µM. The final concentration of SECO started with 1000 µM with 2 times serial 
dilutions. All of the drugs tested were diluted in cell culture media as follows: docetaxel final concentration 
range of 0.06 - 1000 nM; doxorubicin final concentration range of 0.005 – 86.2 µM; carboplatin final 
concentration range 4.7 – 300 µM. The working concentration range for 5-flurouracil (positive control) 
was 0.78 - 100 µM. DMSO <1% was used as vehicle control. 
3.3.2 Cell culture 
SKBR3 and MDA-MB-231 cells were obtained from ATCC (American Type Culture Collection, 
Manassas, VA, US). SKBR3 cells were maintained in McCoy's 5A medium supplemented with 10% FBS. 
MDA-MB-231 cells were cultured in Leibovitz's L-15 Medium supplemented with 20% FBS. All the culture 
media was supplemented with 1% penicillin/streptomycin (penicillin (100 U/mL)/streptomycin 
(100μg/mL)). SKBR3 cells were cultured in 5% CO2 incubator at 37 C while MDA-MB-231 cells were kept 
in a 0% CO2 incubator. All the experiments were conducted within three passages after thawed from liquid 
nitrogen. 
3.3.3 Calcein AM cell viability assay 
SKBR3 cells were seeded into 96 well plates at a density of 4000 cells per well and kept under 5% CO2 at 
37 C overnight. The cells were washed subsequently with 150 µL D-PBS once, and 100 µL of fresh media 
containing the desired concentration of drugs with or without flaxseed lignan metabolites was added 
(with DMSO as negative control and 5-flurouracil as positive control). After treatment for 72 hours, the 
cells were washed with D-PBS once and then incubated with 100 µL of D-PBS containing 5 µM Calcein 
AM for 45 min. Calcein AM is a cell-permeable dye which converts to a fluorescent product after 
acetoxymethyl ester hydrolysis by intracellular esterases, which is used to determine the cell viability 
(413). The fluorescence was read at an excitation wavelength of 485 nm and emission of 528 nm using 
an HT Synergy microplate reader (Bio-Tek Instruments, Winooski, VT). 
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3.3.4 CellTiter-Glo® luminescent cell viability assay 
The cytotoxicity of the MDA-MB-231 cell line was measured using the CellTiter-Glo® luminescent 
cell viability assay kit to measure the cellular ATP content. The overexpression of P-glycoprotein in MDA-
MB-231 cells make Calcein AM unsuitable for the cell viability assay in this cell line, as Calcein AM is the 
substrate. The cytotoxicity IC50 values generated by different cell viability assays were compatible in a 
majority of cancer cell lines  (413). Briefly, 7,500 cells were seeded in 96 well plates and treated for 72 h 
as described above. Then 100 µL of CellTiter-Glo buffer containing beetle luciferin and luciferase was 
added to each well and mixed thoroughly. The plates were then incubated at room temperature for 45 
min and luminescent signals were recorded at an integration time of 0.25 sec per well using the HT Synergy 
microplate reader. 
3.4 Data analysis 
Each experiment was conducted in replicates of three on three different occasions. Fluorescence 
or luminescence data of the cytotoxicity assays were normalized to negative control wells. Concentration-
response curves were then generated using a four parameter nonlinear regression equation with variable 
slope in GraphPad Prism (GraphPad Prism 5.0 software, San Diego, CA) to estimate IC50 values, which were 
reported as mean and 95% confidence interval (CI). Some of the experimental data could not be fitted 
using this model and were analyzed using two-way ANOVA with Tukey’s post hoc analysis. Significance 
was set at p ≤ 0.05. 
In order to assess whether lignan metabolites increase the sensitivity of tumor cells to various 
chemotherapeutic agents, the dose reduction index (DRI) was calculated according to following equation: 
DRI = ୍େఱబ,   ఽౢ౥౤౛
୍େఱబ,   ి౥ౣౘ
   Equation 1 
Since we were unable to carry out a complete combination study (353), DRI was used to 
approximate a dose-reduction for each drug in the therapeutic applications. DRI indicates the fold 
decrease in dose required to achieve the same cell response as drug alone. IC50, Alone is the IC50 value of 
drug in absence of the flaxseed lignans; IC50, Comb represents the IC50 value of drugs in combination with 
flaxseed lignans. A DRI greater than 1 indicates increased sensitivity of cells to the combination treatment. 
3.5 Results 
3.5.1 IC50 values of flaxseed lignan metabolites against metastatic breast cancer cell lines 
The cytotoxicity of flaxseed lignans against HER2 positive (SKBR3) and triple negative (MDA-MB-
231) breast cancer cell lines was initially determined through use of the Calcein AM assay (SKBR3) and the 
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CellTiter-Glo® cell viability assay (MDA-MB-231) (Appendix C-Figure C-4). The Calcein AM and the ATP 
content assay yield comparable IC50 values in various human cell lines (414); however, high expression of 
p-glycoprotein in MDA-MB-231 prevented use of the Calcein AM cell viability assay in this cell line. The 
IC50 values of flaxseed lignan metabolites in SKBR3 and MDA-MB-231 cells listed in Table 3-1 indicate that 
ENL caused moderate cytotoxicity to both MDA-MB-231 and SKBR3 cells with MDA-MB-231 cells requiring 
slightly lower concentration to achieve 50% cell death compared with SKBR3 cells. When compared to 
ENL, more than a 6-fold greater concentration of SECO was required to cause 50% cell death in MDA-MB-
231 cells. In SKBR3 cells the concentration of SECO producing a 50% reduction in cell viability exceeded 
the solubility limit of this lignan metabolite (1000 µM). No obvious toxic effect was caused by ENL-Gluc 
(data not shown). 
Table 3-1. The mean IC50 values of flaxseed lignan metabolites, enterolactone (ENL) and 
secoisolariciresinol (SECO), in SKBR3 and MDA-MB-231 cells after 72 h exposure. Experiments were 
carried out in triplicate on three separate occasions and data are presented as mean IC50 values with 95% 
confidential interval (CI). No loss in cell viability was observed with enterolactone glucuronide (data not 
reported). 
 
SKBR3 MDA-MB-231 
SECO ENL SECO ENL 
IC50 µM 45.3%* 149 625 101 
95% CI - 134-165 282-1388 90-114 
*IC50 values were not achievable. Values displayed are for % inhibition achieved at 1000 µM for 
SECO. 
3.5.2 Combination effect of flaxseed lignan metabolites in SKBR3 
To investigate whether flaxseed lignans may enhance cytotoxicity of anticancer agents in HER2 
positive breast cancer, cytotoxicity assays with three different anticancer drugs were conducted in SKBR3 
cells in the absence and presence of SECO, ENL, and ENL-Gluc (Table 3-2, and Appendix C-Figure C-5). 
SECO and ENL, but not ENL-Gluc, decreased the IC50 values of docetaxel in SKBR3 cells, while doxorubicin 
and carboplatin IC50 values remain unchanged. The DRI values for docetaxel showed a concentration-
dependent response, with 3.9- and 4.4-fold increase in cytotoxicity when combined with 50 µM SECO and 
ENL, respectively (Table 3-3). No combination effects were observed in SKBR3 cells when the lignan 
metabolites were combined with doxorubicin and carboplatin.  
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Table 3-2. IC50 values of docetaxel, carboplatin and doxorubicin in combination with different 
concentrations of enterolactone (ENL) and secoisolariciresinol (SECO) in SKBR3 cells. Data are reported as 
mean IC50 values with 95% confidence interval (CI). No loss in cell viability was observed with 
enterolactone glucuronide (data no reported). Combination with ENL and SECO decreased the IC50 values 
of docetaxel via a concentration-dependent manner. No positive results were found from combination of 
ENL and SECO with doxorubicin or carboplatin. 
SKBR3 Drug only 
Plus SECO Plus ENL 
25 µM 50 µM 25 µM 50 µM 
Docetaxel     IC50 nM 
(95% CI) 
0.75 0.34 0.19 0.31 0.17 
(0.53-1.06) (0.20-0.59) (0.09-0.42) (0.17-0.6 (0.1-0.29) 
Doxorubicin IC50 nM 
(95%CI) 
4.3 5.1 4.7 4.1 5.1 
(3.6-5.3) (3.9-6.7) (3.5-6.4) (3.2-5.2) (4.0-6.6) 
Carboplatin  IC50 nM 
(95%CI) 
25 30 30 33 29 
(21-29) (26-35) (25-36) (27-40) 24-35) 
 
 
Table 3-3. Dose reduction index (DRI) values for combination of anticancer drugs with secoisolariciresinol 
(SECO) and enterolactone (ENL) in SKBR3 cells. The baseline of DRI (drug only) was set to be 1. 
DRIs -SKBR3 Drug only 
Plus SECO Plus ENL 
25 µM 50 µM 25 µM 50 µM 
Docetaxel 1 2.2 3.9 2.4 4.4 
Doxorubicin 1 0.8 0.9 1.0 0.8 
Carboplatin 1 0.8 0.8 0.7 0.8 
 
3.5.3 Combination effect of flaxseed lignan metabolites with anticancer drugs in MDA-MB-231 cells 
To investigate whether flaxseed lignan metabolites may enhance the cytotoxicity of anticancer 
agents in triple negative breast cancer, cytotoxicity studies were conducted with three different 
anticancer drugs in MDA-MB-231 cells in the absence and presence of SECO, ENL and ENL-Gluc (Table 3-
4, Figure 3-1, and Appendix C-Figure C-6). At 50 µM, ENL decreased the IC50 value of docetaxel from 1.0 
nM to 0.1 nM. SECO and ENL did not alter the IC50 values of doxorubicin. ENL-Gluc, had no effect on the 
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IC50 values of any drug (data not shown). ENL at 50 µM increased the sensitivity of MDA-MB-231 cells to 
docetaxel by 10 fold (Table 3-5). 
Due to the solubility limits of carboplatin, the maximum concentration of carboplatin used was 300 
µM in all treatments. No significant results were found in combination with SECO (Figure 3-2). ENL, 
however, significantly reduced the cell viability of carboplatin (P<0.0001). The maximum effect was 
observed with a combination of 75 µM carboplatin and 50 µM ENL which decreased cell viability by 27% 
(Figure 3-2). 
Table 3-4. The mean IC50 values of docetaxel and doxorubicin in combination with different concentrations 
of enterolactone (ENL) and secoisolariciresinol (SECO) in MDA-MB-231 cells. Experiments were performed 
in triplicate on three separate occasions. Data are reported as mean IC50 values with 95% confidence 
interval (CI). No loss in cell viability was observed with enterolactone glucuronide (data not reported). 
Combination with SECO and ENL decreased the IC50 values of docetaxel via a concentration-dependent 
manner. No positive results were observed from doxorubicin. 
 
 
Table 3-5. Dose reduction index (DRI) values for the combination of anticancer drugs with enterolactone 
(ENL) and secoisolariciresinol (SECO) in MDA-MB-231 cells. The baseline of DRI (drug only) value was set 
to 1. 
DRIs Drug only 
Plus SECO Plus ENL 
25 µM 50 µM 25 µM 50 µM 
Docetaxel 1 1.0 1.6 1.0 10.0 
Doxorubicin 1 0.8 0.8 1.0 1.0 
 
 
MDA-MB-231 Drug only 
Plus SECO Plus ENL 
25 µM 50 µM 25 µM 50 µM 
Docetaxel     IC50 nM 
95% CI 
1.0 1.0 0.61 1.0 0.1 
0.77-1.3 0.66-1.5 0.38-1.0 0.73-1.35 0.03-0.36 
Doxorubicin   IC50 µM 
95%CI 
0.7 0.86 0.87 0.73 0.7 
0.6-0.83 0.76-0.97 0.72-1.06 0.65-0.82 0.56-0.87 
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Figure 3-1. Combination of carboplatin with secoisolariciresinol (SECO) (A), and enterolactone (ENL) (B) in 
MDA-MB-231 cells. MDA-MB-231 cells were incubated with carboplatin (open circle, solid line) alone or 
in combination with 25 µM (closed circle, dashed line) or 50 µM (open rectangle, dashed line) SECO or 
ENL for 72 h in triplicate on three separate occasions. Cell viability was determined using CellTiter-Glo® 
luminescent cell viability assay kit. Due to solubility issues, the maximum concentration of carboplatin was 
300 µM in all treatments. No significant change in cell viability was found in combination with SECO. ENL 
enhanced the cytotoxicity of carboplatin (P<0.0001). At 75 µM carboplatin, co-administration of 50 µM 
ENL resulted in a decrease in cell viability by 27%. 
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3.6 Discussion 
The treatment of metastatic breast cancer is complex. Chemotherapy is the major option and the 
type of chemotherapy used is largely dependent on the molecular subtypes of the cancer cells. Almost 
half of the breast cancer patients are diagnosed with HER2 positive (25-30%) (182) or triple negative 
breast cancer (TNBC) (15%) (415). These are typically associated with an increased likelihood of recurrence 
and poor prognosis (183). Despite new chemotherapeutic regimens, the prognosis and overall survival for 
metastatic breast cancer remains poor (396, 397). Recent evidence elucidated from epidemiological (193) 
and animal studies (189, 190, 359) suggests that dietary flaxseed lignans in combination with other 
chemotherapeutic agents may improve treatment outcomes of metastatic breast cancer. This study 
evaluated the combination effect of purified flaxseed lignan metabolites with several chemotherapeutic 
agents used in breast cancer treatment against triple negative and HER2 positive cell lines. The study was 
designed to provide direct evidence of the ability of flaxseed lignan metabolites to improve the cytotoxic 
activity of various anticancer drugs for the potential application of oral flaxseed lignan supplementation 
as adjuvant therapy in this important disease. 
The combination study suggests that flaxseed lignans, SECO and ENL, could enhance the anticancer 
activity of therapeutic agents against breast cancer cell lines. SECO usually is recognized as a major plant 
precursor of the mammalian lignans, ED and ENL (64-66), while recent evidence suggest it exhibits better 
oral bioavailability (80). Our study first demonstrated that SECO also exhibits moderate anti-proliferative 
properties against breast cancer cells. Furthermore, SECO selectively enhanced the cytotoxicity of 
docetaxel in SKBR3 and MDA-MB-231 cells. Since a significant portion of SECO was detected in human and 
rodent plasma following oral consumption of lignan enriched complex (79, 80), our data suggest that in 
future studies on the relationship between health benefits and flaxseed lignans following oral 
consumption should consider measurement of plasma SECO levels. ENL, a key lignan associated with 
anticancer effect of flaxseed lignans, caused moderate cytotoxic effect alone or in combination with 
several therapeutic agents that exhibit different mechanisms of action. Exposure with 50 µM ENL plus 
docetaxel gave the most stable combination effect and consistently resulted in very high DRI values of up 
to 10 fold in SKBR3 and MDA-MB-231 cells. The high DRI values suggest it might be possible to reduce 
docetaxel dosage when used in combination with ENL, while still achieving the cytotoxicity of docetaxel 
alone. Consequently, combination with flaxseed lignans might lead to docetaxel dosage reductions with 
concomitant reductions in docetaxel side effects. This promises an improvement in the clinical efficacy 
and the quality of life in patients with metastatic breast cancers. 
69 
 
Although cytotoxic chemotherapy treatments have improved the overall survival in patients with 
metastatic breast cancer where few alternative treatments are available (397), treatment associated side 
effects often result in dosage reductions below an optimal regimen, which limits the utility of cytotoxic 
chemotherapy in clinical practice. These side effects become more problematic for patients with late-
stage metastatic breast cancer, where chemotherapy is primarily intended to ease symptoms and improve 
quality of life in such patients. Consequently, any decrease in quality of life as a result of treatment is 
unacceptable (416). In conjunction with supportive published data in animal models (359, 360) and the 
purported safety of dietary flaxseed lignans following from human clinical trial evaluations of 
pharmacologically relevant doses of lignans (47, 333, 412), our in vitro data support the possibility of using 
flaxseed lignan supplementation as adjuvant therapy to decrease  cytotoxic chemotherapeutic drug 
dosage requirements while enhancing their effectiveness. Minimizing the decrease in quality of life 
expected with use of cytotoxic chemotherapeutic agents has immense value to patients. 
3.7 Conclusion 
In conclusion, this study provides experimental support for the utility of flaxseed lignans as adjuvant 
therapy with typical therapeutic agents against metastatic breast cancer. The flaxseed lignans, especially 
ENL, selectively enhance the cytotoxicity of chemotherapeutic agents with different mechanisms of action 
in Her 2 positive, SKBR3 breast cancer cells and triple-negative MDA-MB-231 breast cancer cells. Our 
results warrant further in vitro studies to understand the mechanism that contributes to the combination 
effects with cytotoxic chemotherapeutic agents. Furthermore, human clinical trials should explore the 
clinical utility of dietary flaxseed lignan supplementation as adjuvant therapy in patients with metastatic 
breast cancer. 
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Relationship of the manuscript to the thesis:  
This manuscript describes the generation and validation of a pharmaceutical strategy in vitro. The 
combination studies suggest that flaxseed lignans, mainly ENL, could significantly enhance the cytotoxicity 
of chemotherapeutic agents, while glucuronide conjugate (ENL-Gluc) is confirmed to be inactive. The 
fusion protein D7-hbG is generated for the purpose of site specific activation of ENL from circulating 
glucuronide conjugate at tumor area. The ADEPT approach (the D7-hβG system with ENL-Gluc as prodrug) 
offers a therapeutic strategy in cancer treatment by taking advantage of an extensive first-pass effect 
associated with oral flaxseed lignan consumption. 
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4.1 Abstract 
Evidence from preclinical and animal studies demonstrated an anti-cancer effect of flaxseed lignans, 
particularly enterolactone (ENL), against prostate cancer. However, extensive first-pass metabolism 
following oral lignan consumption results in their systemic availability primarily as glucuronic acid 
conjugates and their modest in vivo effects. To overcome the unfavorable pharmacokinetics and improve 
their effectiveness in prostate cancer, antibody-directed enzyme prodrug therapy (ADEPT) may offer a 
novel strategy to allow for restricted activation of ENL from circulating ENL-Gluc within the tumor 
environment. The anti-prostate specific membrane antigen (PSMA) antibody D7 was fused with human β-
glucuronidase (hβG) via a flexible linker. The binding property of the fusion construct, D7-hβG, against 
purified or cell surface PSMA was determined by flow cytometry and Octet® Red 384 system, respectively, 
with a binding rate constant, Kd, of 2.5 nM. The enzymatic activity of D7-hβG was first tested using the 
probe, 4-methylumberlliferone glucuronide. A 3.8-fold greater fluorescence intensity was observed at pH 
4.5 at 2 hours compared with pH 7.4. The ability of D7-hβG to activate ENL from ENL-Gluc was tested and 
detected using LC-MS/MS. Enhanced generation of ENL was observed with increasing ENL-Gluc 
concentrations and reached 3,613.2 ng/mL following incubation with 100 µM ENL-Gluc at pH 4.5 for 0.5 
h. D7-hβG also decreased docetaxel IC50 value from 23 nM to 14.9 nM in C4-2 cells. These results 
confirmed the binding and activity of D7-hβG and additional in vitro investigation is needed to support 
the future possibility of introducing this ADEPT system to animal models. 
4.2 Introduction 
Dietary natural products have gained general public attention for their putative ability to reduce 
the risk of cancer or improve cancer treatment outcomes. A wide range of biologically active compounds 
have been identified from dietary natural products that are responsible for anti-cancer effects including 
flavonoids, lignans, and catechins (16). The evolving evidence suggests that these naturally occurring 
compounds have chemotherapeutic effects against multiple human cancers and could enhance the 
cytotoxic effects of standard chemotherapeutic agents when used in combination (417, 418). A synergistic 
effect between chemotherapeutic agents and natural products might allow for optimization and 
reduction of the dosage regimen of chemotherapeutic drugs while ameliorating severe side effects caused 
by chemotherapy. 
Flaxseed lignans are a group of compounds possessing an unique diphenolic structure (57). Studies 
on the effect of flaxseed lignan supplementation on prostate cancer have demonstrated that flaxseed 
lignans inhibit tumor growth in vivo (174, 333, 350). The health benefits are positively correlated with 
elevated serum concentration of total lignans, and in particular to the mammalian lignan, enterolactone 
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(ENL), which is produced in the mammalian gastrointestinal tract through bacterial metabolic reactions 
following oral consumption of flaxseed lignan-rich products (48, 65). Multiple mechanisms of action (e.g. 
antiproliferation, antioxidation, and antiangiogenesis) may be involved in the chemotherapeutic effect of 
ENL (113, 169). Recent safety data published from in vivo human clinical studies of flaxseed lignan-
enriched products indicate no adverse side effects and demonstrated good tolerability with long-term 
oral daily administration at a low pharmacological dose (47, 412). This human clinical trial information is 
important to support the use of flaxseed lignans against prostate cancer. However, translation from bench 
to clinic remains challenging as flaxseed lignans exhibit very low bioavailability due to extensive first-pass 
metabolism following oral consumption. This property limits its utility to effect more than modest health 
benefits. The flaxseed lignans undergo extensive phase II metabolism, in particular by uridine 5'-
diphospho-glucuronosyltransferases (UGTs), and exist in the plasma predominantly as glucuronide 
conjugates (ENL-Gluc), which are believed to be inactive (75, 347). Recent data (manuscript submitted) 
demonstrates a lack of cytotoxicity for ENL-Gluc against prostate cancer cell lines, while ENL exhibits 
moderate cytotoxicity and synergism with docetaxel. 
To overcome the unfavorable pharmacokinetic profile associated with oral lignan consumption, 
antibody-directed enzyme prodrug therapy (ADEPT) may offer a novel strategy to allow for specific 
activation of high levels of ENL from circulating ENL phase II metabolites (e.g. ENL-Gluc) with the activation 
mainly restricted within the tumor environment. ADEPT localizes an antibody-enzyme conjugate to the 
tumor area through specific interactions between the antibody and tumor specific cell surface antigens 
where the localized enzyme then may activate systemically available ‘prodrug’ into an active cytotoxic 
drug (224, 419). Since high circulating levels of the ENL-Gluc phase II metabolite follows from an oral 
administration of flaxseed lignan rich products, the non-cytotoxic ENL-Gluc can be considered a ‘prodrug’. 
Fusion of the enzyme β-glucuronidase to an antibody that targets a specific prostate cancer cell surface 
antigen would result in specific targeting of the fusion complex to the prostate cancer sites with ENL-Gluc 
undergoing conversion into the pharmacologically active, ENL, via the action of the enzyme human β-
glucuronidase (hβG) fused to an antibody. 
To investigate the ADEPT approach as a pharmaceutical strategy to improve therapeutic outcomes 
associated with flaxseed lignan oral consumption as adjuvant therapy to currently available 
chemotherapeutic agents, we first require construction of an antibody-enzyme fusion construct and 
validation of both its specific targeting to a prostate cancer specific cell-surface antigen and ability of the 
fusion construct to mediate the cleavage of the glucuronide group from the prodrug, ENL-Gluc, to yield 
cytotoxic ENL. Given the enhanced expression of prostate specific membrane antigen (PSMA) in some 
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prostate cancers (268), the purpose of this work is to generate an antibody-enzyme fusion construct 
targeting PMSA, assess its specific binding to PMSA in vitro, and determine the ability of the fused enzyme, 
human β-glucuronidase, to efficiently cleave the glucuronic acid moiety from ENL-Gluc to generate 
effective levels of ENL to kill prostate cancer cells in vitro. 
4.3 Materials and Methods 
4.3.1 Materials 
Enterolactone glucuronide (ENL-Gluc) was synthesized according to a previously established 
method in our laboratory (347) (Appendix A). Materials used in generating the fusion protein including, 
Poly-Prep® Chromatography columns, precision plus ProteinTM kaleidoscopeTM standards, Immun-Blot® 
PVDF membrane, 0.4% trypan blue, sodium dodecyl sulfate (SDS), 8% sodium dodecyl sulfate-
polyacrylamide gel, horseradish peroxidase (HRP) conjugated mouse anti-rabbit antibody, ClarityTM 
Western ECL Blotting Substrate, and bromophenol blue were purchased from Bio-Rad (Mississauga, ON, 
Canada). All FastDigest restriction enzymes including SspI, BamHl, Bgl ll, EcoRI, Xhol, Scal and Sfil, glycine, 
OptimaTM LC/MS acetonitrile (ACN), OptimaTM LC/MS water, OptimaTM LC/MS methanol, and 384-well 
tilted-bottom microplates were purchased from ThermoFisher Scientific (Toronto, ON, Canada). Rabbit 
anti c-myc epitope antibody and type A biotin (Type A) conjugation kit was obtained from Abcam (Toronto, 
ON, Canada). Dam-/Dcm- competent E. coli (C2925) and Phusion® High-Fidelity DNA Polymerase were 
purchased from New England Biolabs Ltd (Ipswich, MA, US). Dip and Read™ Streptavidin (SA) Biosensors 
were purchased from ForteBio (Menlo Park, CA, US). Amicon Ultra-15 centrifugal filter unit with Ultracel-
50 membrane was obtained from EMD Millipore (Etobicoke, ON, Canada). Ni-NTA Agarose was purchased 
from Qiagen (Germantown, MD, US). Purified recombinant human PSMA was purchased from Sino 
Biological (Beijing, China). Tryptone and yeast extract were purchased from Becton Dickinson (BD) 
(Mississauga, ON, Canada). Diethyl ether was purchased from EMD Chemicals Limited (Gibbstown, NJ). 
Whatman Mini-UniPrep Syringeless Filter vials, Dulbecco’s Modified Eagle’s Medium (DMEM)/high 
glucose medium, Roswell Park Memorial Institute (RPMI) 1640 medium were purchased from GE 
Healthcare Life Sciences (Mississauga, ON, Canada). Goat anti-rabbit Ig R-phycoerythrin (RPE) was 
purchased from Cayman (Ann Arbor, Michigan, US). Human plasma EDTA-K2 was obtained from 
BioreclamationIVT (Baltimore, MD, US). Double deionized water was provided from a MilliQ Synthesis 
Water Purification system (Millipore, Bedford, MA). tag DNA polymerase (native), InvitrogenTM dNTP mix 
(10 mM), dATP, 1 Kb plus DNA Ladder, ultra-low IgG fetal bovine serum (FBS), Lipofectamine® 2000 
transfection reagent, Purelink Gel extraction kit were purchased from Invitrogen Inc. (Burlington, ON, 
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Canada). pHUGP-hβG, COS-7 cell line, cell culture grade dimethyl sulfoxide (DMSO), and Dulbecco's 
Phosphate-Buffered Saline (D-PBS) was obtained from American Type Culture Collection (ATCC, Manassas, 
VA, US). pGEM®-T Easy Vector and BCA Protein Assay kit was purchased from Pierce (ThermoFisher 
Scientific, Toronto, ON, Canada). DH5α cells, Imidazole solution, 0.25% (w/v) trypsin – 0.53 mM EDTA 
solution, and penicillin (100 U/mL)/streptomycin (100 μg/mL) solution, protease inhibitor cocktail (100X) 
in DMSO, 4-methylumberliferone glucuronide (4-MuGluc) were bought from Sigma-Aldrich (Oakville, ON, 
Canada). The Spectra/Por standard RC trial kit (6-8 kDa) was from Spectrum Laboratories (Rancho 
Dominguez, CA, US). pSectag-D7-VHVL and pSectag2a vectors were gifts from Dr. Philipp Wolf (Freiburg, 
Germany). HRP conjugated mouse anti-rabbit antibody was a gift from Dr. Adil Nazarali (University of 
Saskatchewan). C4-2 cells were a gift from Dr. Kishor Wasan (University of Saskatchewan). 100 mm falcon 
cell culture dishes were purchased from Corning (NY, US). All other chemicals were cell culture grade. 
4.3.2 Cell Culture 
COS-7 cells were maintained in (DMEM)/high glucose medium with 10% FBS, 1% penicillin and 1% 
streptomycin. C4-2 cells and LNCap cells were maintained in RPMI 1640 medium supplemented with 10% 
FBS, 1% penicillin and 1% streptomycin. Cells were grown in 100 mm falcon cell culture dishes and cell 
culture media was changed every two to three days. All cell lines were cultured at 37 C, 95% humidity 
and 5% CO2 in a ThermoFisher incubator (ThemoFisher Scientific, Toronto, ON, Canada). 
4.3.3 Generation of the D7-hβG Fusion Construct by Overlap-Extension PCR (OE-PCR) 
The fusion construct was designed according to the steps depicted in Appendix D-Figure D-8. The 
fusion construct was established using OE-PCR, a variant of PCR which uses primers complementary to 
each other. For this project the DNA sequence (GGGGS)3 was used. Briefly, the anti-PSMA single-chain 
antibody fragment D7 (scFv) in VH-VL orientation (D7-VHVL) cDNA sequence was amplified from the 
pSectag-D7-VHVL plasmid with EcoRI restriction sites introduced to the 5’ end and a reverse-
complementary (GGGGS)3 sequence to the 3’ end, which is mutated from a template linker between the 
VH and VL chain in order to reduce interference in the overlap PCR reaction. The hβG cDNA sequence was 
amplified using forward and reverse primers, betaG5 and betaG3, which added the forward-
complementary (GGGGS)3 sequence to the 5’ end of the PCR products and a XhoI enzyme restriction site 
to the 3’ end of the hβG DNA sequence (Table 4-1). Subsequently, equal amounts of D7-VHVL cDNA and 
hβG cDNA were mixed together and fused by a two-step process. First, 2.5 μL 5X HP buffer, 2.5 μL D7 
cDNA fragment (250 ng), 2.5 µL hβG cDNA (250 ng), 0.5 μL dNTP (10 mM), and 0.5 μL Phusion® high-
fidelity DNA polymerase were combined and adjusted to 25 µL with DNase/RNase free water and then 
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mixed together into a 0.2 mL PCR tube. The reaction conditions at the start of the PCR were 30 s at 98 °C, 
followed by 30 cycles of 30 s at 98 °C, 40 s at 55 °C, and 90 s at 72 °C, with a final extension for 5 min at 
72 °C. After completion of the PCR cycles, a new 25 µL mixture containing 5 μL 5X HP buffer, 2.0 μL FC5B 
forward primer (10 µM), 2.0 μL betaG3 reverse primer (10 µM), 0.5 µL dNTP (10 mM), 0.5 μL Phusion® 
high-fidelity DNA polymerase, and 15 µL water was added to the previous PCR mixture to make a final 
volume of 50 µL. The qPCR reaction was carried out with a slight modification of the previous PCR reaction 
conditions. The reaction was initiated with 30 s at 98 °C, followed by 30 cycles of 30? s at 98 °C, 40 s at 
55 °C and 120 s at 72 °C, with a final extension of 5 min at 72 °C. The PCR products were submitted to 1% 
DNA gel electrophoresis for 40 min at 120 voltages. The target bands on the gel were identified under a 
UV transilluminator (VWR, Radnor, PA, US) and carefully excised using scalpel. The gel slice containing the 
DNA fragment of interest was collected using a scale (Columbus, OH, US) and extracted using the Purelink® 
Gel extraction kit according to the manufacturer’s protocol. The concentration of the purified PCR 
products were quantified on a Nanoview spectrophotometer (GE Healthcare, Baie d’Urfe, Quebec, 
Canada). The recombinant DNA sequence was subcloned into pGEM®-T Easy Vector and verified by 
sequencing (National Research Council of Canada). For DNA sequencing, betaG F, betaG R, M13 forward 
and reverse primers were used (additional betaG F and betaG R was designed for the middle of the DNA 
fragment to ensure every single base in the fusion construct was correct). The correct sequence was then 
subcloned into pSectag2a expression vector using the EcoRI/XhoI double enzyme digestion system. 
 
4.3.4 D7-hβG Transfection and Purification 
pSectag2a vector was chosen for expression of the fusion protein in eukaryotic cells since the vector 
contains a special Igκ signaling peptide that allows for extracellular secretion of the fusion protein. 
Plasmids were transfected into COS-7 cells with lipofectamine® 2000 transfection reagent. Briefly, 0.5 × 
106 cells were seeded in 6-well plates and allowed for overnight attachment in non-antibiotic 
supplemented DMEM medium with 10% FBS. 4 µL of lipofectamine® 2000 was diluted with 150 µL of 
DMEM. 150 µL of DMEM containing 4 µg plasmids was then added to the previous mixture and incubated 
for 20 min at room temperature before adding to the cells. The COS-7 cells were switched to full medium 
after 8 h of incubation with transfection agents. The cell culture supernatant was collected at 72 h and 
subjected to purification. For purification, the supernatant from transfected COS-7 cells was added to 1X 
protease inhibitor cocktail and incubated with Ni-NTA agarose at 4 °C for 1 h before loading onto a poly-
pre-chromatography gravity column. Then, the resins were collected and washed three times with 
imidazole binding buffer (20 mM NaH2PO4, 0.5 M NaCl, 25 mM imidazole, pH 8.0). The fusion protein was 
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eluted by 1 mL binding buffer containing 300 mM imidazole. The elution was collected and dialyzed in D-
PBS overnight at 4 °C using the Spectra/Por standard RC trial kit (6-8 kDa). The dialyzed solution was 
transferred into an Amicon Ultra-15 centrifugal filter unit and spun at 6000×g for 30 min. Protein 
concentration was determined using a Pierce BCA Protein Assay kit according the manufacturer’s 
instructions. 
Table 4-1. Primer sequences. FC5B and FC3 were the forward and backward primers that amplified the 
cDNA sequence of D7 antibody. betaG5 and betaG3 were the forward and backward primers used for 
amplification of the cDNA sequence of human β-glucuronidase. Due to the long size of fusion fragment, 
primers betaG F, betaG R, M13 forward, M13 backward were designed for DNA sequencing. 
 
 
 
 
4.3.5 Western Blot of D7-hβG Protein 
D7-hβG was mixed with 4X sample loading buffer (2.5% SDS, 5% 2-mercaptoethanol, 2.5% glycerol, 
0.025% bromophenol blue, 0.015 M Tris-HCl, pH 6.8) and boiled at 95 °C for 10 min. The supernatants 
were then loaded on an 8% sodium dodecyl sulfate-polyacrylamide (SDS) gel for electrophoresis and 
subsequently blotted onto a PVDF protein membrane. Blots were blocked with 5% skim milk for 1 h at 
room temperature followed with three rounds of washing in PBST buffer (8 mM Na2HPO4, 150 mM NaCl, 
2 mM KH2PO4, 3 mM KCl, 0.05% Tween 20, pH 7.4), and incubated with rabbit anti c-myc epitope primary 
antibody overnight at 4 °C. Membranes were washed with PBST again for 3 × 10 min on a shaker. 
Membranes were incubated with horseradish peroxidase (HRP) conjugated mouse anti-rabbit antibody 
Primer Sequence 5’-3’ 
FC5B GAATTCAGGTGCAGCTGCAGCAGTCTGG 
FC3 
TGATCCACCGCCACCAGAGCCACCACCGCCTGAGCCACCTCCACC 
CCGTTTTATTTCCAGCTTGGTCC 
betaG5 
GGTGGAGGTGGCTCAGGCGGTGGTGGCTCTGGTGGCGGTGGATCA 
CTGCAGGGCGGGATGCTGTACCC 
betaG3 CTCGAGCAGTAAACGGGCTGTTTTCCAAAC 
betaG F TGGACGGCCTCTGGAGCTTCC 
betaG R TTGAAGTCCTTCACCAGCAGC 
M13 Forward GTTTTCCCAGTCACGAC 
M13 Reverse CAGGAAACAGCTATGAC 
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as secondary antibody for 2 h at room temperature before visualization with ClarityTM Western ECL 
Blotting Substrate in a GBOX F3 documentation system (Syngene, Frederick, MD) installed with GeneSys 
automatic control software (Syngene, Frederick, MD). 
4.3.6 Binding of D7-hβG to PSMA 
The cell binding affinity of the D7-hβG against cellular surface PSMA antigen was evaluated by flow 
cytometry. Briefly, 2×105 LNCap cells were suspended in 1 mL D-PBS containing 3% ultra-low IgG PBS. 25 
µL of D7-hβG fusion protein (final concentration from 0.318 – 3.18 µM) was added to LNCap cells and 
incubated on ice for 1 h. Following three rounds of washing with D-PBS, cells were incubated with rabbit 
anti-human c-myc mAb for 40 min on ice.  After another three rounds of washing, the cells were incubated 
with 25 µL goat anti-rabbit Ig-RPE (1:100) for another 40 min on ice. The cells were rewashed and finally 
suspended in 500 μL PBS containing 1 μg/mL propidium iodide (PI). Cells stained with goat anti-rabbit Ig-
RPE were used to extract background. The relative fluorescence of the stained cells was measured using 
a flow cytometer (BD Biosciences, Mississauga, ON, Canada) and CellQuest software (BD Biosciences, 
Mississauga, ON, Canada). 
The binding affinity between D7-hβG and purified recombinant PSMA was tested by determination 
of the association rate (kon) and dissociation rate (koff) constants using an Octet® 384 System (Menlo Park, 
CA, US). The biosensor study was performed at 25 °C using the ForteBio Octet® Red biosensor system. 
Purified recombinant PSMA was pre-labeled with biotin using a Biotin (Type A) conjugation kit. Briefly, 1 
µL of modifier reagent from the kit was added into 10 µL of recombinant PSMA (1 mg/mL). Recombinant 
PSMA was then mixed with the biotin reagent by gently withdrawing and re-dispensing the liquid twice 
using a pipette. The mixture was incubated overnight at room temperature in the dark. One µL of 
Quencher reagent was added to the PSMA mixture to neutralize free biotin in the solution. The 
recombinant PSMA was ready for use after 30 min. PSMA was diluted to a concentration of 122 nM. D7-
hβG was prepared at a two-fold serial dilution in D-PBS starting at 6.36 µM with seven different 
concentrations. PBS was used as control for background non-specific binding. The binding assay was 
conducted in 384-well tilted-bottom microplates. The Octet® 384 system program was set as follows: the 
streptavidin biosensors were first washed in D-PBS for 120 s for baseline stabilization. The biosensors 
were then dipped in diluted biotin labeled PSMA solution for 300 s, followed by 120 s washing in PBS to 
stabilize a new baseline. The biosensors were then transferred into different concentrations of D7-hβG 
(0.1 µM-6.36 µM) for 300 s (association) followed with another 300 s washing procedure (dissociation) in 
D-PBS. Data were collected and analyzed using Octet® pro data analysis software 7.1 (ForteBio, Menlo 
Park, CA, US). Binding kinetics were measured using a standard one binding site model to determine 
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association rate (kon) and dissociation rate (koff) constants, which were used to calculate the equilibrium 
binding affinity constant (Kd) according to equation 2. 
۹ࢊ =
ܓ࢕ࢌࢌ
ܓ࢕࢔
               Equation 2 
4.3.7 Enzymatic Activity of D7-hβG 
Enzymatic activity of D7-hβG was confirmed using 4-methylumberliferone glucuronide (4-MuGluc) 
as substrate. 1.6 mM 4-MuGluc, ENL-Gluc (10, 20 or 100 µM) or vehicle control (1 µL D-PBS) was added 
to phosphate-citrate buffer (pH 4.5 or pH 7.4, mix of 0.2M Na2PO4 and 0.1 M citrate). The reaction was 
initiated by adding 2 μL of D7-hβG (0.7 µg/µL) into each well resulting in a total volume of 100 µL. 30 µL 
of samples were collected at 0.5, 1, and 2 hour time points. 150 µL of stop buffer (0.2 M sodium carbonate, 
pH 10) was then added to terminate the reaction. For 4-MuGluc, its fluorescent product, 4-methyl-
umbelliferone (4-Mu), was measured using an excitation wavelength of 370 nm and an emission 
wavelength of 450 nm using a Synergy HT microplate reader (Bio-Tek Instruments, Winooski, US). For ENL-
Gluc, the samples were analyzed using a previously validated 10-min running time LC/MS method 
(manuscript submitted). Briefly, 30 µL of samples were well mixed with 300 µL of blank human serum and 
spiked with 30 µL internal standard (ENL-13C3). 4 mL diethyl ether was added and vigorously shaken to 
extract the analytes. Then samples were frozen and the organic phase was collected and dried. Samples 
were then reconstituted in 150 µL (85% acetonitrile with 0.1% formic acid) and filtered through a 0.45 µM 
membrane before proceeding to analysis. 
4.3.8 Cytotoxicity Assay 
The stock solution of ENL and docetaxel were dissolved in DMSO while ENL-Gluc was prepared in 
ddH2O. The final concentration of DMSO in each well as well as the vehicle control was <1 %. Docetaxel 
was diluted in cell culture medium with concentrations ranging from 0.06-1000 nM. C4-2 cells were 
seeded at 5,000 cells per well in 96 well plates pre-coated with poly-L-Lysine (70 kDa – 150 kDa), and 
attached overnight before treatment. Then cells were treated with the desired concentration of docetaxel 
and lignans. After treatment for 72 h, the media was removed and cells were washed with 150 µL D-PBS 
once, and then incubated for 45 min with 100 µL of 1X Calcein AM DW buffer containing 5 µM Calcein AM. 
The cell viability was read from the top of the plate at an excitation wavelength of 485 nm and emission 
of 528 nm using a Synergy HT microplate reader. For the combination study of docetaxel with D7-hβG and 
100 µM ENL-Gluc, C4-2 cells were incubated with 99 µL full culture media (RPMI 1640 with 10% FBS, 1% 
penicillin and 1% streptomycin) containing purified D7-hβG (0.209 µM) and 100 µM ENL-Gluc for 2 h 
before adding serially diluted docetaxel solutions (0.06 – 1000 nM). 
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4.4 Data Analysis 
Fluorescence data of the cytotoxicity assays were normalized to control wells. IC50 estimates were 
generated by conducting a four parameter non-linear regression analysis between percent cell viability 
and log concentration using GraphPad Prism 5.0 for Windows (GraphPad Software, La Jolla, CA, USA). 
Experiments were conducted on at least three different occasions in replicates where appropriate. 
Experimental data were analyzed using a one-way ANOVA with tukey’s post-hoc test (IBM SPSS Statistics 
Version 22, Armonk, NY, US). Significance was set at p ≤ 0.05. 
4.5 Results 
4.5.1 Construction and Identification of D7-hβG Fusion Protein 
The fusion construct was fused together by OE-PCR with a flexible (GGGGS)3 linker introduced 
between two structures. The linker allowed for maximum self-folding freedom for the antibody and 
enzyme separately. The fusion cDNA construct had a total of 2838 bp including EcoRI, 748 bp of D7-VHVL, 
45 bp of (GGGGS)3 linker, 1887 bp of hβG, XhoI, c-myc, and His6 tag sequence (Figure 4-1). The translation 
of the fusion cDNA construct resulted in a fusion protein with 946 amino acids containing c-myc and His6 
tag (Appendix D-Figure D-8). Figure 4-2A shows the electrophoresis gel results of DNA fragments with a 
size of 0.77 kb, 1.9 kb, and 2.7 kb for D7 cDNA, hβG cDNA, and D7-hβG cDNA fragment, respectively (from 
up to lower). The expression plasmid pSectag2a introduced a c-myc and a His6 tag to the C-terminus of 
the protein to allow for the identification and purification of the appropriate fusion construct. The 
predicted size of the fusion construct, D7-hβG, was 110 kDa which was compatible with the positive 
control in figure 4-2B (a c-myc protein with size of 105 kDa). 
 
 
Figure 4-1. Scheme of linearized anti-PSMA D7-VHVL-hβG fusion protein with c-myc and His6 tag attached 
to the C’ Terminal of hβG. D7 represents the scFv antibody against PSMA. hβG contains the amino acids 
of human β-glucuronidase with removal of the signal peptide. (GGGGS)3 is the flexible linker containing 
15 amino acids with repeat of glycerin and serine. c-myc and His6 are tags used for identification and 
purification of the fusion protein. 
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Figure 4-2. Confimation of recombinant cDNA construct (Panel A) by gel electrophoresis and fusion 
protein, D7-hβG, by western blot (Panel B). Panel A shows DNA gel electrophoresis results of 1kb DNA 
ladder, D7-hβG cDNA, hβG cDNA and D7 cDNA sequences from left to right. Panel B shows the western 
blot results of purified D7-hβG fusion protein. The positive control is c-myc protein with a size of 105 kDa. 
The predicted size of the recombinant fusion construct is around 110 kDa. 
4.5.2 Binding Affinity to PSMA Assessed by Flow Cytometry 
A simplified cell surface binding experiment was conducted to qualitatively assess the existence of 
binding of D7-hβG against cell surface PSMA in LNCap cells, a cell line that expresses PSMA. Flow 
cytometry analysis indicates binding of the fusion protein to cell surface PSMA antigen in LNCap cells 
(Figure 4-3, light blue peak). 
 
Figure 4-3. Binding of D7-hβG against LNCap cells (PSMA positive). LNCap cells were incubated with fusion 
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protein, D7-hβG, (0.318 µM) for 1 h. After three washes, cells were washed three times and then stained 
with rabbit anti c-myc mAb and goat anti rabbit lg-RPE mAb. Histograms represent logarithms of RPE-
fluorescence flow cytometry. The dark blue line represents natural fluorescence of cells only. Light green 
line represents cells treated with goat anti rabbit lg-RPE mAb to correct background. Light blue line shows 
cells with surface binding of D7-hβG. 
4.5.3 Binding Dissociation Constant 
To assess the binding affinity of D7-hβG to PSMA antigen, a binding kinetic profile between D7-hβG 
and purified PSMA antigen was conducted using the Octet® Red 384 system (Appendix D-Figure D-9). The 
kon (association rate constant) and koff (dissociation rate constant) were measured separately and used to 
calculate the binding rate constant, Kd, according to Equation 1. Estimated kon and koff values were 4.432 × 
104 (1/Ms) and 1.109 × 10-4 (1/s), respectively. D7-hβG had a Kd value of 2.5 nM, which was consistent 
with previous reports of the Kd value for the antibody fragment, D7, only (315, 420) (Appendix D-Figure 
D-10). The Kd value suggests that conjugation of hβG has almost no effect on the binding affinity of 
antibody to the antigen. 
4.5.4 Enzymatic Activity of D7-hβG Using 4-Methylubelliferone Glucuronide (4-MuGluc) 
The ability of D7-hβG to cleave glucuronic acid group was measured using the standard substrate, 
4-methylubelliferone glucuronide (4-MuGluc), at pH 4.5 and pH 7.4. The reaction buffer without protein 
was used as control. D7-hβG displays a much higher activity at pH 4.5 than pH 7.4 in converting 4-MuGluc 
to its fluorescent product 4-Mu (excitation at 370m, emission at 450 nm) in phosphate-citrate buffer, with 
a 3.8-fold greater fluorescence intensity at 2 h (Figure 4-4). The fluorescence intensity of 4-Mu was 
increased via a time-dependent manner from zero to 2 h at both pH 4.5 and pH 7.4. 
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Figure 4-4. Enzymatic activity of D7-hβG in phosphate-citrate buffer at pH 7.4 (closed symbols and solid 
line) and pH 4.5 (open symbols and dashed line). 1 mM of probe substrate, 4-methylumberliferone 
glucuronide (4-MuGluc), was incubated with D7-hβG (0.128 µM). D7-hβG converted 4-MuGlu into the 
fluorescent product, 4-methylumberliferone (4-Mu), with an excitation at 370 nm and emission at 450 
nm. (Closed symbols and solid line, pH 7.4; open symbols and dashed line, pH 4.5). Data is presented as 
mean (±SD) of three replicates on three separate occasions. 
4.5.5 Enzymatic Activity of D7-hβG Against Prodrug, Enterolactone Glucuronide (ENL-Gluc) 
The ability of D7-hβG to convert ENL-Gluc into ENL was also tested in phosphate-citrate buffer at 
37 °C and at two pH levels, 4.5 and 7. Samples were collected at 0.5, 1 and 2 hour time-points. The 
activated ENL in phosphate-citrate buffer was detected using LC-MS/MS with a previously validated 
method in our laboratory. The production of ENL increased with an increase in ENL-Gluc concentration. 
At pH 4.5, incubated with 10, 20, and 100 µM ENL-Gluc for 0.5 h resulted in ENL levels of 261.3, 528.1, 
and 3613.2 ng/mL, respectively (Figure 4-5). The production of ENL was slightly increased with increasing 
incubation time. Interestingly, no significant difference was observed between pH 4.5 and pH 7.4 group, 
which was different from the results reported with 4-MuGluc. 
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Figure 4-5. D7-hβG mediated cleavage of the glucuronic acid group from enterolactone glucuronide (ENL-
Gluc) in phosphate-citrate buffer at pH 7.4 (solid bar) and pH 4.5 (grey bar). The figure shows the 
production of enterolactone (ENL) as determined by LC-MS/MS for different concentrations, duration of 
incubation, and pH levels. Data is presented as mean (+SD) of three replicates on two separate occasions. 
4.5.6 Cytotoxicity of D7-hβG with Prodrug, Enterolactone Glucuronide (ENL-Gluc), in Prostate Cancer 
Cells in Combination with Docetaxel 
C4-2 cells were first treated with ENL and docetaxel to determine their combination effect. 
Docetaxel alone had an IC50 value of 23.3 nM (95% CI; 18.6-29.0 nM) and ENL increased cytotoxicity of 
docetaxel in a concentration-dependent manner. Treatment with 25 µM ENL decreased the docetaxel IC50 
value to 6.2 nM (95% CI: 3.2-11.9 nM) and 50 µM ENL decreased the docetaxel IC50 value to 4.9 nM (95% 
CI: 2.6-9.2 nM) (Figure 4-6A). Co-culture of 25 µM ENL decreased the IC50 value of docetaxel by 3.8 fold, 
while 50 µM ENL decreased the IC50 value of docetaxel by 4.8 fold. 
C4-2 cells were then treated with ENL-Gluc mixed with D7-hβG to determine whether the 
glucuronidase-mediated activation of ENL-Gluc could also lead to a similar combination effect as ENL. C4-
2 cells were pre-incubated with 100 µM ENL-Gluc and D7-hβG (0.209 µM) for 2 hours before adding the 
desired concentration of docetaxel. After treatment for 72 h, cell viability was determined using 5 µM 
Calcein AM. Cells treated with ENL-Gluc and D7-hβG caused a minor reduction in the IC50 value of 
docetaxel to 14.9 nM (95% CI: 10.1-21.9 nM) (Figure 4-6B). This confirms that activation of ENL-Gluc did 
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occur in the cellular system since incubation with 100 µM ENL-Gluc and D7-hβG for 72 h caused a decrease 
in cell viability to 88%, compared with 100 µM ENL-Gluc or D7-hβG only group (Figure 4-7).  However, co-
incubation with ENL-Gluc and D7-hβG did not significantly decrease cell viability compared with docetaxel 
alone, as large variation in cell viability was observed with this co-treatment (Figure 4-7). Furthermore, 
under these conditions it appears the amount of activated ENL is likely insufficient to cause a significant 
decrease in cell viability compared to ENL. 
Considering that ENL undergoes UDP-glucuronosyltransferase (UGT)-mediated metabolism with 
conversion to ENL-Gluc by intracellular UGT, we tested the ability to form and then re-activate glucuronide 
conjugated ENL in C4-2 cell media (421). Cells were treated with D7-hβG and 50 µM ENL or 50 µM ENL 
alone to determine whether a further decrease in cell viability could be observed. Figure 4-7 shows that 
almost no change in cell viability was observed in cells treated with 50 µM ENL and D7-hβG (68.6%), 
compared with cells treated with 50 µM ENL alone (66.5%) (P>0.05). Similar results were obtained from 
docetaxel plus 50 µM ENL plus D7-hβG (25.6%), compared with docetaxel plus 50 µM ENL (28.3%) (P>0.05). 
The above results indicated that almost no re-activation of ENL occurred or the amount was too small to 
have an apparent impact on C4-2 cell viability. 
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Figure 4-6. Combination effect of (Panel A) enterolactone (ENL) and docetaxel, and (Panel B) fusion 
construct, D7-hβG, prodrug enterolactone glucuronide, ENL-Gluc, and docetaxel on cell viability of 
prostate cancer cell line, C4-2. Panel A shows that cytotoxic curves of serial dilutions of docetaxel only 
(open symbol, solid line), and with 25 µM ENL (closed symbol, dashed line) or 50 µM ENL (solid diamond, 
dashed line). Panel B displays the cytotoxicity curve of serial dilutions of docetaxel only (open symbol, 
solid line) or with 100 µM ENL-Gluc and 0.209 µM D7-hβG (solid symbol, dashed line) from where a minor 
shift in the cytotoxicity curve was observed. The IC50 value of docetaxel with D7-hβG and ENL-Gluc 
decreased to 14.9 nM from 23.3 nM. Data is presented as mean (±SD) of three replicates on three separate 
occasions. 
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Figure 4-7. Cell viability results of docetaxel, prodrug ENL-Gluc, active ENL, and fusion construct, D7-hβG, 
on the cell viability of PSMA positive prostate cancer cell line, C4-2, with different combinations at selected 
concentrations. C4-2 cells were first treated with a selected concentration of D7-hβG and/or ENL-Gluc to 
confirm the production of ENL from ENL-Gluc. The ability of activated ENL from ENL-Gluc (100 µM) by D7-
hβG (0.209 µM) to enhance the cytotoxic effect of docetaxel was then tested by comparing the group co-
treated with all three components with the docetaxel only group (P>0.05). The combination effect of 
docetaxel plus 50 µM ENL with/without D7-hβG was also measured. 5-Fluorouracil was used as positive 
control, while DMSO <1% was used as vehicle control. Data is presented as mean (±SD) of three replicates 
on three separate occasions. One-way ANOVA with tukey’s post hoc test was used to analyze the 
significance between groups (p<0.05). 
4.6 Discussion 
Many natural dietary anticancer compounds exhibit low oral bioavailability due to extensive 
presystemic metabolism such that these compounds exist in the systemic circulation predominantly as 
inactive glucuronide conjugates or other phase II enzyme metabolites. Although human epidemiological 
and preclinical studies support a therapeutic effect when dietary flaxseed lignans are used in conjunction 
with chemotherapeutic agents, the in vivo efficacy is typically very modest (52, 347). Extensive 
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presystemic metabolism restricts the clinical application of flaxseed lignans, as well as other natural 
products that exhibit similar first-pass effects in human. To overcome this limitation, we designed and 
successfully generated a recombinant fusion protein (D7-hβG), where β-glucuronidase was fused to an 
antibody fragment, D7, specific to PSMA, to allow cleavage of the glucuronide group from ENL-Gluc 
(prodrug) to generate the bioactive lignan form, ENL. The fusion of the glucuronidase enzyme to the 
antibody allows for specific tumor targeting while creating opportunity to generate high intratumor 
concentrations of the bioactive lignan, ENL, from the circulating prodrug, ENL-Gluc. 
Correct folding into spatial structures is the basis for a protein’s ability to perform its biological 
function. A linker is an indispensable component of a recombinant fusion protein, and ensures the 
construction of a stable, bioactive fusion construct while allowing the protein (e.g. enzyme) to assume its 
appropriate spatial folding structure (422). The literature reports that use of the (GGGGS)3 flexible linker 
often results in the retention of the maximum activity for two functional domains that require fusion 
together (423, 424). Based on these reports we used this flexible linker to maximize the likelihood of 
generating a fully functional fusion construct composed of an antibody fragment and enzyme. To confirm 
the binding activity and ensure that fusion of D7 with human β-glucuronidase did not influence binding 
affinity of D7 to PSMA, we used flow cytometry and a prostate cancer cell line known to express PSMA 
(LNCap cells) to qualitatively assess cell surface binding as well as bio-layer interferometry (BLI) to assess 
the binding kinetics of the fusion construct. Flow cytometry clearly indicates binding of D7-hβG to the cell 
surface of LNCap cells (supposedly to PSMA). Furthermore, the fusion protein D7-hβG displays a similar 
binding affinity constant as the D7 antibody fragment, which is consistent with literature reports (420). 
The binding specificity of the D7 antibody alone or the fusion construct has been comprehensively 
determined in LNCap (PSMA positive) DU-145 (PSMA negative), BOSC cells (PSMA negative) and BOSC 
cells (PSMA transfected) by a patent (423). In another study, a different protein fused to the C’ Terminal 
of D7 (VH-VL) had a minimum effect on D7 binding against PSMA when (GGGGS)3 flexible linker was used 
(420). These data confirm the ability of the fusion construct to bind to PSMA. To allow for optimization of 
the fusion protein concentration used in the ADEPT system it will be necessary to determine the kd value 
for binding between PSMA expressed natively within the cell membrane and D7-hβG in the future. 
Subsequently, to confirm β-glucuronidase activity of the fusion construct, D7-hβG, we first chose a 
known probe substrate of β-glucuronidase, 4-MuGluc, to assess the ability of the fused enzyme to cleave 
the glucuronic acid group. Since human β-glucuronidase is mainly localized intracellularly in lysosomes 
and possesses a maximum activity at pH 4.5 and since an acidic pH exists in the microenvironment of 
tumor tissue in vivo, we evaluated enzymatic activity of hβG at pH 4.5 and pH 7.4 (425, 426). Our data 
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suggest that our fusion protein is able to hydrolyze the glucuronic acid group of 4-MuGluc, and higher 
activity is observed at pH 4.5 than pH 7.4 at 2 h (Figure 4-4). Interestingly, the fusion protein shows a 
different kinetic profile when incubated with our prodrug, ENL-Gluc, in which the generation of active ENL 
is only dependent on the concentration of the ENL-Gluc prodrug (Figure 4-5). With time, we observe no 
further increases in the concentration of ENL, which suggests ENL-Gluc might have very high affinity 
towards the fusion protein and thus the reaction is complete before the first sample interval. The lack of 
detection of ENL-Gluc on LC-MS/MS analysis by 0.5 hours (data not shown) supports our hypothesis of 
rapid and complete cleavage of glucuronide group from ENL-Gluc. Again, these data confirm that β-
glucuronidase remains biologically active in the fusion construct. 
To assess the fusion protein function at a cellular level, we chose C4-2 cells in anticipation of a 
future in vivo prostate cancer xenograft mouse model study as this cell line expresses surface PSMA and 
is typically utilized for xenograft models. The generation of ENL was observed with an accompanying 
decrease in cell viability, although variability in the data precludes any definitive conclusions (Figure 4-6). 
In our combination study, we also observed some promising results whereby a slight decrease in the IC50 
value of docetaxel from 22.3 nM to 14.9 nM was observed when we co-incubated docetaxel with the 
fusion protein in the presence of 100 µM ENL-Gluc as compared with no fusion protein, although we again 
observe significant variability. These cytotoxicity results do suggest a need to understand the source of 
variability with the fusion construct/prodrug (i.e. ADEPT) in combination with docetaxel so as to allow 
further optimization of the fusion construct and its application in a preclinical animal model system. 
Generation of sufficient quantities of fusion construct from our COS-7 expression system remains a 
significant limitation and optimal conditions for expression are also required. Nonetheless, reports 
suggest that low dose chemotherapy might be more effective than a high dose regimen against tumors 
without promoting multidrug resistance (427, 428). Our observations of an enhanced cytotoxic effect 
when docetaxel is co-administered with both D7-hβG and ENL-Gluc against PSMA positive cancer cells 
warrant additional in vitro assessments to support future animal xenograft model studies and potential 
translation to human patients. 
The concept of ADEPT as a strategy for site-specific drug delivery is not new; however progress 
towards clinical realization of this technique has stalled at phase I/II trials mainly as a result of an elevated 
immune response and shortage in prodrug candidates (282). More recent developments in antibody 
techniques to overcome this limitation include use of antibody fragments to decrease the likelihood of an 
elevated immune response, which prompted our use of the D7 scFv. The use of a prodrug is attractive 
from a drug discovery perspective for its potential to attenuate systemic side effects, a significant 
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potential benefit of an ADEPT delivery system (234). In this particular project, ENL-Gluc was chosen as the 
prodrug not only as a result of rich natural dietary sources but also the compelling safety profile of long-
term supplementation of flaxseed lignan enriched complex (~38% secoisolariciresinol diglucoside) 
following oral administration (47, 412). Dietary lignan sources are precursors for ENL-Gluc generation in 
vivo, and studies in our laboratory (manuscript under review) indicate a significant combination effect 
between ENL and anticancer drugs used in prostate cancer treatment. At the tumor site, cleavage of the 
glucuronide group from ENL-Gluc generates ENL and its high passive cellular permeability to reach 
intracellular sites of action supports an important feature of ADEPT, known as a bystander effect (87, 429). 
Our current results are not sufficient to conclude that our current ADEPT system will have a notable 
therapeutic effect against prostate cancer. However, with further optimization we see a potential for 
ADEPT with oral flaxseed lignan supplementation as adjuvant therapy along with several major 
chemotherapeutic drugs to improve antitumor efficacy and allow for dosage reductions in the standard 
chemotherapeutic drugs. Cancer chemotherapies usually have very narrow therapeutic windows and 
even a minor modification in the dosage regimen may enhance therapeutic effects with less systemic 
adverse effects (430). This feature is particularly important in patients with late stage cancers who usually 
have complicated health conditions, less tolerance with chemotherapy, and where emphasis on quality 
of life becomes exceedingly important (431).  With further study, we hope our proposed ADEPT approach 
can lead to improvements in the effectiveness of chemotherapeutic agents and, in turn, improvements in 
the quality of life in prostate cancer patients. 
4.7 Conclusion 
The fusion construct, D7-hβG, displays comparable binding affinity against PSMA and enzymatic 
activity against both standard probe 4-methylumberllifone and the lignan metabolite ENL-Gluc. D7-hβG 
also slightly enhanced the cytotoxicity of docetaxel in the prostate cancer cell line C4-2 cells. However, 
further optimization experiments are needed to determine the potential of ADEPT as adjuvant therapy 
against prostate cancer with oral consumption of flaxseed lignans. 
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Chapter 5 Influence of flaxseed lignan supplementation to older adults on biochemical and 
functional outcome measures of inflammation 
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Relationship of this manuscript to the thesis: 
The in vivo assessment of flaxseed lignan-enriched product indicated no adverse side effects suggesting 
the safety and tolerability of flaxseed lignans for long-term oral exposure at a low pharmacological dose. 
The safety outcomes from this clinical trial supports the APDET strategy which uses the oral flaxseed lignan 
as the source of circulating ENL-Gluc (the prodrug). Furthermore, the study provided opportunity to 
determine plasma parent and total flaxseed lignans, which will guide future dosage selection of oral 
flaxseed lignan products. 
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5.1 Abstract 
Evidence from literature suggests that dietary flaxseed lignans have the ability to modulate 
inflammation, which is recognized as the underlying basis of multiple chronic human diseases in older 
adults. We designed a randomized, double-blind, placebo-controlled clinical trial to assess the effects of 
flaxseed lignan-enriched complex (~38% secoisolariciresinol diglucoside) supplementation on biochemical 
and functional indicators of inflammation. We also assessed its safety and tolerability in older healthy 
adults after 6 months of once daily oral administration. The clinical trial confirmed that plasma 
concentration of total flaxseed lignans (free and conjugated forms) secoisolariciresinol, enterodiol, and 
enterolactone were significantly associated with daily oral supplementation of flaxseed lignan-enriched 
complex (p<0.05). A significant decrease in systolic blood pressure (SBP) (from a mean of 155±13 mmHg 
at baseline to 140±11 mmHg at 24 weeks) was observed in lignan supplemented participants stratified 
into a SBP≥140 mmHg subcategory (p=0.04). No differences were found between treatment or placebo 
groups in terms of respiratory rate, pulse, cognition, pain, activity, physical measurements (calf, waist, 
and upper arm circumstances), and grip strength. With respect to blood inflammatory markers, lipid 
profiles, and biochemical parameters no significant differences were found between treatment and 
placebo groups at the end of the 6-month supplementation. No adverse effects were reported during 
supplementation. These data further support the safety and tolerability of long-term flaxseed lignan-
enriched complex supplementation in older adults and identify an ability to favourably modulate systolic 
blood pressure, an important risk factor of cardiovascular disease. 
5.2 Introduction 
Inflammation is well recognized as the underlying basis of diverse age-related chronic diseases 
including hypertension (432), cardiovascular disease (433), and Alzheimer’s disease (434). Predominant 
markers of inflammation such as C-reactive protein (CRP), TNF-alpha, and IL-6 are positively associated 
with cardiovascular disease morbidity and mortality (435-438), and long-term observational studies have 
shown that elevated levels of such inflammatory markers were related to cognitive decline or impairment 
(439, 440). Such studies suggest control of inflammation might be a potential strategy to mitigate the 
adverse effects of age-related chronic diseases. 
Recently, flaxseed lignans have gained significant interest for their anti-inflammatory properties 
and proposed health benefits. Secoisolariciresinol diglucoside (SDG) is the major plant lignan found in 
flaxseed hull, and a review on the health benefits of SDG supplementation suggests lignans may protect 
against multiple human diseases such as type 2 diabetes, hypertension, diabetes, and cancer (333). A 
number of studies report benefits of lignan supplementation on inflammatory markers (49, 441), and 
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other risk factors of cardiovascular disease including plasma total cholesterol, LDL-cholesterol, and high 
blood pressure (48, 442-448), while other clinical trials report inconsistent results (46, 449, 450). An 
important factor that contributes to inconsistency in clinical trial outcomes is the use of non-standardized 
flaxseed products that contain an undetermined lignan content. Such products include milled, whole 
ground, partial defatted, roasted and flaxseed lignan extracts all containing variable and unknown 
percentages of SDG (333, 451, 452). A number of these products also contain variable amounts of the 
omega-3 fatty acid, alpha-linolenic acid, and fibre, which are known to contribute to the health benefits 
of flaxseed supplementation (453). Very few randomized clinical trials report the use of a standardized 
lignan-enriched product with known lignan content. 
The epidemiological and randomized clinical trial evidence of health benefits with flaxseed lignan 
interventions warrant continued investigations with lignans to further support their ability to mitigate risk 
factors of chronic disease, particularly in older adults. Nonetheless, to draw clear associations between 
lignan dose and reductions in biomarkers of age-related chronic inflammatory disease, such studies 
should use standardized flaxseed products with known lignan content. To augment current evidence in 
the elderly on safety, tolerability, and efficacy, we report a Phase IIa randomized, double-blind, placebo-
controlled clinical pilot trial of long-term oral administration of a standardized flaxseed lignan-enriched 
product in healthy older adults. We used BeneFlax®, a standardized flaxseed product containing ~38% 
SDG manufactured according to Good Manufacturing Practice (GMP) guidelines and approved by Health 
Canada. The primary outcome measure of this clinical trial is the safety and tolerability profile of flaxseed 
lignan enriched complex during a 6-month daily exposure of healthy older adults to a pharmacological 
dose. The secondary outcome measures are to determine the effects of flaxseed lignan supplementation 
on biomarkers of inflammation, risk factors of cardiovascular disease, quality of life indicators 
(musculoskeletal strength, cognitive function, daily activity, and pain) and trough steady state plasma 
concentrations of lignans. 
5.3 Experimental Methods 
5.3.1 Clinical Trial Overview 
A double-blind randomized placebo-controlled clinical pilot trial was conducted to assess the safety, 
tolerability, and anti-inflammatory effects of SDG-enhanced flax lignan complex, BeneFlax®, following 
once daily oral administration in an older healthy population. This clinical study was approved by the 
Natural Health Products Directorate, Health Canada (NCT01846117), and by the institutional Biomedical 
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Research Ethics Board (See Appendix E). Active recruitment of participants occurred during 2013 April and 
2014 March. 
Details of the protocol study design and methodology are published separately (Manuscript 
submitted, see Appendix F). Thirty-two participants between the ages of 60 and 80 years old who met all 
inclusion criteria were randomized into an intervention group and a control group. The pharmacist 
responsible for dispensing the study products used a computer-aided randomization system to ensure 
participants and study assistants were blinded to the treatment. The intervention consisted of SDG-
enhanced food grade flax lignan complex, BeneFlax®, at a dose of 600 mg SDG per day, which was 
contained in 1.6 grams of, plus 1,000 IU Vitamin D3. The placebo control was whey protein (Natural Factors, 
Whey Factors unflavoured) plus 1,000 IU Vitamin D3. A total 35 mL of blood was collected from every 
participant at each visit (baseline, 8, 16 and 24 weeks) to determine blood clinical chemistry, blood 
inflammatory markers, and plasma flaxseed lignan metabolites. The Clinical Chemistry Laboratory 
determined blood clinical chemistry parameters and CRP. The inflammatory markers, IL-6 and TNF-alpha, 
were determined in-house using a commercial kit. The plasma levels of flaxseed lignan metabolites were 
determined using previous validated LC-MS/MS method. Additional assessments at participant visits 
included vital signs (pulse, respiration rate, heart rate), height, weight, and other body measurements, 
cognitive tests, pain perception and grip strength (by dynamometer) and were measured by research staff 
after appropriate training to assure standardization. Activity and food frequency questionnaires were 
completed by participants at all visits. All participants were asked to maintain a daily log of possible 
adverse events with administration of BeneFlax® and placebo whey protein. 
5.3.2 Chemicals, Reagents, and Supplies 
BeneFlax® (38% secoisolariciresinol diglucoside (SDG)-enhanced flax lignan complex) was a kind gift 
from Archer Daniels Midland Co (Decatur, IL). Secoisolariciresinol (SECO) (purity > 95% by HPLC analysis) 
was previously isolated from raw flaxseed in our laboratory (352). Chemicals including enterolactone 
(ENL), enterodiol (ED), β-glucuronidase type H-5 from Helix pomatia (G-1512), and formic acid were 
purchased from Sigma-Aldrich (Oakville, ON, Canada). Racemic enterolactone-13C3, enterodiol-13C3, and 
racemic secoisolariciresinol-d6 was from Toronto Research Center (TRC) (Toronto, ON, Canada). PotimaTM 
LC/MS acetonitrile (ACN), PotimaTM LC/MS water, PotimaTM LC/MS methanol were bought from 
ThermoFisher Scientific (Toronto, ON, Canada). Diethyl ether was purchased from EMD Chemicals Limited 
(Gibbstown, NJ). Whatman Mini-UniPrep Syringeless Filter vials were bought from GE Healthcare Life 
Sciences (Mississauga, ON, Canada). Human blank plasma EDTA-K2 was obtained from BioreclamationIVT 
(Baltimore, MD, US). Double deionized water was provided from a MilliQ Synthesis Water Purification 
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system (Millipore, Bedford, MA). TNF-alpha and IL-6 elisa kits were purchased from Cayman (Ann Arbor, 
Michigan, US). All other solvents were LC/MS grade and all other chemicals were reagent grade. 
5.3.3 Quantification of Flaxseed Lignans in Plasma 
Stock solutions (1 mg/mL) of the lignans (ENL, ED, and SECO) and internal standards (IS) (ENL-13C3, 
ED-13C3, and SECO-d6) were prepared in methanol followed by dilution with mobile phase (90%, A (H2O) : 
10% B (acetonitrile) (90A : 10B). The working solutions were prepared by serial dilution of the stock with 
mobile phase (90A : 10B), which ranged from 0.2 ng/mL – 50 ng/mL for ENL and ED, and 1 ng/mL – 50 
ng/mL for SECO. Quality control samples (QC) were prepared in a similar manner by a different analyst to 
achieve working stock solutions. All stock and working solutions were stored at -20°C. The final internal 
standard concentrations were 33.3 ng/mL for SECO-d6, 7 ng/mL for ED-13C3, and 25 ng/mL for ENL-13C3 
in plasma. 
Samples were prepared on day of analysis by adding 30 µL of standard lignan working solutions and 
30 µL of IS mixed into 300 µL blank human plasma in 15 mL Eppendorf tubes and vortexed for 10 s. To this 
4 mL diethyl ether was added and vigorously shaken for 10 min. The samples were centrifuged 1,000 x g 
at 4°C for 5 min and then transferred into -80°C freezer to freeze the aqueous layer for 10 min. The organic 
phase was then transferred into glass tubes and dried using a rotary concentrator (Eppendorf, Mississauga, 
ON, Canada) with pressure set to 300 mbp. Samples were re-constituted in 150 µL of mobile phase (85% 
A (H2O) : 15% B (acetonitrile) containing 0.1% formic acid) and filtered through Whatman Mini-UniPrep 
Syringeless Filter vials. For measuring the total lignan in plasma (unconjugated and conjugated lignan 
metabolites), 330 µL plasma and 60 µL β-glucuronidase (2600 units) were added into 330 µL sodium 
acetate buffer (0.1 M, pH 5.0) and incubated at 37°C for 4 hours in an incubator shaker before proceeding 
to the extraction procedure. 
A Porshell 120 EC-C18 column, 2.1 × 50 mm, 2.7 μm column and a 2.1 × 5 mm, 2.7 μm guard column 
(Agilent Technologies) were used to analyze flaxseed lignan concentrations in plasma. Samples were 
separated using an Agilent series 1200 binary bump (G1311A) with an online degasser (G1322A), column 
oven (G1316A), and auto sampler (G1329A), and detected using a linear ion trap quadrupole LC-MS/MS 
mass spectrometer (AB Sciex Instruments, Concord, ON, Canada) under Turbo V electrospray ionization 
(ESI) source in the negative mode. The flow rate was set at 250 µL/min. The mobile phase gradient stated 
at 85% A (H2O) : 15% B (acetonitrile) containing 0.1% formic acid for 0.5 min, then quickly changed to 50% 
A (H2O):50% B (acetonitrile) at 1.5 min and to 5% A (H2O) : 95% B  (acetonitrile) at 2.5 min. The mobile 
phase was kept at 5% A (H2O) : 95% B  (acetonitrile) with 0.1% formic acid for 2 min and returned to 85%A 
(H2O) : 15% B (acetonitrile) with 0.1% formic acid at 5 min and continued in isocratic mode for 5 min. Data 
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were collected using Analyst software version 1.6 (AB Sciex Instruments, Concord, ON, Canada). The LC-
MS/MS parameters for flaxseed lignans and IS were optimized as follows: Curtain gas pressure = 10 psi; 
GS1 = 50 psi; GS2 = 50 psi; Ion spray voltage = -4500 V, ESI source interface temperature = 700°C. The 
flaxseed lignan fragment ionization is listed in Table 5-1. 
 
Table 5-1. LC-MS/MS parameter conditions for all flaxseed lignan and relative IS fragments. 
Analyte Fragment 
Declustering 
potential 
Collision 
energy 
Collision cell 
exit potential 
SECO 361.019 > 164.800 -90 -36 -11 
SECO-D6 (IS) 367.126 > 168.000 -95 -36 -13 
ED 301.000 > 253.000 -95 -32 -5 
ED-13C3 (IS) 304.000 > 273.000 -95 -32 -5 
EL 297.000 > 189.000 -90 -30 -7 
EL-13C3 (IS) 299.942 > 255.100 -75 -30 -12 
 
Since the assay was previously validated in the laboratory, a partial assay validation was conducted 
according to USFDA guidelines (454) (Appendix G). The sensitivity was determined by limit detection (LOD) 
and lowest limit of quantification (LLOQ) where LOD was the lowest concentration with signal-to-noise 
ratio of 3 from blank and LLOQ defined as the concentration with signal-to-noise ratio of 10 from blank 
and falling within 20% of the nominal value for accuracy and precision. Accuracy was calculated using the 
formula ((calculated concentration/nominal concentration) × 100), which was acceptable within 15% 
deviation from the nominal concentrations for all QC samples except at LLOQ, which was allowed 20% 
deviation. Precision (percent coefficient of variation) was determined using the calculated concentration 
mean of replicates over standard deviation (SD). Precision was allowed to be within 15% for all QC samples 
while LLOQ was allowed to have a 20% variation. The intra- and inter-day precision and accuracy of the 
method was determined by analyzing six replicates at each of LLOQ, low QC (LQC), medium QC (MQC), 
and high QC (HQC) on three different days. The linearity of the method was assessed by processing an 8-
point calibration curve for ENL and ED, and a 6-point calibration curve for SECO on three different days. 
The ratio of peak areas of the analytes and internal standards were plotted against the nominal 
concentration of the calibration curve samples. A linear least-squares regression analysis using 1/X2 as 
96 
 
weighting factor was conducted to determine slope, intercept and coefficient of determination (r2) to 
demonstrate linearity of the method. 
5.4 Statistics Analysis 
All data were analyzed using SPSSv22 (IBM SPSS Statistics 22, NY, US). Statistical analysis involved 
generalized linear model with repeat measurements including one-way ANOVA and two-way ANOVA with 
Bonferroni post hoc test, and data are presented as mean ± standard deviation. The level of significance 
was set at p ≤ 0.05. 
5.5 Results 
5.5.1 Demographic Characteristics and Compliance 
The study enrolled 32 participants of which 17 were male and 15 females. The average age of the 
study population was 68.0 ± 4.9 years with a BMI of 27.2 ± 4.2 k/m2. All the participants were randomized 
into BeneFlax® (n=19) or placebo (n=13) group and baseline characteristics are listed in Table 5-2. In the 
BeneFlax® group, 17 participants had a mean age of 67.9 ± 5.2 y, with a mean BMI value of 26.0 ± 3.3 
k/m2. The mean age was 68.1 ± 4.7 years with a BMI of 28.8 ± 5.0 k/m2 in 13 participants that received 
placebo control. No statistical difference in age, weight, height, or BMI was found between the BeneFlax® 
group and placebo group at baseline. Waist, upper arm, and calf circumference was also measured at all 
visit times to assess body adipose composition. No change in body composition including waist, upper 
arm, and calf circumferences were observed at the end of study as compared with baseline measurements. 
No significant change in dietary patterns, which was monitored by a food questionnaire at every time 
point of visit, was noted during the supplementation period. All participants were 100% compliant with 
no reported incidences of missed doses. 
Table 5-2. Demographic and anthropomorphic measures (mean (SD)) of study participants at the 
baseline visit. 
Baseline Parameter 
BeneFlax® Placebo 
p Value 
Mean (SD) Mean (SD) 
N (M,F) 19 (10,9) 13 (7,6) 0.92 
Age (y) 67.9 (5.2) 68.1 (4.7) 0.63 
Weight (kg) 76.1 (17.3) 81.6 (19.4) 0.40 
Height (cm) 170 (12.5) 167 (10.2) 0.62 
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BMI (kg/m2) 26.0 (3.3) 28.8 (5.0) 0.06 
Waist Circumference (cm) 90.4 (11.0) 100.2 (13.4) 0.03 
Upper Arm Circumference (cm) 31.7 (3.4) 32.0 (3.8) 0.86 
Calf Circumference (cm) 36.7 (3.2) 37.3 (3.1) 0.66 
M, males; F, females. All values are mean (SD). The treatment to placebo p value was determined 
using one-way ANOVA. 
5.5.2 Flaxseed Lignan Plasma Levels 
The mean plasma lignan levels at baseline and at end of the intervention period (24 weeks) are 
summarized in Table 5-3. Unconjugated ENL remained under the limit of quantification (0.2 ng/mL) in all 
tested plasma samples. Some plasma samples had quantifiable unconjugated ED (0.2 ng/mL) and SECO (1 
ng/mL) levels. The number of participants with quantifiable levels of unconjugated ED increased from 2 
participants at baseline to 18 participants by the end of the 6-month supplementation in participants 
receiving BeneFlax®. Oral supplementation of flaxseed lignan complex resulted in significant elevations in 
plasma lignan levels in participants receiving BeneFlax® equivalent to 600 mg SDG compared with placebo 
group (whey protein) during the 24-week intervention. At baseline detectable levels of total ENL and ED 
(unconjugated and conjugated) was observed in all participants. Considerable levels of total SECO 
(unconjugated and conjugated) were detected at baseline in both the BeneFlax® and placebo groups. By 
week 24, total SECO level increased to 235.8±236 ng/mL compared with 97.5±18 ng/mL in the placebo 
group (P=0.053). The mean plasma level of total ENL and ED increased significantly from baseline at week 
8, and remained stable at week 16 and 24. Very high levels of total flaxseed lignans were observed in 
certain participants supplemented with BeneFlax® contributing to the large interindividual variation 
observed between participants administered the same BeneFlax® dose. In participants receiving 
BeneFlax® supplementation, plasma levels of total lignan ranged from 3.4 – 514 ng/mL for ENL, 2.2 – 941 
ng/mL for ED, and 79.8 – 1090 ng/mL for SECO, at the end of the 24-week supplementation period. In 
participants displaying very high plasma levels of total flaxseed lignans no adverse events were reported. 
Table 5-3. Mean ±SD plasma concentration (Ctrough) of flaxseed lignans in healthy older participants after 
oral consumption of 600 mg SDG/day or placebo (equivolume whey protein) for 6 months.f 
Week Group 
Totala ENLb 
(ng/mL) 
Totala ED 
(ng/mL) 
Unconjugated 
ED (ng/mL) 
Totala SECO 
(ng/mL) 
Unconjugated 
SECO (ng/mL)* 
0 BeneFlax® Mean±SD 8.1±7.9 1.6±2.6 2.8±3.5 89.7±4.5 ND 
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Nc 19 19 2 19 ND 
Placebo 
Mean±SD 20.6±24.9 1.33±1.0 ND 83.0±18.7 ND 
Nc 13 13 ND 13 ND 
8 
BeneFlax® 
Mean±SD 192.0±257.6e 349.6±278.6e ND 168.2±82.0 ND 
Nc 18 18 ND 18 ND 
Placebo 
Mean±SD 60.5±129.4 109.2±368.1 ND 119.0±49.7 ND 
Nc 11 12 ND 11 ND 
16 
BeneFlax® 
Mean±SD 196.1±199.1e 464.2±322.3d,e 11.0±6.4 212.1±136.2d,e 1.93±1.1 
Nc 18 18 18 19 2 
Placebo 
Mean±SD 25.4±27.4 2.1±1.4 ND 99.3±24.5 ND 
Nc 11 11 ND 12 ND 
24 
BeneFlax® 
Mean±SD 164.2±150.7d,e 312.7±271.0d,e 10.8±9.2 235. 8±235.7e 5.7±5.2 
Nc 19 19 18 19 3 
Placebo 
Mean±SD 13.1±10.8 9.18±26.3 ND 97.5±18.3 ND 
Nc 12 12 ND 12 ND 
aTotal lignan refers to the sum of unconjugated lignan and its glucuronic acid or sulfate conjugate forms. 
bUnconjugated ENL was below the limit of quantification in all plasma samples. 
cN is the number of participants with quantifiable levels of the specific lignan. 
dStatistically significant from placebo at a particular time point evaluation. 
eStatistically significant from baseline. 
fInter- and intraday precision and accuracy for SECO, END and ENL in human plasma was within 15% of 
the nominal value. All standard calibration curves were linear with r2>0.99. All other validation parameters 
were determined previously (454) (Appendix G). 
5.5.3 Primary Outcome Measures 
The primary outcome measures used to consider the safety and tolerability of 6 month 
administration of 600 mg SDG per day to healthy older adults included the reporting of clinical adverse 
signs and symptoms, vital signs, serum clinical chemistry, and hematology parameters. Participants 
reported no major treatment related adverse effects or illness during the 6 month study. As milled or 
whole flaxseed is known to have a laxative effect, bowel movement was monitored in all participants. 
Only a few participants reported a temporary experience of loose stool or diarrhea. The remaining 
participants reported no change in bowel movements. All hematological and clinical chemistry 
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parameters (baseline and 8, 16 and 24 weeks) fell within the normal reference range of the clinical 
diagnostic laboratory criteria for both study groups (Appendix H-Table H-3). One participant was 
monitored for HbA1c/total hemoglobin ratio due to a single elevated fasting glucose level. Mean vital 
signs were unchanged except for systolic blood pressure in a subgroup of participants as described below 
(Table 5-4). 
5.5.4 Secondary Outcome Measures 
The secondary outcome measures on BeneFlax® supplementation included biomarkers of 
inflammation, risk factors of cardiovascular disease, quality of life indicators, and trough steady state 
plasma concentrations of lignans. Plasma lipid profiles including total cholesterol, triglyceride, HDL-
cholesterol (HDL-C), LDL-cholesterol (LDL-C), and total cholesterol/HDL-C ratio fell within the reference 
ranges at all measured time points and no difference was found in the lipid profile between the BeneFlax® 
and placebo group during the 24-week study (Appendix H-Table H-4). In terms of inflammatory markers, 
no significant reduction in TNF-alpha, IL-6, and CRP were found in participants receiving BeneFlax® 
compared with participants receiving whey protein only and all values fell within reference ranges 
(Appendix H-Table H-5). The effect of BeneFlax® oral supplementation on quality of life indicators in all 
participants were determined by measuring physical function (grip strength), cognitive function (Mini-
Mental State Examination (MMSE)) daily activity, and pain (Appendix H-Table H-2). Activity and pain were 
determined using the Godin Leisure-Time Exercise Questionnaire at every visit and compared 
descriptively (455-457). Analysis of the questionnaires identified no statistical difference between the 
BeneFlax® intervention group and placebo at all visits and no significant differences between baseline 
value and 24 weeks within a treatment group. No significant differences in grip strength and cognitive 
functions were identified between baseline values and 24 weeks both between and within treatment 
groups (data not shown). 
5.5.5 Subgroup Analysis for Changes in Systolic Blood Pressure with BeneFlax® Intervention 
Participants were divided into a subcategory by systolic blood pressure using 140 mmHg as the cut-
off criteria. BeneFlax® 24-week supplementation to participants with systolic blood pressure (SBP) ≥140 
mm Hg at baseline displayed a statistically significant reduction in SBP with a reduction from a mean of 
155±13 mmHg at baseline to 140±11 mmHg at 24 weeks, compared with placebo group (154±10 mmHg) 
(treatment vs. placebo, p=0.04) (Table 5-4). No difference was observed in treatment and placebo groups 
and within a treatment group when SBP was <140 mmHg at baseline. For diastolic blood pressure (DBP), 
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respiratory rate, and heart rate, no statistical differences were found between and within a treatment 
group during the supplementation period (Table 5-4). 
Table 5-4. Mean (SD) systolic and diastolic blood pressure, respiratory rate and heart rate of participants 
who received BeneFlax® supplementation or placebo whey protein. 
Outcome Subcategory Treatment nc 
Mean (SD) 
Range 
Baseline 2 hours 24 weeks 
SBPa,b 
≥140 
mmHg 
BeneFlax® 7 155 (13) 156 (14) 140 (11)* 124-178 
Placebo 6 157 (8) 153 (9) 154 (10) 137-167 
p value  0.79 0.57 0.04*  
<140 
mmHg 
BeneFlax® 12 120 (11) 125 (14) 128 (14) 100-155 
Placebo 7 122 (10) 118 (13) 125 (18) 98-153 
p value  0.65 0.27 0.6  
DBPa  
BeneFlax® 19 79 (10) 80 (9) 79 (9) 64-109 
Placebo 13 77 (6) 74 (5) 76 (7) 64-89 
Respiratory 
rate 
 
BeneFlax® 19 16 (5) 13 (3) 13 (3) 7.0-24 
Placebo 13 15 (4) 15 (4) 14 (3) 9.0-24 
Heart ratea  
BeneFlax® 19 63 (9) 66 (7) 69 (11) 47-88 
Placebo 13 64 (9) 67 (7) 63 (11) 49-86 
aSystolic blood pressure (SBP), diastolic blood pressure (DBP), and heart rate measurements were 
completed in duplicate for all participants at each visit. 
bParticipants were subcategorized by SBP levels (≥140 mmHg) at baseline. 
cNumber of participants in each group. 
*p<0.05. 
5.6 Discussion 
The clinical trial evidence evaluating the health benefits of flaxseed lignan interventions show 
sufficient promise to warrant their further investigation into the mitigation of risk factors of chronic 
disease, particularly in older adults. However, the reliability of the clinical trial evidence to date is 
questionable as many clinical trials involve the use of nonstandardized flaxseed products where lignan 
content is unknown and variable (55, 412, 452, 458). Randomized clinical trials using flaxseed products of 
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known and enriched lignan content are necessary to more clearly associate safety and efficacy of flaxseed 
supplementation with the lignans of flax. 
The primary outcome measure of this phase IIa trial was to determine the safety and tolerability of 
a standardized flaxseed lignan enriched product during a 6 month daily supplementation of a 
pharmacological dose of SDG to healthy older adults (46). Our study indicated no differences in primary 
outcome measures for participant safety and tolerability between lignan supplemented group and 
placebo. This is consistent with a previous study where we evaluated the daily administration of flaxseed 
lignan-enriched complex containing 300 mg SDG to frail, older adults residing in long-term care homes 
(412). Although this latter study involved a small sample size, the study population exhibited significant 
age-related physiological changes and/or presence of multiple co-morbidities and polypharmacy, which 
could pose a greater risk to unintended effects of chronic SDG administration. Additional studies 
evaluating standardized lignan-enriched products also report no adverse events with chronic lignan 
supplementation (46, 48, 49). Despite the limitations of study sample sizes, the lack of reported adverse 
effects is supportive of the safety of flaxseed lignan supplementation in younger and older adults. 
Our results also indicated no significant changes in the secondary outcome measures, which 
included biomarkers of inflammation, lipid profiles, and quality of life indicators, namely cognitive 
function, pain scores, muscular strength, and daily activity. We expected these findings since we selected 
a healthy participant population; the measured values fell within the reported normal reference ranges, 
and lack of statistical changes in these measured values further supports the safety of lignan 
administration. We did observe an elevated cognitive function score in both the lignan and placebo 
supplemented groups, which likely relates to familiarity with repetition of the test every 8 weeks rather 
than any treatment effect. 
The effect of dietary flaxseed lignans on inflammatory markers is controversial. We observed no 
change in blood inflammatory biomarkers, CRP, IL-6, TNF-alpha, which was consistent with our previous 
evaluations in older adults  and other studies reported in the literature (46, 412, 459). A systemic review 
on the relationship between flaxseed lignans and inflammatory biomarkers reported a significant 
decrease in CRP and IL-6 levels in participants with a body mass index (BMI) ≥30 kg/m2 (441, 460). Type 2 
diabetic patients (BMI 31.2 ±2.2 kg/m2) receiving 600 mg SDG daily for 3 months also demonstrated 
reductions in these cytokines (441). Our study participants had BMI  30 kg/m2 and maintenance of blood 
inflammatory biomarkers within the reference ranges supports the safety of lignan supplementation in 
older adults. Nonetheless, the role of inflammation has been emphasized in the chronic diseases, 
particularly diseases that involve changes in the vascular system (461-464). Biomarkers of endothelial 
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dysfunction may provide a more sensitive indicator of vascular inflammatory processes (464). Hence, 
future clinical studies should include markers of endothelial function to provide a more comprehensive 
evaluation of flaxseed lignan effects on inflammation. 
Flaxseed supplementation is known to favourably modulate blood lipid levels (49, 445, 465). In a 
review of the scientific evidence, Health Canada’s Food Directorate suggests daily consumption of 40 g of 
whole ground flaxseed is sufficient to reduce elevated blood cholesterol levels (466). To avoid the 
influence of fibre and alpha-linolenic acid, studies with the flaxseed lignan-enriched standardized product, 
BeneFlax®, report significant reductions in blood total and LDL cholesterol in hypercholesterolemic 
patients (48, 49). In our study, all participants had normal blood lipid profiles and we did not expect the 
decreases in cholesterol levels typically reported in patients with hypercholesterolemia or dyslipidemia 
(48, 465). Our data further supports the safety of lignan supplementation in healthy older adults. 
In a post-hoc subgroup analysis involving participants with elevated SBP, lignan supplementation 
caused a statistically significant mean reduction (15 mmHg) in SBP (from a mean of 155±13 mmHg at 
baseline to 140±11 mmHg at 24 weeks) without change in DBP. Although the sample size was small, the 
ability of lignan supplementation to return participants to the recommended range (BP  140/90) 
identifies a clinically meaningful outcome (467, 468). A recent meta-analysis on randomized clinical trials 
suggested flaxseed supplementation results in significant reductions in both SBP and DBP (469). This 
analysis, though, included trials involving nonstandardized flaxseed products. The lack of DBP change in 
our study might be important as elevated pulse pressure (difference between systolic and diastolic 
pressure) is a risk factor for cardiac outcomes (467, 470). Two studies using 30 g milled flaxseed for over 
a 6 month period report a significant decrease in SBP in participants with high SBP (≥140 mm Hg) 
compared with placebo (447, 448). Interestingly, the authors of these two trials suggest that alpha-
linolenic acid in the milled flaxseed mainly accounts for the anti-hypertensive effect. BeneFlax® used in 
our study is not a source of alpha-linolenic acid, and therefore, this bioactive of flaxseed could not 
contribute to the reduction in SBP observed in our study. Finally, our limited sample size precluded any 
further statistical analysis to adjust for possible confounders such as age, gender, and BMI, which are 
important risk factors for high blood pressure (471). 
Few studies report SDG and SDG metabolite plasma levels particularly following supplementation 
with flaxseed products of known lignan content. In our study, participants receiving BeneFlax® 
demonstrate large interindividual variation in their steady state trough plasma levels of flaxseed lignan 
metabolites. Detectable levels of SDG were not observed, which is consistent with other studies that 
indicate the lack of oral bioavailability of this lignan (79, 80, 83).  Very few participants showed detectable 
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levels of the unconjugated form of the aglycone of SDG, SECO, as well as the mammalian lignans, ED and 
ENL. Rather, these lignans largely existed in their conjugated forms (glucuronic acid and sulfate) in the 
plasma again suggesting significant first-pass metabolism and low bioavailability following their oral 
administration (61, 80). Interestingly, we observed stable baseline levels of total SECO (unconjugated and 
conjugate) and minor amounts of total ED and EL in all participants despite their strict adherence to a low 
lignan diet and requirement to avoid foods known to be high in lignan content during the study duration 
(472). Their presence at baseline and in the placebo group suggests a common dietary factor not 
previously identified as a rich source of lignan. 
5.7 Conclusion 
Overall, it appears that supplementation with a flaxseed lignan-enriched standardized product is 
well tolerated in healthy older adults following once daily chronic administration of a pharmacological 
dose of SDG (600 mg) for 6 months. Further, it appears that lignan supplementation may decrease systolic 
blood pressure, so future study is required to determine its effects on hypertensive participants. 
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Chapter 6 Discussion and future work 
6.1 General Discussion 
Cancers are the largest burden on the health care system on a global scale (473). For metastatic 
cancers such as prostate (474) and breast cancer (475), systemic chemotherapy remains the major 
therapeutic choice although the prognosis and overall survival rates are still unfavorable. In addition to 
limited prolonged survival, the treatment associated and adverse short- or long-term effects (399) as well 
as acquired multiple drug resistance (400) further reduces the benefits gained from systemic 
chemotherapy.  As a result of these challenges, more interest has turned to natural compounds and their 
active metabolites for possible adjuvant therapy with current cancer chemotherapy. With an 
understanding that differences in diet and lifestyle caused by geography and economics appear to have an 
important impact on prostate (339, 342, 343) and breast cancer incidence (403, 404) and mortality, 
research is focusing on the diverse array of biologically active compounds identified from the diet, 
including flavonoids, lignans, and catechins, that may be responsible for such anti-cancer effects (16). The 
evolving evidence suggests that these naturally occurring compounds could enhance the cytotoxic effects 
of current standard chemotherapeutic agents when used in combination (417, 418). The health benefits, 
abundant natural sources, and good safety profiles in human oral supplementation studies make them 
possible adjuvant candidates in conjunction with current chemotherapy (476). 
Lignans, one class of dietary natural compounds with a unique diphenolic structure (57), exist in 
minor quantities in many foods, but have appreciable levels in flaxseed (58). Human clinical and animal 
studies demonstrate a protective role of flaxseed lignans against multiple human chronic diseases 
following oral consumption of lignan-rich food (113, 169, 333). Studies on the mechanisms suggest that 
the anti-cancer effects of flaxseed lignans involving diverse mechanisms such as anti-proliferative, anti-
oxidant, and anti-angiogenic effects (113, 169). The few safety data published thus far from human clinical 
studies of flaxseed lignan-enriched products indicate no obvious adverse side effects and demonstrated 
good tolerability with long-term oral daily administration at a low pharmacological dose (47, 412). With 
respect to efficacy in cancer, previous evidence demonstrates that oral supplementation alone with whole 
ground flaxseed (174, 350), or in combination with classic chemotherapeutic drugs (189, 359, 360) is 
inversely associated with cancer cell proliferation in prostate and breast cancers in human and animal 
xenograft models. The problem is that those supplementations contain very low levels of lignans, and 
unlikely to provide appropriate lignan levels to exert modest therapeutic benefits. 
A previous review of the literature suggested that the lowest pharmacological dose of flaxseed 
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lignans was 543 mg/d of  SDG (46). It is unlikely for the majority of human studies to achieve a 
pharmacological dose when supplied with 30-50 g/d whole ground flaxseeds (174, 350). Flaxseed products 
generally include considerable quantities of other flaxseed bioactives, such as alpha-linolenic acid and 
fibre, which are known to contribute to the health benefit of flaxseed supplementation (447, 469, 477). 
In addition to these challenges, in vivo studies typically report health benefits associated with total lignan 
levels, which exist predominantly as glucuronide and sulfate conjugates, while in vitro studies focus mainly 
on the parent (unconjugated) flaxseed lignans (113). Controversy exists concerning the actual bioactive 
lignan form, whether the plant lignan, SDG, or its aglycone, SECO, have bioactivity or whether activity 
resides in the metabolites of SECO, the mammalian lignans, ED and ENL. Conjugative metabolism is 
typically a pharmacological deactivation process, although examples of bioactive conjugated metabolites 
of parent drugs do exist, which raises the question whether lignan conjugated metabolites have bioactivity. 
The reported health benefits of flaxseed lignan consumption in prostate and breast cancer prompts 
their further investigation. However, the understanding that lignans exist in the blood circulation 
principally as conjugated metabolites, which are likely pharmacologically inactive, requires consideration 
in any investigation into their putative health benefits. This understanding became a fundamental aspect 
in our evaluations of the flaxseed lignans. Given the very modest reported benefits of flaxseed 
consumption, we set out to identify a strategy that can possibly improve the therapeutic benefits of the 
lignans as adjuvant therapy with the standard systemic chemotherapeutics used in breast and prostate 
cancer. To understand their value as safe adjuvant therapeutics, we first conducted in vitro evaluations to 
investigate the cytotoxic effect of flaxseed lignans and their metabolites in metastatic prostate cancer (PC 
3, and LNCap) and breast cancer (SKBR3, and MDA-MB-231) alone and in combination with typical 
chemotherapeutic agents. We also evaluated the safety and tolerability of a standardized lignan enriched 
flaxseed product containing a pharmacological dose of SDG in elderly participants as a population likely 
to require adjuvant therapy for prostate or breast cancer. These initial investigations are essential 
complementary studies to our additional proof-of-concept investigations into a pharmaceutical strategy 
that might improve therapeutic efficacy of oral lignan administration in cancer. 
As an important complement to the development of the ADEPT, we first evaluated the combination 
of lignans with different chemotherapeutic agents to determine whether lignans could enhance their 
cytotoxic effects (Hypothesis 1). We chose to focus on the flaxseed lignans SECO, ENL and ENL-Gluc, for in 
vitro evaluations. SECO, usually considered as a precursor of mammalian lignans, exhibits the best oral 
bioavailability with consumption of flaxseed lignan product, while little investigation has been conducted 
on it (80). SECO is then converted into mammalian lignans, ED and ENL, and the literature points to ENL 
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as the bioactive lignan (61). To evaluate the ability of SECO, ENL, and ENL-Gluc to enhance the cytotoxicity 
of typical anticancer agents, the combination study involved multiple cancer cell lines to cover a wide 
range of tumors with different characteristics, particularly an overall more aggressive phenotype. Prostate 
cancer cell lines, PC3 (PSMA negative) and LNCap (PSMA positive) cells are typical prostate cancer models 
that represent the androgen dependent and androgen independent situations in prostate cancer, 
respectively, that almost encompass all prostate cancer phenotypes. SKBR3 and MDA-MB-231 cells 
represent breast cancer types believed to be more aggressive and associated with poor prognosis. In the 
combination study, we found ENL and SECO, but not ENL-Gluc displayed an anti-proliferative effect against 
the studied prostate and breast cancer cell lines, with ENL demonstrating greatest potency. The IC50 values, 
though, were high suggesting ENL or SECO as a single agent treatment is unlikely to have much benefit in 
prostate and breast cancer patients. As a major circulating lignan form following oral consumption, the 
inability of the conjugated form of ENL to elicit any cytotoxicity further supports the contention that 
lignans alone are not likely effective therapeutics in cancer. However, both SECO and ENL significantly 
increased the sensitivity of cancer cells against multiple chemotherapeutic agents used in the treatment 
of prostate and breast cancers with ENL being the most potent.  A stable combination result was observed 
from the co-treatment of 50 µM ENL with docetaxel in both prostate and breast cancer cell lines, which 
suggests a potential application of flaxseed lignans as adjuvant therapy to decrease docetaxel dosage. We 
thought combination results from prostate and breast cancer cell lines met objectives a and b, as 
combination effects were observed in the majority experiments treated with flaxseed lignans with 
chemotherapeutic agents in vitro. These observations complemented results from previous animal 
studies which demonstrated lignans from whole ground flaxseed enhance the cytotoxic effect of classic 
chemotherapeutic agents with ENL being the major lignan involved in this effect (189, 359, 360). 
Interestingly, a moderate cytotoxicity effect was observed with SECO alone or in combination with 
other chemotherapeutic agents. SECO is commonly recognized as a major precursor of mammalian lignan, 
ENL, with only a small portion detected in plasma as the glucuronide conjugate (80). Only a few studies 
have reported a minor growth inhibitory effect of SECO against cancer cells (409, 478). Our cell viability 
experiments suggest the ability of SECO to cause limited cytotoxicity deserves attention, as interesting 
enhanced cytotoxicity was observed in certain anti-cancer drug combinations especially in prostate cancer 
cell lines. A study in rats demonstrated that SECO exhibits better oral bioavailability (26%) compared with 
ENL (<1%) (79), and the multiple daily dose study in human elderly healthy participants also indicated 
SECO was present at detectable levels unlike ENL. The enhanced systemic availability of SECO following 
the oral consumption of flaxseed lignan products suggests SECO may also contribute to the health benefits 
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reported in clinical trials using whole ground flaxseed products. Few studies evaluate systemic levels of 
SECO or its conjugative metabolites. This questions the reliability of results when researchers only 
consider plasma mammalian lignan levels when studying oral flaxseed lignan supplementation (174). 
Nonetheless, our in vitro study identified that multiple flaxseed lignans have bioactivity that could 
enhance the cytotoxic effects of typical and novel chemotherapeutic agents.  This provides important 
preliminary evidence to support the future utility of flaxseed lignans as adjuvant therapy to reduce 
chemotherapeutic dosage without affecting their efficacy. Dosage reductions, though, may improve the 
adverse event profile such that side effects do not become a treatment limiting factor for the current 
chemotherapeutic agents used in prostate and breast cancer treatment. 
Although our in vitro combination study identified promising results, effective translation of in vitro 
results into in vivo applications proves more difficult due to the complexity of the human biological system. 
The epidemiological literature seems to suggest ENL as the bioactive lignan form. This is interesting since 
extensive phase II metabolism by glucuronosyltransferases (UGTs) and sulfotransferases (STs) in 
enterocytes and hepatocytes following oral consumption is a common fate of many natural products (347). 
Upon oral consumption the SDG polymer of flaxseed, undergoes serial biotransformations and is 
converted into ED and subsequently ENL by colonic bacteria (61). ENL is then further metabolized by UGTs 
and STs prior to entry into the systemic circulation and exists predominantly as the glucuronide conjugate, 
ENL-Gluc. Numerous in vitro and in vivo studies support extensive metabolism of ENL, which results in a 
very low circulating plasma concentrations of ENL (75, 79, 87). Similar to these reported results, our data 
from clinical trial indicate that ENL concentration from many participant plasma samples was below the 
limit of quantification (0.2 ng/mL) by LC-MS/MS analysis, ENL existing predominantly as its glucuronic acid 
conjugate. 
The ENL-Gluc conjugate is believed to be an inactive form. SECO and ED also undergo similar 
metabolic transformations and likely their conjugated forms are inactive as well (75, 347). In our 
combination study, we specifically tested ENL-Gluc and confirmed its lack of cytotoxicity with the 
acknowledgement that we would extrapolate these outcomes to the other glucuronidated lignan 
metabolites. Of the flaxseed lignans, ENL exhibited the most potent cytotoxicity, consistent with literature 
evidence associating ENL with the health benefits in cancer. Yet in vitro studies using pure ENL 
demonstrate that ENL initiates inhibitory effects against MCF-7 cells at the micromolar level (332) 
consistent with our own data in prostate and breast cancer cell lines. In combination with other anticancer 
agents, minor enhancements in their cytotoxicity were observed at very low micromolar ENL 
concentrations. Since circulating ENL exists at the nanomolar range it is difficult to explain the in vivo 
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observations with oral consumption of flaxseed lignan products from the in vitro cytotoxicity data. A clear 
disconnect is present that exceeds the explanation by current conventional 
pharmacokinetic/pharmacodynamics (PK/PD) concept, which links the plasma concentration with 
observed effect. Such a PK/PD disconnect is not unusual amongst natural products and herbal products. 
A cellular pharmacokinetic-pharmacodynamic model was recently elaborated to explain the effectiveness 
of herbal medicines that exhibit extensive phase II metabolism such as flaxseed lignans (479). The authors 
suggest a need to view the whole cell as an entity and to analyze the intact PK profile at the cellular level, 
rather than plasma concentrations. This cellular PK/PD concept emphasizes the need to understand 
concentration at the sites of action to study efficacy, even though appropriate plasma concentrations 
cannot be reached.  
The literature also suggests the health benefits are actually gained from ENL derived from 
deconjugation of ENL-Gluc in the human body at specific tissue sites. ENL-Gluc is a substrate of beta-
glucuronidase (hG) enzyme. However, this enzyme localizes in cellular lysosomes and catalyzes the 
hydrolysis of β-D-glucuronic acid residues from the non-reducing end of mucopolysaccharides (321). 
Elevated hG activity has been detected in humans taking flaxseed lignan supplementation (330). 
Upregulated hG activity in tumor tissue was also reported (328), which might be associated with tumor 
invasion and metastasis (329). Although the literature reports that ENL-Gluc seems to concentrate in the 
prostate (98), circulating ENL-Gluc is unlikely to undergo passive diffusion across the cell membrane to 
gain access to intracellular beta-glucuronidase. Unless, this enzyme is extracellularly available or ENL-Gluc 
gains cellular access via a carrier-mediated process, deconjugation of circulating ENL-Glu at tissue sites is 
unlikely. In tumor sites, high levels of extracellular hG with enzymatic activity does exist (480, 481). The 
anti-cancer effects observed from oral flaxseed lignan product consumption may be partially due to 
deconjugation of ENL-Gluc to cytotoxic ENL at the tumor site by hG released extracellularly due to tumor 
necrosis.  
Since high circulating levels of ENL-Gluc follow from oral consumption of flaxseed lignans and ENL-
Gluc has no inherent cytotoxicity, the use of lignans in cancer treatment requires the presence of the 
cytotoxic form, ENL, at the tumor site. Studies have shown that anchoring functional β-glucuronidase on 
bacterial cell surfaces increased the activation of glucuronide prodrugs resulting in an increased 
cytotoxicity against tumor cells (319). These observations led to development of ADEPT strategies for 
functional localization of hG at specific sites to generate pharmacologically active compounds from 
glucuronide prodrugs. As a strategy to improve therapeutic outcomes with oral consumption of flaxseed 
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lignan products as adjuvant therapy to currently available chemotherapeutic agents, we proposed a 
proof-of-concept approach to determine whether a similar strategy could be exploited with the flaxseed 
lignans (which comprises Hypothesis 2). We speculated that the introduction of exogenous hG to the 
targeted tumor tissues may result in a higher production of ENL, which may be sufficient to result in tumor 
cell death. 
Objective c was derived from Hypothesis 2, which was to design and generate a recombinant fusion 
protein, D7-hG, where hG was fused to an antibody fragment D7, specific to PSMA. This fusion protein 
demonstrated good binding affinity and enzyme activity. When tested in vitro in combination with 
docetaxel, we noted minor improvements in docetaxel cytotoxicity. These improvements did not warrant 
in vivo assessments in an animal xenograft model in consideration of the Three R’s Tenets (Replacement, 
Reduction, Refinement) of Animal Experimentation, and did not met the expectation described in 
objective d. We identified several problems that might account for the limited benefits of ADEPT system. 
The optimization experiments between the combinations were restricted due to the limitation of D7-hβG 
production is sufficient amounts. Thus, we were not sure whether the concentration of fusion construct 
at the cellular level was sufficient to produce high levels of ENL. The stability of fusion protein in cell 
culture media and serum at physiological temperature was not determined. Since the cell viability assay 
was conducted for 72 hours, we could not confirm the existence of fusion construct throughout the 
duration of the exposure period. The rapid and continuous internalization of cell surface PSMA after ligand 
binding also challenged the application of our ADEPT (420). The internalization process cannot be impeded 
as it is mediated by the cytoplasmic tail of PSMA (301). Thus, identification of another cell surface antigen 
that does not internalize may help improve experimental outcomes. 
Our current results suggest a potential for this ADEPT strategy with oral flaxseed lignan 
supplementation as adjuvant therapy along with classic chemotherapeutic agents to improve antitumor 
efficacy and allow for anticancer drug dosage reductions. PSMA positive prostate cancer is the major 
target for this particular ADEPT, however the utility of ADEPT could have a broader application in cancer 
therapy. For example, PSMA is also widely expressed in the tumor neovasculature of non-prostatic tumors 
(287, 288) and related to a poor prognosis (289). In addition, hG has a broad range of glucuronide 
substrates, including certain chemotherapeutic agents that are deactivated by glucuronidation. Tumor 
localized hG could make it possible to cause secondary toxicity against tumor cells. Approximately 10% 
of drugs are marketed as prodrugs which may provide a rich prodrug library amenable to an ADEPT 
approach (482). 
Despite their promise, the progress of enzyme-directed prodrug systems towards clinical 
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application has been impeded at early clinical trials (282). Diverse factors have contributed to the lack of 
clinical success including elevated human immune response, selectivity of prodrug, and short life half lives 
(282). Recent developments in antibody techniques are designed to decrease the likelihood of immune 
response; one of these techniques, use of D7 scFv, has been implemented in our study. The use of 
prodrugs is attractive from a drug discovery perspective for its potential to attenuate systemic side effects. 
Thus, a good prodrug should exhibit a reasonable pharmacokinetic profile and safety following oral 
administration. In this particular project, ENL-Gluc was employed as a prodrug generated by the 
mammalian system from dietary sources rich in lignans and is associated with a compelling safety profile 
following long-term supplementation of flaxseed lignan products with oral administration (47, 450). As an 
important component in enzyme-directed prodrug system, pharmacokinetic information on the dose 
selection and plasma concentration of our prodrug, ENL-Gluc, are required to optimize the ADEPT system 
(483). 
A purpose of adjuvant therapy in cancer is to improve therapeutic outcomes of the principal 
chemotherapeutic agent through dosage reductions, which in turn, decreases the likelihood of treatment 
limiting side effects. Lignans as adjuvant therapy should demonstrate safety and tolerability with long-
term oral consumption. The safety and tolerability of flaxseed lignan products has been elucidated in 
randomized clinical trials in healthy populations (46). However, data on safety and efficacy in elderly 
populations is more limited, and these populations tend to  have significantly higher percentages of NHPs 
consumption  (484). The elderly populations are also more likely to have drug-drug interactions due to 
physiological changes and to a higher incidence of polypharmacy in elderly patients.  To determine 
whether daily administration of a lignan enriched natural product is safe and well tolerated and can 
produce sufficient levels of circulating glucuronide metabolites (hypothesis 3), a double-blind randomized 
placebo-controlled clinical trial was conducted to assess the safety, tolerability, and anti-inflammatory 
effects of the SDG-enhanced flax lignan complex, BeneFlax, following once daily oral administration in 
an older healthy population (MOD study). A low pharmacological dose (equivalent to 600 mg/d SDG) was 
selected based on the outcomes from previous clinical trials using BeneFlax (46, 412). No adverse effects 
were reported following the 24-week intervention with daily dosing of 600 mg/d SDG suggesting that this 
dose is safe in a healthy elderly population. 
The MOD study provided opportunity to assess the steady state levels of parent and conjugated 
lignan metabolites following a known dose of flaxseed lignan. At present, there is no existing well defined 
relationship between flaxseed lignan oral dose and plasma concentration. Epidemiological studies that 
assess lignan dose based on food questionnaires are highly dependent on participant recall of the foods 
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consumed daily with no knowledge of the actual lignan content of the foods consumed. Such studies are 
not able to relate blood lignan levels with lignan oral doses. Clinical trials that use whole ground flaxseed 
products or extracts provide a more stable oral source of lignan, but significant limitations exist with these 
studies as well. The lignan content in those products varies by cultivar and growing conditions, or 
extraction techniques, and can only provide an approximate lignan dosage (55). Very few studies report 
SDG and SDG metabolite plasma levels following supplementation with flaxseed products of known lignan 
content (47, 412). Studies evaluating plasma levels following lignan consumption suggest plant and 
mammalian lignans have an elimination half-life of 4-15 hours in humans (80, 83). In our study lignans 
reached steady state concentration at the first sampling time point (8-week) (485). The average steady 
state minimum plasma concentrations of total ENL (ENL plus conjugated forms) was 644 nM with levels 
up to 1.72 µM in some participants at a 600 mg/d SDG dosage at week 8. Supplementation of BeneFlax 
equivalent to 600 mg SDG significantly increased the steady state plasma levels of flaxseed lignans and 
their metabolites during the 24-week intervention, which met objective e. We expect that a higher oral 
dose of flaxseed lignans may provide sufficient ENL-Gluc for an ADEPT strategy to ensure that sufficient 
levels of ENL-Gluc gain access to beta-glucuronidase localized at the tumor to facilitate the conversion 
into ENL, leading to improved cancer cell death. 
The MOD study also provided opportunity to assess the anti-inflammatory properties of lignans 
through indices such as plasma biological markers and quality of life parameters, which comprises 
objective f. Flaxseed lignan administration did not improve any of these inflammatory indices in the 
healthy elderly population, which on the other hand indicates the safety of oral flaxseed lignans as 
mentioned in objective f. Interestingly, a number of participants had elevated blood pressure upon 
recruitment into the study. We noted a considerable decrease in SBP in the subcategory of ≥ 140 mmHg 
in participants receiving BeneFlax. It is intriguing that flaxseed lignan-enriched product might reduce 
blood pressure. A meta-analysis on randomized clinical trials suggested significant reductions in both SBP 
and DBP following flaxseed supplementation (469). The authors suggest that that alpha-linolenic acid in 
the milled flaxseed mainly accounts for the anti-hypertensive effect  (447, 448). In the MOD study, we 
only observed changes in high SBP, not DBP with BeneFlax supplementation, a defatted product that 
does not contain alpha-linolenic acid. The limited sample size and general healthy condition of the study 
participants may explain the lack of significant effect on DBP (47). Furthermore, the low statistical power 
limits the potential discussion of the role of lignans on blood pressure reduction as poor participant 
recruitment limited the sample sizes of the MOD study. In the future, it will be worthwhile to investigate 
the effect of flaxseed lignans on SBP and DBP with adjustment for possible confounders such as age, 
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gender, and body mass index, which are important risk factors for high blood pressure (471). 
6.2 Conclusion 
Dietary flaxseed lignans have been recognized for their possible chemopreventive and 
chemotherapeutic role against multiple human cancers including prostate and breast cancers. However, 
the poor bioavailability of the bioactive lignans, which undergo extensive first-pass effect and exist 
systemically as glucuronide conjugates, has restricted the clinical application of flaxseed lignans. To fully 
realize the potential for lignan oral supplementation in prostate and breast cancer, this proof-to-principle 
study provided experimental evidence that flaxseed lignans, SECO and ENL, could enhance the cytotoxicity 
of chemotherapeutic agents against prostate and breast cancer cell lines when used in combination, and 
that oral supplementation of flaxseed lignan products in healthy older adults had a good tolerability and 
safety profile. A pharmaceutical strategy, ADEPT, was developed to exploit a role for flaxseed lignans as 
adjuvant therapy. This ADEPT approach (the D7-hβG system with ENL-Gluc as prodrug) offers a 
therapeutic strategy in cancer treatment by taking advantage of phase II metabolic processes, and is 
supported by our information on oral safety and tolerability reported from the human clinical study. This 
particular D7-hβG system still has limitations which prevent its use in a clinic trial, but the concept of 
localization of drug converting enzyme to restrict activation of a cytotoxic drug has the potential to 
improve overall efficacy of systemic chemotherapy. Thus, to improve the ADEPT system, the next direction 
is to identify a better tumor cell surface target. The combination study also suggests a need for further 
investigation on the mechanism of flaxseed lignans against prostate and breast cancers. 
6.3 Future Work 
The combination study suggests that ENL could significantly enhance the cytotoxicity of 
chemotherapeutic agents in both prostate and breast cancer cell lines. However, the mechanisms of the 
anticancer effect of ENL and how its mechanism might complement the other cytotoxic agents remains 
unclear. We propose that the effect of flaxseed lignans on cholesterol homeostasis could be one possible 
underlying mechanism. Flaxseed lignans exhibit moderate health benefit against prostate and breast 
cancers following oral consumption of flaxseed lignan products despite their extensive first pass phase II 
metabolism. These clinical trials also consistently reported that oral flaxseed lignans lowered plasma total 
cholesterol and LDL-cholesterol (466, 486). Currently, there is no direct link between cholesterol and 
cancer risk; however, use of statins is related with lowered cancer risk. Such evidence leads to an 
assumption that modulation of cholesterol metabolism by flaxseed lignans might influence cancer and 
cancer risk. An old literature reports lowering LDL-cholesterol could decrease bile acid secretion, which is 
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necessary for absorption of exogenous cholesterol from gastrointestinal tract (487). In addition to that, 
flaxseed lignans is reported to undergo enterohepatic circulation which allows representation of the 
lignans to the gastrointestinal mucosa, and studies have demonstrated ability of lignans to significantly 
reduce total and LDL-cholesterol in hypercholesterolemic adults (48). Our lab currently focuses on the 
interaction between ENL-Gluc and cholesterol trafficking. An understanding of lignan influence in 
cholesterol homeostasis pathway may provide further support that modulation of cholesterol metabolism 
has an impact on cancer and cancer risk. Further investigations into the relationship between lignan 
impact on cholesterol homeostasis and prostate and breast cancer cell cytotoxicity would be warranted. 
We did not observe a marked benefit from D7-hβG/ENL-Gluc system in combination with docetaxel 
in C4-2 cells, although the fusion protein displayed excellent binding against purified PSMA and enzymatic 
activity in citrate-phosphate buffer. The fast and continuous internalization of the fusion protein may limit 
the amount of fusion protein retained at the cell surface. We were unable to optimize the amount of D7-
hβG added to cell culture due to the lack of availability of purified D7-hβG and further in vitro evaluations 
on the current D7-hβG/ENL-Gluc system with optimal amounts are warranted. Favourable outcomes 
would then necessitate large scale production and purification of the fusion protein to allow for future 
pharmacokinetic and pharmacodynamic studies. This would first require a determination of the Kd value 
of the fusion protein against cell surface PSMA in C4-2 cells to guide the fusion protein dosage in animal 
xenograft models. Furthermore, investigations into the optimal combination between fusion protein, ENL-
Gluc and chemotherapeutic agent are also required to maximize the cytotoxic effect in C4-2 cells. These 
investigations will then lead to in vivo biodistribution studies of fusion protein in tissues and organs using 
an Odyssey Clx imaging system with IRDdye800 and efficacy evaluations in a mouse prostate cancer 
xenograft model. However, rapid internalization will continue to challenge the current system and we 
propose that another future direction is to seek a more appropriate antibody fragment that does not 
internalize into cells. 
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Appendix A  Enterolactone Glucuronide (ENL-Gluc) synthesis and purification 
A.1 Rat liver microsome preparation 
Enterolactone glucuronide was synthesized using a rat hepatic microsomal system and incubation 
conditions suitable for glucuronidation. Hepatic microsomes were prepared according to standard 
operating procedure of the lab (347). Briefly, 1.5 g of rat liver was thawed from -80°C and homogenized 
in 3 mL homogenization buffer (50 mM Tris, 150 mM KCL, 0.1 mM dithiothreitol, 1 mM EDTA, disodium 
salt, 20% (v/v) glycerol, pH 7.4) containing 0.1 mM PMSF on ice using an ultrasonic homogenizer (Branson, 
Danbury, CT, US). 
The homogenate was centrifuged at 9,184 x g using Beckman Optima MAX-XP ultracentrifuge 
(Beckman Coulter, Mississauga, Canada) for 30 min and the supernatant was discarded. The microsomal 
pellet was washed in 1 mL of 150 mM KCl and centrifuged again at 112,504 x g for 40 min to pellet 
microsomes. The microsome pellets was resuspended in 1 mL of 150 mM KCl and centrifuged again under 
the same condition. Microsomal pellets were suspended in 0.25 M sucrose solution and stored at -80°C 
until use. Protein concentration was determined using bicinchoninic acid (BCA) protein assay kit according 
to manufacturer’s instructions. 
A.2 Enterolactone glucuronide (ENL-Gluc) synthesis 
Enterolactone glucuronide (ENL-Gluc) was synthesized according to a published method (488). 
Briefly, the incubation mixture (8 mL) consisted of 5 mM uridine 5’-diphosphoglucuronic acid trisodium 
salt, 5 mM MgCl2, 5 mM D-saccharic acid 1,4-lactone monohydrate, 100 mM Trizma base (adjusted with 
HCl to pH 7.4), 2 mM ENL and microsomal protein (3.1 mg/mL). The mixture was incubated using incubator 
shaker (VWR, Radnor, PA, US) for 22 h with temperature set to 25℃ at a speed of 90 rpm/min to keep 
enzyme suspended in the solution. Two volumes of methanol was added to terminate the reaction. Then 
the mixture was centrifuged for 10 min at 10,000 × g to precipitate proteins and the supernatant was 
concentrated by rotary evaporation using Buchi Rotarvapor R-200 (New castle, US) connected to Buchi 
vacuum controller V-850 (New castle, US). 
A.3 ENL-Gluc purification and identification 
ENL-Gluc was purified using a reversed-phase semi-preparation column (Allsphere ODS-2 300×10 
mm, 5 µM) with a 26 min run time on HPLC Water 600 system (454). The HPLC system consisted of Waters 
Model 600 solvent delivery system, Model 2996 photodiode Array Detector with the fixed wavelength at 
280 nm, Model 717 plus autosampler. The mobile phase consisted of 0.1% formic acid in HPLC grade water 
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(Solvent A) and 0.1% formic acid in HPLC grade Acetonitrile (Solvent B). The flow rate was set to 3 mL/min. 
The mobile phase was started with 85%:15% A : B at 0 min, and increased to 50% B from 0 to 12 min and 
continuously increased to 90 % at 14 min. The mobile phase remained at 90% B between 14 and 18 min, 
with a decreasing gradient from 90% to 15% water from 18 to 20 min and a return to 15% acetonitrile 
between 20 and 25 min. The right fraction was collected using HPLC fraction collector (Waters, 
Mississauga, ON). The collected fraction was then concentrated by rotary evaporator and dried by freeze 
dryer. The purified compound was then re-injected onto the Agilent 1200 HPLC system (Agilent 
Technologies, Mississauga, ON) to determine the purity and subsequently into the linear ion trap 
quadrupole mass spectrometer (AB Sciex Instruments, Concord, ON, Canada) using negative electrospray 
ionization mode spectrometer to confirm the molecular weight and structure through comparison with 
previous results. The MS parameter were optimized for ENL-Gluc as follows: declusterin potential (DP) -
40V, ion spray voltage (IS) -4500V; ion source gas 1 (GS1) 10 psi; ion source gas 2 (GS2) 10 psi; entrance 
potential (EP) -10V; curtain gas (CUR) 10V; collision energy (CE) -32V; collision activated dissociation (CAD) 
6.0; collision cell exit potential (CXP) -15 V. The fragmentation transition for Q1 and Q3 scan were mass 
to charge ratio [m/z 473.1] to [m/z 2971], [m/z 473.1] to [m/z 253.1] and [m/z 473.1] to [m/z 174.8]. 
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Figure A-1. Purification of enterolactone glucuronide (ENL-Gluc) using a 26 min gradient HPLC-UV 
detection method. ENL-Gluc has a retention time at 14.0 min. ENL-Gluc and enterolactone (ENL) have 
retention times at 14 min and 18.2 min (not detected), respectively (upper figure) and the maximum UV 
absorbance of the glucuronide conjugate is 274.9 nm on the Waters diode-array detector (lower figure). 
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Figure A-2. MS/MS scan of purified ENL-Gluc. The purified ENL-Gluc was analyzed by directed injection 
into a mass spectrometer to determine the molecular weight and structure under negative electrospray 
(ESI) mode.  ENL-Gluc displayed a mass-to-charge ratio (m/z) of 473.2 in the Q1 scan (upper figure). The 
[m/z 473.2] ion could be further fragmented into [m/z 297.1], [m/z 253.1] and [m/z 174.8] using multiple 
reaction monitoring (MRM) mode (lower figure). 
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Appendix B  Percent cell viability of flaxseed lignans in PC3 cells 
 
 
 
 
 
Figure B-3. Cytotoxicity of docetaxel or doxorubicin in combination with different concentrations of 
secoisolariciresinol (SECO), enterolactone (ENL) in PC3 cells. PC3 cells were treated with different 
combinations of docetaxel or doxorubicin and flaxseed lignan metabolites for 72 hours and cell viability 
was measured using Calcein AM fluorescence. Data were plotted in GraphPad Prism and IC50 values were 
estimated using the four parameter variable slope method. ENL and SECO enhances the cytotoxicity of 
docetaxel or doxorubicin in a concentration-dependent manner. Data represent mean ± SD of three 
replicates on three different occasions. 
 
  
145 
 
Appendix C  Percent cell viability of flaxseed lignans in SKBR3 and MDA-MB-231 cells 
 
 
Figure C-4. Percent cell viability of SKBR3 and MDA-MB-231 cells following exposure to the flaxseed 
lignans, secoisolariciresinol (SECO) and enterolactone (ENL). 
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Figure C-5. Combination of docetaxel, doxorubicin or carboplatin with secoisolariciresinol (SECO), and 
enterolactone (ENL) in SKBR3 cells. SKBR3 cells were incubated with chemotherapeutic drugs alone or in 
combination with 25 µM or 50 µM SECO or ENL for 72 h in triplicate on three separate occasions. Cell 
viability was determined using Calcein AM cell viability assay kit. Data were plotted in GraphPad Prism 
and IC50 values were estimated using the four parameter variable slope method. Due to solubility issues, 
the maximum concentration of carboplatin was 300 µM in all treatments. 
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Figure C-6. Combination of doxorubicin or docetaxel with secoisolariciresinol (SECO), and enterolactone 
(ENL) in MDA-MB-231 cells. MDA-MB-231 cells were incubated with therapeutic agents alone or in 
combination with 25 µM or 50 µM SECO or ENL for 72 h in triplicate on three separate occasions. Cell 
viability was determined using CellTiter-Glo® luminescent cell viability assay kit. Data were plotted in 
GraphPad Prism and IC50 values were estimated using the four parameter variable slope method. 
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Appendix D  Generation and validation of D7-hβG fusion protein 
 
 
Figure D-7. Flow chart of construction and expression of D7-hβG recombination protein. 
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Figure D-8. The cDNA sequence of fusion construct D7-hbG. cDNA D7-VHVL was amplified from pSectag-
D7 plasmid with EcoRI (GATATC) restriction enzyme site introduced to 3’ end and (GGGGS)3 linker 
sequence (TGATCCACCGCCACCAGAGCCACCACCGCCTGAGCCACCTCCACC) to the 3’ end. The mature hβG 
cDNA was amplified from pHUGP13 plasmid from 93 bp to 1979 bp which resulted in removal of the signal 
peptide.  The (GGGGS)3 linker sequence was added to 5’ end and XhoI (CTCGAG) to the 3’ end of the 
mature hβG cDNA sequence. To ensure the downstream c-myc and His6 tag with the right reading frame, 
an extra cytosine was added to the end of hβG sequence before the XhoI (CTCGAG) site. The fusion cDNA 
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construct had a total of 2838 bp including EcoRI, 748 bp of D7-VHVL, 45 bp of (GGGGS)3 linker, 1887 bp of 
hβG, XHoI, c-myc, and His6 tag sequence The translation of the fusion cDNA construct resulted in a fusion 
protein with 946 amino acids containing c-myc and His6 tag. 
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Figure D-9. Summary of antibody/antigen interactions. Binding of D7-hβG antibody to recombinant PSMA 
was detected using the ForteBio Octet® Red 384 system. The data from 120 s to 420 s identifies the 
immobilizing process of PSMA onto streptavidin biosensors followed by 120s in PBS to stabilize the new 
base line. The data from 540 s to 1140 s shows a particular association and dissociation binding curve at 
seven different concentrations of D7-hβG with two fold serial dilution. PBS was used as a negative control 
for nonspecific binding (the bottom green curve). 
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Figure D-10. Raw and fitted curves of binding affinity. The upper figure shows the binding of D7-hβG (187.5 
nM) to the PSMA. The raw data was displayed in green and fitted curve in red. Data were fitted to a one 
binding site model to determine association rate (kon) and dissociation rate (koff), and equilibrium binding 
affinity (Kd) was calculated.  D7-hβG binds to PSMA with 2.5 nM apparent affinity.  
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Appendix E  Certificates of Ethics Approval for the MOD study 
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Appendix F  MOD Protocol 
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Appendix G  Partial validation of LC-MS/MS method 
 
Table G-1.  Intraday and Interday assay precision and accuracy for enterolactone (ENL), enterodiol (ED), 
and secoisolariciresinol (SECO) in human plasma (N=6). 
QC levels* 
ENL ED SECO 
Accuracya Precisionb Accuracya Precisionb Accuracya Precisionb 
LLQC 
Day 1 100.1 13.4 100.4 10.1 100.2 10.1 
Day 2 100.2 6.9 99.8 6.7 99.5 5.8 
Day 3 104.9 6.4 100.1 4.8 99.2 8.4 
LQC 
Day 1 89.0 4.2 93.3 5.2 105.6 4.1 
Day 2 103.0 5.3 103.5 5.4 100.6 3.6 
Day 3 101.3 7.1 103.1 3.1 100.3 2.5 
MQC 
Day 1 100.5 3.3 100.1 7.6 105.5 8.7 
Day 2 97.6 0.8 93.4 3.4 96.8 1.7 
Day 3 99.5 2.4 98.1 2.3 99.9 3.1 
HQC 
Day 1 90.1 3.3 89.0 2.9 97.5 7.8 
Day 2 89.0 3.5 89.1 2.7 88.2 1.9 
Day 3 87.4 2.2 87.7 1.9 87.9 2.2 
 
QC levels* ENL ED SECO 
Accuracya Precisionb Accuracya Precisionb Accuracya Precisionb 
LLOQ 101.7 8.9 100.1 7.2 99.6 8.1 
LQC 97.8 5.5 100.0 4.6 102.2 3.4 
MQC 99.2 2.2 97.2 4.4 100.7 4.5 
HQC 88.8 3.0 88.6 2.5 91.2 4.0 
*The LLQC is 0.2 ng/mL for ENL and ED, and for SECO is 1 ng/mL; LQC for ENL and ED is 0.6 ng/mL and for 
SECO is 3 ng/mL; MQC for all three analysts is 25 ng/mL and HQC is 40 ng/mL for all three analysts. 
a: Accuracy was determined as calculated concentration /nominal concentration x 100%. 
b: Precision was calculated as standard deviation/ mean x 100%. 
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Figure G-11. Retention time of analysts. The analyst peaks from left to right was SECO [m/z 164], END [m/z 
253] and ENL [m/z 189]. The internal standards used for these analysts were SECO-D6, END-13C3, and ENL-
13C3, which were in green, pink and light blue color at the same retention time as the analysts. The figure 
shows total plasma levels of SECO, ED and ENL after hydrolysis by β-glucuronidase.  
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Appendix H  Outcomes of MOD study 
 
Table H-2. Impact of BeneFlax® oral supplementation on cognition and grip strength. 
Outcome Treatment 
Mean(SD) 
Range 
Baseline 24 weeks 
Grip strength left* 
BeneFlax® 30.6(9.8) 32.3(11.5) 12.3-55 
Placebo 29.7(4.6) 29.6(5.7) 20.3-37.7 
Grip Strength right* 
BeneFlax® 32.3(10.0) 32.3(11.5) 15-53 
Placebo 32.3(7.9) 31.4(8.6) 20.3-51 
Cognitive 
BeneFlax® 28.1(1.9) 29.3(1) 25-30 
Placebo 28.2(2.0) 29.5(0.9) 23-30 
*: Grip Strength were measured three times for every single subjects at every time point of visit, to 
calculate the mean level. 
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Table H-3. Mean (SD) haematological and clinical chemistry parameters in participants supplemented for 
24 weeks with BeneFlax® or placebo (whey protein). No significant difference in any parameter between 
treatment groups was identified by one-way ANOVA. 
Test Name Reference Unit Beneflax Placebo p value 
Homocysteine 3.00 - 15.00 µmol/L 12.0(2.7) 14.4(4.1) .055 
25-Hydroxyvitamin D 70 - 250 nmol/L 104.8(21.7) 102.2(24.7) .757 
Prealbumin 180 - 450 mg/L 227.1(39.6) 245.4(55.8) .301 
Sodium 135 - 146 mmol/L 139.2(1.8) 138.8(1.8) .542 
Potassium 3.5 - 5.1 mmol/L 4.1(0.2) 3.8(0.4) .065 
Chloride 100 - 110 mmol/L 100.2(1.9) 99.3(2.2) .254 
Carbon Dioxide 22 - 31 mmol/L 25.7(1.9) 26.9(1.3) .060 
Urea 3.7 - 7.0 mmol/L 6.6(1.2) 7.1(1.7) .353 
Creatinine 45 - 90 µmol/L 80.0(17.0) 85.5(15.4) .355 
Anion Gap (Na, Cl, 
CO2) 
8. - 16. mmol/L 23.8(4.9) 21.2(4.5) .425 
Aspartate 
Aminotransferase 
(AST) 
10 - 35 U/L 23.8(4.9) 21.2(4.5) .144 
Leukocytes 4.00 - 11.00 10e9/L 5.0(1.2) 5.2(1.4) .650 
Erythrocytes 3.20 - 5.40 10e12/L 4.9(0.4) 4.8(0.3) .501 
Hemoglobin 110 - 160 g/L 153.9(13.1) 150.7(10.6) .470 
Hematocrit 0.330 - 0.480 L/L 0.46(0.04) 0.45(0.03) .488 
MCV 79.0 - 99.0 fl 93.4(2.2) 93.4(3.5) .979 
MCH 27.0 - 32.0 pg 31.5(0.9) 31.5(1.6) .943 
MCHC 320 - 360 g/L 337.7(6.3) 337.3(7.5) .862 
Erythrocyte 
Distribution Width 
(RDW) 
11.5 - 15.0 % 12.2(0.5) 12.4(1.4) .619 
Platelets 150 - 400 10e9/L 227.5(48.9) 252.3(61.3) .214 
MPV 7.4 - 10.6 fl 7.5(0.9) 7.8(1.2) .399 
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Neutrophils 1.50 - 7.50 10e9/L 2.7(1.0) 2.9(0.9) .625 
Lympohocytes 1.50 - 4.00 10e9/L 1.5(0.5) 1.6(0.6) .620 
Monocytes 0.20 - 1.00 10e9/L 0.4(0.1) 0.4(0.2) .556 
Eosinophils 0.00 - 0.60 10e9/L 0.28(0.42) 0.21(0.16) .599 
Basophils 0.00 - 0.20 10e9/L 0.06(0.02) 0.07(0.03) .036 
Alanine 
Aminotransferase 
(ALT) 
5 - 45 U/L 19.6(5.8) 19.5(8.7) .947 
Albumin; BCP 35 - 52 g/L 37.7(4.9) 39.0(2.1) .387 
Magnesium 0.70 - 1.0 mmol/L 0.87(0.05) 0.86(0.88) .656 
Alkaline Phosphatase 
(ALP) 
30 - 110 U/L 67.7(14.2) 66.3(17.9) .808 
Bilirubin, Total 2. - 22 µmol/L 10.5(7.6) 7.7(2.4) .211 
Protein 60 - 80 g/L 69.2(2.6) 70.5(3.3) .221 
Glucose, Fasting 3.6 - 6.0 mmol/L 5.1(0.5) 5.5(1.1) .266 
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Table H-4. Mean (SD) lipid profiles of participants who received BeneFlax® supplementation or placebo 
whey protein. No statistically significant differences were identified. 
Outcome Reference Unit Treatment Baseline 24 weeks Range 
Cholesterol 2.20 - 6.20 mmol/L 
Beneflax 5.2(0.8) 5.1(1.0) 2.8-6.6 
Placebo 5.3(1.3) 5.3(1.1) 2.8-7.2 
Triglyceride 0.60 - 2.30 mmol/L 
Beneflax 1.1(0.6) 1.0(0.5) 1.0-3.0 
Placebo 1.1(0.3) 1.1(0.4) 1.0-3.0 
HDL-c 0.90 - 2.40 mmol/L 
Beneflax 1.7(0.4) 1.6(0.4) 1.0-4.0 
Placebo 1.7(0.5) 1.6(0.5) 1.0-5.0 
LDL-c; Calculated 2.40 - 4.10 mmol/L 
Beneflax 3.4(0.8) 3.1(1.0) 1.0-5.0 
Placebo 3.3(0.7) 3.2(0.9) 2.0-5.0 
Cholesterol/HDL-c   
Beneflax 1.4(1.6) 3.4(0.9) 0-7.0 
Placebo 4.4(10.3) 3.4(0.8) 0-5.0 
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Table H-5. Mean (SD) of plasma levels of inflammatory biomarkers, CRP, TNF-alpha, and IL-6 at baseline 
and 24 weeks. CRP was determined by the Saskatoon Health Region Clinical Chemistry Laboratory. IL-6 
and TNF-alpha were assessed in-house using commercial kit according to manufacturer’s instructions. 
aThe limit of detection of TNF-alpha is 3.9 pg/mL. 
bThe limit detection of IL-6 is 7.8pg/mL. 
cSome plasma samples fell below the limit of quantification according to the manufacturer’s instructions. 
The mean(SD) was calculated based on quantifiable samples. 
 
Outcome Treatment 
Baseline 24 weeks 
 
Range 
n Mean (SD)c n Mean (SD) c  
TNF-
alphaa 
BeneFlax® 19 10.1 (2.9) 11 2.56 (1.6) 0-15 
Placebo 13 9.8 (2.9) 6 2.0 (1.8) 0-15 
IL-6b 
BeneFlax® 16 20.5 (36.8) 9 48.3 (51.0) 0-151 
Placebo 11 19.4 (35.3) 6 10.0 (3.6) 0-119 
CRP 
BeneFlax® 19 1.42 (1.6) 18 5.6 (14.0) 0-61 
Placebo 12 4.38 (10.3) 13 4.2 (8.3) 0-37 
